-DOCSTART- -X- N

proximal JJ Condition
deep JJ Condition
vein NN Condition
thrombosis NN Condition
. . None
deep JJ Condition
vein NN Condition
thrombosis NN Condition
both DT None
in IN None
general JJ None
surgery NN None
and CC None
in IN None
high-risk JJ None
orthopedic JJ None
surgery NN None
. . None
patients NNS None
with IN None
proximal JJ Condition
vein NN Condition
thrombosis NN Condition
. . None
There EX None
were VBD None
67 CD Size
patients NNS None
in IN None
each DT None
group NN None
. . None
deep JJ Condition
vein NN Condition
thrombosis NN Condition
. . None
-DOCSTART- -X- N

control NN None
subjects NNS None
and CC None
depressed JJ Condition
patients NNS None
. . None
depressed JJ None
and CC None
control JJ None
subjects NNS None
. . None
two CD None
groups NNS None
of IN None
8 CD Size
patients NNS None
-DOCSTART- -X- N

visual JJ Condition
selective JJ Condition
attention NN Condition
. . None
Subjects NNS None
completed VBD None
an DT None
attentional JJ None
capture NN None
task NN None
alone RB None
( ( None
single-task JJ None
) ) None
or CC None
while IN None
engaged VBN None
in IN None
a DT None
working JJ None
memory NN None
task NN None
( ( None
dual-task JJ None
) ) None
. . None
-DOCSTART- -X- N

Increasing VBG None
the DT None
reach NN None
of IN None
health NN None
sponsorship NN None
: : None
using VBG None
a DT None
sponsorship JJ None
kit NN None
to TO None
promote VB None
health NN None
. . None
Australia NNP None
Healthway NNP None
staff NN None
Healthway NNP None
staff NN None
-DOCSTART- -X- N

adults NNS Age
over IN Age
50 CD Age
years NNS Age
of IN Age
age NN Age
: : None
Participants NNS None
were VBD None
recruited VBN None
via IN None
direct JJ None
mailing NN None
within IN None
the DT None
participating VBG None
Municipal NNP None
Health NNP None
Council NNP None
regions NNS None
and CC None
randomized VBN None
to TO None
the DT None
printed VBN None
or CC None
Web-based VBN None
intervention NN None
by IN None
their PRP$ None
region NN None
. . None
-DOCSTART- -X- N

polycystic JJ Condition
liver NN Condition
volume NN Condition
in IN Condition
ADPKD NNP Condition
: : Condition
autosomal-dominant JJ None
polycystic JJ None
kidney NN None
disease NN None
( ( None
ADPKD NNP None
) ) None
. . None
12 CD None
patients NNS None
with IN None
ADPKD NNP None
. . None
-DOCSTART- -X- N

70 CD None
patients NNS None
( ( None
without IN None
previous JJ None
history NN None
of IN None
cerebral JJ None
or CC None
systemic JJ None
embolus NN None
) ) None
undergoing VBG None
cardiac JJ None
catheterization NN None
. . None
-DOCSTART- -X- N

hospitalized JJ Condition
patients NNS Condition
with IN Condition
lower JJR Condition
respiratory NN Condition
tract JJ Condition
infections NNS Condition
. . Condition
121 CD None
patients NNS None
was VBD None
studied VBN None
; : None
92 CD None
were VBD None
clinically RB None
evaluable JJ None
. . None
59 CD None
patients NNS None
were VBD None
treated VBN None
with IN None
ofloxacin NN None
and CC None
33 CD None
with IN None
the DT None
comparator NN None
drug NN None
. . None
-DOCSTART- -X- N

growth NN Condition
hormone-deficient JJ Condition
adults NNS Age
] FW None
. . None
patients NNS None
with IN None
growth NN Condition
hormone NN Condition
deficiency NN Condition
( ( Condition
GHD NNP Condition
) ) Condition
. . None
patients NNS None
with IN None
GHD NNP Condition
. . None
20 CD Size
adult NN Age
patients NNS None
with IN None
GHD NNP Condition
( ( None
eleven JJ Size
male NN None
, , None
nine CD Size
female NN None
, , None
mean JJ None
age NN None
42.5 CD Age
years NNS Age
) ) Age
were VBD None
included VBN None
in IN None
the DT None
study NN None
-DOCSTART- -X- N

childhood NN None
autism NN Condition
: : Condition
38 CD None
male JJ Age
youths NNS Age
( ( Age
7-16 CD Age
years NNS Age
old JJ Age
) ) Age
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
young JJ None
individuals NNS None
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
-DOCSTART- -X- N

human JJ None
cigarette NN Condition
smoking NN Condition
normal JJ Condition
volunteers NNS None
. . None
-DOCSTART- -X- N

breast NN Condition
fibroadenomas NN Condition
in IN Condition
Chinese JJ Condition
women NNS Condition
. . Condition
Participants NNS None
were VBD None
women NNS None
in IN None
a DT None
breast NN None
self-examination NN None
trial NN None
in IN None
Shanghai NNP None
, , None
China NNP None
who WP None
were VBD None
diagnosed VBN None
with IN None
fibroadenomas NN None
( ( None
n JJ None
= NNP None
258 CD None
) ) None
and CC None
1035 CD None
controls NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
critical JJ Condition
limb NN Condition
ischaemia NN Condition
: : None
patients NNS None
with IN None
allodynia NN Condition
, , None
hyperalgesia NN Condition
and CC None
hyperpathia NN Condition
secondary JJ Condition
to TO Condition
critical JJ Condition
limb NN Condition
ischaemia NN Condition
. . None
Thirty-five JJ None
patients NNS None
completed VBD None
the DT None
study NN None
, , None
18 CD None
17 CD None
-DOCSTART- -X- N

rectal JJ None
cancer NN None
. . None
rectal JJ None
cancer NN None
patients NNS None
. . None
rectal JJ None
carcinoma NN None
patients NNS None
without IN None
distant JJ None
metastasis NN None
or CC None
peritoneal JJ None
carcinomatosis NN None
. . None
Between NNP None
January NNP None
1998 CD None
and CC None
December NNP None
2003 CD None
, , None
51 CD None
rectal JJ None
carcinoma NN None
patients NNS None
without IN None
distant JJ None
metastasis NN None
or CC None
peritoneal JJ None
carcinomatosis NN None
rectal JJ None
carcinoma NN None
patients NNS None
-DOCSTART- -X- N

hyperglycemic JJ Condition
patients NNS Condition
with IN None
non-ST JJ None
elevation NN None
acute NN Condition
coronary JJ Condition
syndrome NN Condition
. . None
patients NNS None
with IN None
diabetes NNS None
receiving VBG None
standard JJ None
treatment NN None
for IN None
diabetes NNS None
and CC None
randomized VBN None
to TO None
ranolazine VB None
or CC None
placebo VB None
within IN None
the DT None
MERLIN-TIMI-36 NNP None
( ( None
MERLIN NNP None
) ) None
study NN None
. . None
patients NNS None
with IN None
diabetes NNS None
and CC None
A1C NNP None
of IN None
> NNP None
or=8-10 JJ None
% NN None
at IN None
randomization NN None
( ( None
n JJ None
= NNP None
171 CD None
) ) None
placebo-adjusted JJ None
( ( None
n JJ None
= NNP None
182 CD None
) ) None
patients NNS None
with IN None
FPG NNP None
of IN None
150-400 JJ None
mg/dl NN None
at IN None
randomization NN None
, , None
ranolazine NN None
( ( None
n JJ None
= NNP None
131 CD None
) ) None
placebo NN None
( ( None
n JJ None
= NNP None
147 CD None
) ) None
patients NNS None
with IN None
cardiovascular JJ None
disease NN None
and CC None
poorly RB None
controlled VBN None
diabetes NNS None
. . None
-DOCSTART- -X- N

iron-deficient JJ None
patients NNS None
undergoing VBG None
bilateral JJ None
total JJ None
knee NN None
replacement NN None
arthroplasty NN None
. . None
iron-deficient JJ None
patients NNS None
. . None
METHODS NNP None
A NNP None
total NN None
of IN None
108 CD None
iron-deficient JJ None
patients NNS None
were VBD None
requirements NNS None
in IN None
iron-deficient JJ None
patients NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
rheumatoid JJ None
arthritis NN None
receiving VBG None
outpatient JJ None
clinical JJ None
nurse NN None
specialist NN None
care NN None
, , None
inpatient NN None
care NN None
, , None
or CC None
day NN None
patient JJ None
team NN None
care NN None
. . None
patients NNS None
with IN None
rheumatoid JJ None
arthritis NN None
( ( None
RA NNP None
) ) None
. . None
210 CD Size
RA NNP None
patients NNS None
who WP None
participated VBD None
in IN None
a DT None
randomized JJ None
trial NN None
The DT None
questionnaire NN None
was VBD None
returned VBN None
by IN None
174 CD Size
patients NNS Size
( ( Size
83 CD Size
% NN Size
) ) Size
. . None
RA NNP None
patients NNS None
. . None
-DOCSTART- -X- N

15 CD Size
healthy JJ Condition
male NN Sex
volunteers NNS None
( ( None
mean JJ None
age NN None
31 CD Age
yr NN None
) ) None
and CC None
over IN None
30 CD None
, , None
45 CD None
and CC None
80 CD None
min NN None
in IN None
six CD Size
females NNS None
( ( None
mean JJ None
age NN None
32 CD Age
yr NN None
) ) None
. . None
-DOCSTART- -X- N

women NNS Sex
with IN None
a DT None
family NN None
history NN None
of IN None
breast NN Condition
cancer NN Condition
first-degree JJ None
relatives NNS None
of IN None
index NN None
breast NN None
cancer NN None
patients NNS None
200 CD Size
women NNS None
aged VBN None
35 CD Age
years NNS Age
and CC None
older JJR None
who WP None
had VBD None
a DT None
family NN None
history NN None
of IN None
breast NN None
cancer NN None
in IN None
a DT None
first-degree JJ None
relative NN None
Women NNS None
with IN None
a DT None
personal JJ None
history NN None
of IN None
cancer NN None
were VBD None
excluded VBN None
-DOCSTART- -X- N

Thailand NNP None
Philippines-two JJ None
27 CD Size
healthy JJ None
, , None
Thai NNP None
adults NNS Age
received VBD None
a DT None
40 CD None
IU NNP None
kg NN None
( ( None
-1 NNP None
) ) None
dose NN None
of IN None
either DT None
Erig NNP None
PMC NNP None
( ( None
n JJ None
= NNP None
12 CD None
) ) None
or CC None
PHT-Erig NNP None
( ( None
n JJ None
= NNP None
15 CD None
) ) None
via IN None
the DT None
intramuscular NN None
( ( None
i.m JJ None
. . None
) ) None
route NN None
; : None
71 CD Size
healthy JJ None
volunteers NNS None
-DOCSTART- -X- N

persons NNS Condition
using VBG Condition
interdental JJ Condition
brushing NN Condition
than IN Condition
in IN Condition
those DT Condition
flossing NN Condition
smokers NNS Condition
-DOCSTART- -X- N

chronic JJ None
alcoholics NNS Condition
. . None
alcoholics NNS Condition
who WP None
took VBD None
their PRP$ None
assigned JJ None
medication NN None
( ( None
lithium NN None
or CC None
placebo NN None
) ) None
for IN None
the DT None
first JJ None
6 CD None
months NNS None
after IN None
discharge NN None
from IN None
an DT None
inpatient JJ None
rehabilitation NN None
program NN None
alcoholics NNS Condition
who WP None
took VBD None
their PRP$ None
medication NN None
erratically RB None
or CC None
not RB None
at IN None
all DT None
. . None
Attendance NN None
at IN None
Alcoholics NNP Condition
Anonymous NNP None
( ( None
AA NNP None
) ) None
meetings NNS None
-DOCSTART- -X- N

non-hyperlipidaemic JJ Condition
primary JJ Condition
hypertension NN Condition
. . None
hypercholesterolaemic JJ None
hypertensive JJ None
subjects NNS None
hypertensive JJ Condition
subjects NNS Condition
with IN Condition
lower JJR Condition
plasma NN Condition
cholesterol NN Condition
Fourteen JJ None
non-hyperlipidaemic JJ None
primary JJ None
hypertensive JJ None
subjects NNS None
( ( None
10 CD None
men NNS None
; : None
overall JJ None
mean?SD NN None
age NN None
58?12 CD None
years NNS None
) ) None
. . None
non-hyperlipidaemic JJ None
subjects NNS None
with IN None
primary JJ None
hypertension NN None
, , None
simvastatin JJ None
-DOCSTART- -X- N

children NNS Age
with IN None
high JJ Condition
functioning VBG Condition
autism NN Condition
and CC None
Asperger NNP Condition
Syndrome NNP Condition
. . None
for IN None
6-11 JJ Age
year NN None
olds NNS None
with IN None
high JJ Condition
functioning VBG Condition
autism NN Condition
and CC None
Asperger NNP Condition
Syndrome NNP Condition
. . None
Children NNP None
1 CD None
h/week NN None
over IN None
18 CD None
weeks NNS None
. . None
other JJ None
groups NNS None
on IN None
autism-specific JJ None
social JJ None
interaction NN None
scores NNS None
LEGO NNP None
and CC None
SULP NNP None
groups NNS None
compared VBN None
to TO None
the DT None
control NN None
group NN None
. . None
SULP NNP None
and CC None
LEGO NNP None
groups NNS None
-DOCSTART- -X- N

tongue NN None
and CC None
floor NN None
of IN None
the DT None
mouth NN Condition
cancers NNS Condition
. . None
Since IN None
January NNP None
1974 CD None
, , None
95 CD None
patients NNS None
with IN None
anterior JJ Condition
tongue NN Condition
and CC Condition
floor NN Condition
of IN Condition
the DT Condition
mouth NN Condition
cancers NNS Condition
one-third NN None
of IN None
the DT None
patients NNS None
received VBD None
chemotherapy NN None
one-third JJ None
of IN None
the DT None
patients NNS None
received VBD None
immunotherapy JJ None
with IN None
weekly JJ None
C. NNP None
parvum NN None
injections NNS None
remaining VBG None
third NN None
Patients NNS None
who WP None
previously RB None
received VBD None
radiotherapy NN None
-DOCSTART- -X- N

advanced JJ None
non-small-cell JJ Condition
lung NN Condition
cancer NN Condition
( ( Condition
NSCLC NNP Condition
) ) Condition
: : None
Since IN None
July NNP None
1996 CD None
, , None
198 CD Size
patients NNS None
with IN None
non-operable JJ Condition
NSCLC NNP Condition
and CC None
measurable JJ None
disease NN None
without IN None
previous JJ None
chemotherapy NN None
entered VBD None
the DT None
trial NN None
. . None
Ninety NNP Size
nine CD Size
patients NNS None
( ( None
group NN None
A DT None
) ) None
-DOCSTART- -X- N

ovarian JJ Condition
cancer NN Condition
patients NNS Condition
with IN Condition
a DT Condition
pathologically RB Condition
complete JJ Condition
remission NN Condition
after IN Condition
platinum-based JJ Condition
intravenous JJ Condition
chemotherapy NN Condition
. . Condition
patients NNS None
who WP None
achieve VBP None
a DT None
pathological JJ None
complete JJ None
remission NN None
( ( None
pCR NN None
) ) None
at IN None
second-look NN None
surgery NN None
but CC None
in IN None
whom WP None
a DT None
high JJ None
rate NN None
of IN None
relapses NNS None
still RB None
occurs VBZ None
. . None
Between JJ None
1988 CD None
and CC None
1997 CD None
, , None
153 CD None
patients NNS None
in IN None
pCR JJ None
following VBG None
platinum-based JJ None
intravenous JJ None
CT NNP None
includes VBZ None
16 CD None
patients NNS None
who WP None
were VBD None
not RB None
eligible JJ None
and CC None
17 CD None
patients NNS None
who WP None
had VBD None
protocol NN None
violations NNS None
. . None
two CD None
groups NNS None
were VBD None
well RB None
balanced VBN None
in IN None
terms NNS None
of IN None
age NN None
( ( None
median JJ None
= VBZ None
55 CD None
years NNS None
) ) None
, , None
performance NN None
status NN None
( ( None
78 CD None
% NN None
P.S NNP None
. . None
O NNP Condition
) ) Condition
, , Condition
FIGO NNP Condition
stage NN Condition
( ( Condition
96 CD Condition
% NN Condition
stage NN Condition
III NNP Condition
) ) Condition
, , Condition
histology NN Condition
( ( Condition
serous JJ Condition
in IN Condition
66 CD Condition
% NN Condition
) ) Condition
, , Condition
grade VBD Condition
( ( Condition
2 CD Condition
or CC Condition
3 CD Condition
in IN Condition
80 CD Condition
% NN Condition
) ) Condition
, , Condition
and CC Condition
residuum NN Condition
before RB Condition
intravenous JJ Condition
CT NNP Condition
( ( Condition
> $ Condition
1 CD Condition
cm NN Condition
in IN Condition
40 CD Condition
% NN Condition
) ) Condition
. . Condition
-DOCSTART- -X- N

steroid-dependent JJ Condition
asthma NN Condition
. . None
subjects NNS None
with IN None
corticosteroid-requiring JJ None
asthma NN Condition
. . None
Ten CD Size
subjects NNS Size
completed VBD None
the DT None
study NN None
. . None
subjects NNS None
with IN None
steroid-dependent JJ None
asthma NN Condition
. . None
-DOCSTART- -X- N

weaned JJ None
alcoholics NNS Condition
. . None
Five CD Size
hundred JJ Size
and CC Size
sixty-nine JJ Size
alcoholics NNS Condition
One CD Size
hundred CD Size
and CC Size
eighty-one JJ Size
patients NNS None
in IN None
the DT None
CA NNP None
group NN None
versus VBD None
175 CD Size
in IN None
the DT None
placebo NN None
group NN None
completed VBD None
the DT None
three-month JJ None
study NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
left JJ None
ventricular JJ None
systolic JJ None
dysfunction NN None
and CC None
heart NN None
failure NN None
receiving VBG None
either CC None
candesartan NN None
or CC None
enalapril NN None
or CC None
both DT None
. . None
patients NNS None
with IN None
systolic JJ None
dysfunction NN None
and CC None
heart NN None
failure NN None
receiving VBG None
therapeutic JJ None
inhibition NN None
of IN None
the DT None
renin-angiotensin-aldosterone NN None
system NN None
. . None
768 CD None
treated JJ None
patients NNS None
with IN None
heart NN None
failure NN None
measured VBN None
at IN None
baseline NN None
treated JJ None
patients NNS None
with IN None
heart NN None
failure NN None
-DOCSTART- -X- N

bone NN Condition
marrow NN Condition
transplantation NN Condition
patients NNS None
. . None
patients NNS None
undergoing VBG None
BMT NNP None
Twenty-four JJ Size
BMT NNP None
patients NNS None
patients NNS Condition
undergoing VBG Condition
high-dose JJ Condition
chemotherapy NN Condition
-DOCSTART- -X- N

Labeo NNP None
rohita JJ None
fingerlings NNS None
reared VBD None
at IN None
higher JJR None
water NN None
temperature NN None
. . None
Labeo NNP None
rohita VBP None
fingerlings NNS None
exposed VBN None
to TO None
an DT None
elevated JJ None
temperature NN None
( ( None
ET NNP None
) ) None
of IN None
33 CD None
?C NNS None
. . None
Two CD None
hundred VBD None
and CC None
seventy JJ None
fingerlings NNS None
( ( None
6.71 CD None
? . None
0.32 CD None
g NN None
) ) None
were VBD None
responses NNS None
of IN None
L. NNP None
rohita JJ None
fingerlings NNS None
to TO None
status NN None
of IN None
L. NNP None
rohita JJ None
fingerlings NNS None
reared VBD None
at IN None
higher JJR None
water NN None
temperature NN None
. . None
-DOCSTART- -X- N

myocardial JJ None
revascularization NN None
in IN None
elderly JJ None
patients NNS None
: : None
elderly JJ None
patients NNS None
elderly JJ None
patients NNS None
. . None
160 CD None
patients NNS None
aged VBD None
more JJR None
than IN None
70 CD None
years NNS None
scheduled VBN None
to TO None
undergo VB None
isolated JJ None
myocardial JJ None
revascularization NN None
. . None
80 CD None
patients NNS None
undergoing JJ None
total JJ None
arterial JJ None
revascularization NN None
( ( None
left VBN None
internal JJ None
thoracic NN None
artery NN None
on IN None
left JJ None
anterior JJ None
descending VBG None
coronary JJ None
artery NN None
plus CC None
radial JJ None
artery NN None
) ) None
80 CD None
patients NNS None
undergoing JJ None
standard JJ None
coronary JJ None
artery NN None
bypass NN None
graft NN None
surgery NN None
( ( None
left VBN None
internal JJ None
thoracic NN None
artery NN None
on IN None
left JJ None
anterior JJ None
descending VBG None
coronary JJ None
artery NN None
plus CC None
saphenous JJ None
veins NNS None
) ) None
. . None
Preoperative JJ None
characteristics NNS None
and CC None
risk NN None
factors NNS None
( ( None
EuroSCORE NNP None
: : None
group NN None
1 CD None
= $ None
7.9 CD None
vs NN None
group NN None
2 CD None
= $ None
8.1 CD None
) ) None
, , None
number NN None
of IN None
grafted JJ None
coronary JJ None
vessels NNS None
( ( None
group NN None
1 CD None
= $ None
2.4 CD None
vs NN None
group NN None
2 CD None
= $ None
2.5 CD None
) ) None
, , None
aortic JJ None
crossclamping NN None
time NN None
( ( None
group NN None
1 CD None
= $ None
37 CD None
+/- JJ None
7 CD None
minutes NNS None
vs JJ None
group NN None
2 CD None
= $ None
38 CD None
+/- JJ None
7 CD None
minutes NNS None
) ) None
, , None
ventilation NN None
time NN None
( ( None
group NN None
1 CD None
= $ None
22 CD None
+/- JJ None
12 CD None
hours NNS None
vs JJ None
group NN None
2 CD None
= $ None
23 CD None
+/- JJ None
11 CD None
hours NNS None
) ) None
, , None
intensive JJ None
care NN None
unit NN None
stay NN None
( ( None
group NN None
1 CD None
= $ None
39 CD None
+/- JJ None
10 CD None
hours NNS None
vs JJ None
group NN None
2 CD None
= $ None
40 CD None
+/- JJ None
9 CD None
hours NNS None
) ) None
, , None
and CC None
hospital JJ None
mortality NN None
( ( None
group NN None
1 CD None
= RB None
3.8 CD None
% NN None
vs NN None
group NN None
2 CD None
= RB None
5 CD None
% NN None
) ) None
were VBD None
comparable JJ None
between IN None
the DT None
groups NNS None
. . None
elderly JJ None
patients NNS None
. . None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
mixed JJ Condition
dyslipidaemia NN Condition
and CC Condition
metabolic JJ Condition
syndrome NN Condition
metabolic JJ None
syndrome NN None
( ( None
MetS NNP None
) ) None
patients NNS Condition
with IN Condition
mixed JJ Condition
dyslipidaemia NN Condition
and CC Condition
MetS NNP Condition
patients NNS Condition
with IN Condition
MetS NNP Condition
were VBD None
included VBN None
-DOCSTART- -X- N

laryngeal JJ Condition
squamous JJ Condition
cell NN Condition
carcinomas NN Condition
patients NNS None
with IN None
laryngeal JJ None
squamous JJ None
cell NN None
carcinoma NN None
( ( None
LSCC NNP Condition
) ) None
36.7 CD None
% NN None
( ( None
37 CD Size
of IN None
102 CD Size
) ) None
patients NNS None
-DOCSTART- -X- N

49 CD Size
patients NNS None
( ( None
22 CD Size
women NNS Sex
, , None
27 CD Size
men NNS Sex
, , None
mean JJ None
age NN None
43.7 CD Age
[ JJ None
21-65 JJ Age
] NNP None
years NNS None
) ) None
with IN None
Hodgkin NNP Condition
's POS Condition
disease NN Condition
median NN None
of IN None
5.37 CD None
( ( None
2-10 JJ Age
) ) None
years NNS None
after IN None
the DT None
end NN None
of IN None
chemotherapy NN None
( ( None
given VBN None
according VBG None
to TO None
the DT None
COPP/ABVD NNP None
scheme NN None
, , None
with IN None
or CC None
without IN None
mediastinal JJ None
irradiation NN None
) ) None
successfully RB None
treated VBN None
patients NNS None
with IN None
Hodgkin NNP Condition
's POS Condition
disease NN Condition
-DOCSTART- -X- N

primary JJ None
and CC None
repeat VB None
lower JJR None
extremity NN None
amputation NN None
: : None
African JJ None
Americans NNPS None
Randomly NNP None
selected VBD None
medical JJ None
records NNS None
were VBD None
reviewed VBN None
for IN None
248 CD None
African JJ None
American NNP None
, , None
30 CD None
Hispanic NNP None
, , None
and CC None
235 CD None
white JJ None
or CC None
other-race JJ None
patients NNS None
undergoing VBG Condition
above- JJ Condition
or CC Condition
below-knee JJ Condition
amputation NN Condition
between IN None
1995 CD None
and CC None
2003 CD None
at IN None
three CD None
Chicago NNP None
teaching VBG None
hospitals NNS None
. . None
African JJ None
American JJ None
amputees NNS None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
. . None
children NNS Age
with IN None
autistic JJ None
disorder NN None
who WP None
have VBP None
serious JJ None
behavior NN None
problems NNS None
Forty-eight JJ Size
children NNS Age
( ( Age
5 CD Age
years NNS Age
to TO Age
16 CD Age
years NNS Age
, , Age
5 CD Age
months NNS Age
) ) Age
who WP None
showed VBD None
behavioral JJ None
improvement NN None
during IN None
acute JJ None
treatment NN None
with IN None
risperidone NN None
children NNS None
with IN None
autistic JJ None
disorder NN None
-DOCSTART- -X- N

humans NNS None
. . None
randomized JJ None
study NN None
of IN None
patients NNS None
with IN None
gastric JJ None
, , None
pancreatic JJ None
and CC None
colorectal JJ None
cancer NN None
randomized JJ None
study NN None
of IN None
patients NNS None
with IN None
resectable JJ None
cancer NN None
of IN None
the DT None
colon NN None
of IN None
patients NNS None
with IN None
malignant JJ None
melanoma NN None
and CC None
stage NN None
IV NNP None
carcinoma NN None
of IN None
the DT None
breast NN None
of IN None
patients NNS None
with IN None
advanced JJ None
gastrointestinal JJ None
cancer NN None
selective JJ None
stimulation NN None
of IN None
the DT None
immune NN None
system NN None
with IN None
NED NNP None
137 CD None
-DOCSTART- -X- N

coronary JJ None
spasm NN None
13 CD None
patients NNS None
with IN None
vasospastic JJ None
angina NNS None
All DT None
patients NNS None
had VBD None
a DT None
coronary JJ None
spasm NN None
during IN None
coronary JJ None
arteriography NN None
, , None
either CC None
spontaneously RB None
or CC None
ergometrine-induced JJ None
. . None
patients NNS None
with IN None
vasospastic JJ None
angina NN None
. . None
-DOCSTART- -X- N

heart NN Condition
failure NN Condition
patients NNS None
with IN None
preserved JJ Condition
ejection NN Condition
fraction NN Condition
. . None
heart NN Condition
failure NN Condition
patients NNS Condition
with IN Condition
preserved JJ Condition
ejection NN Condition
fraction NN Condition
( ( Condition
HFpEF NNP Condition
) ) None
chronic JJ None
outstanding JJ None
and CC None
stable JJ None
patients NNS None
with IN None
HFpEF NNP Condition
. . None
All NNP None
patients NNS None
underwent VBD None
an DT None
echocardiogram NN None
and CC None
radioisotopic NN None
ventriculography NN None
rest/exercise NN None
L-arginine NNP None
group NN None
( ( None
n JJ None
= VBZ None
15 CD None
; : None
8 CD None
g/day NN None
) ) None
; : None
and CC None
the DT None
citrulline NN None
malate NN None
group NN None
( ( None
n JJ None
= VBZ None
15 CD None
; : None
citrulline NN None
to TO None
patients NNS None
with IN None
HFpEF NNP None
improved VBD None
-DOCSTART- -X- N

anthracycline-pretreated JJ Condition
patients NNS Condition
with IN Condition
advanced JJ Condition
breast NN Condition
cancer NN Condition
: : None
metastatic JJ None
breast NN None
cancer NN None
anthracycline-pretreated JJ Condition
patients NNS Condition
with IN Condition
MBC NNP Condition
. . None
women NNS Sex
with IN None
anthracycline-pretreated JJ Condition
MBC NNP Condition
. . None
-DOCSTART- -X- N

endotracheal JJ Condition
intubation NN Condition
: : None
impending JJ None
hypoxic NN Condition
patient NN None
. . None
Three CD Size
hundred VBD Size
adult NN Age
patients NNS None
were VBD None
enrolled VBN None
in IN None
this DT None
study NN None
. . None
difficult JJ Condition
intubation NN Condition
-DOCSTART- -X- N

lower JJR Condition
rectal NN Condition
cancer NN Condition
] NNP None
locally RB Condition
advanced VBN Condition
lower JJR Condition
rectal JJ Condition
cancer NN Condition
. . None
Sixty NNP Size
lower JJR Condition
rectal JJ Condition
cancer NN Condition
patients NNS None
30 CD Size
patients NNS None
-DOCSTART- -X- N

selected VBN Condition
patients NNS Condition
following VBG Condition
aortocoronary JJ Condition
bypass NN Condition
operation NN Condition
] NNP None
Two CD None
groups NNS None
of IN None
9 CD Size
male JJ Sex
patients NNS None
( ( None
age NN Age
: : Age
59 CD Age
+/- JJ Age
4 CD Age
and CC Age
56 CD Age
+/- JJ Age
6 CD Age
years NNS Age
, , Age
resp NN Age
. . None
) ) None
each DT None
trained VBN None
on IN None
bicycle NN None
ergometer JJ None
start NN None
on IN None
post-operative JJ None
days NNS None
24 CD None
and CC None
26 CD None
, , None
resp NN None
. . None
-DOCSTART- -X- N

in IN Condition
patients NNS Condition
with IN Condition
acute JJ Condition
respiratory NN Condition
distress NN Condition
syndrome NN Condition
. . Condition
acute JJ Condition
respiratory NN Condition
distress JJ Condition
syndrome JJ Condition
patients NNS Condition
acute JJ Condition
respiratory NN Condition
distress JJ Condition
syndrome JJ Condition
patients NNS Condition
Intensive JJ None
Care NNP None
Unit NNP None
of IN None
the DT None
Ohio NNP None
State NNP None
University NNP None
Medical NNP None
Center NNP None
. . None
A DT None
total NN None
of IN None
67 CD None
patients NNS None
were VBD None
enrolled VBN None
who WP None
met VBD None
defined VBN None
criteria NNS None
for IN None
acute NN None
lung NN None
injury/acute NN None
respiratory NN None
distress JJ None
syndrome NN None
. . None
-DOCSTART- -X- N

smoking VBG Condition
cessation NN Condition
total NN None
of IN None
1,524 CD Size
smokers NNS None
( ( None
649 CD Size
men NNS Sex
and CC None
875 CD Size
women NNS Sex
) ) None
of IN None
average JJ Age
age NN Age
45.1 CD Age
years NNS Age
-DOCSTART- -X- N

Twenty-six JJ Size
patients NNS None
with IN None
relapsed JJ Condition
Hodgkin NNP Condition
's POS Condition
disease NN Condition
Their PRP$ None
median JJ None
age NN None
was VBD None
31 CD Age
years NNS None
( ( None
range NN None
, , None
22-59 JJ None
) ) None
and CC None
14 CD Size
patients NNS None
were VBD None
males NNS Sex
and CC None
12 CD Size
were VBD None
females NNS Sex
. . None
Patients NNS None
were VBD None
pretreated VBN None
with IN None
a DT None
median NN None
of IN None
eight CD None
cycles NNS None
of IN None
cytotoxic NN None
chemotherapy NN None
, , None
while IN None
18 CD Size
patients NNS None
had VBD None
undergone JJ None
extended JJ None
field NN None
irradiation NN None
. . None
patients NNS None
with IN None
Hodgkin NNP Condition
's POS Condition
disease NN Condition
-DOCSTART- -X- N

acute JJ Condition
non-lymphocytic JJ Condition
leukaemia NN Condition
. . Condition
Between NNP None
January NNP None
1975 CD None
and CC None
December NNP None
1977 CD None
, , None
264 CD None
adult NN None
patients NNS None
with IN None
acute JJ None
non-lymphocytic JJ None
leukaemia NN None
entered VBD None
the DT None
Australian JJ None
National NNP None
Leukaemia NNP None
Trial NNP None
. . None
251 CD None
evaluable JJ None
patients NNS None
-DOCSTART- -X- N

postmenopausal JJ Condition
women NNS Condition
who WP None
receive VBP None
endocrine NN None
treatment NN None
for IN None
highly RB None
endocrine-responsive JJ None
, , None
node-positive JJ None
breast NN Condition
cancer NN Condition
Breast NNP Condition
Cancer NNP Condition
Study NNP None
Group NNP None
postmenopausal JJ Condition
women NNS Condition
with IN None
highly RB None
endocrine JJ None
responsive JJ None
breast NN Condition
cancer NN Condition
. . None
12-93 JJ Condition
, , None
postmenopausal JJ Condition
women NNS Condition
with IN None
node-positive JJ None
, , None
estrogen JJ None
receptor NN None
( ( None
ER NNP None
) ) None
-positive CD None
or CC None
ER-negative JJ None
, , None
operable JJ None
breast NN Condition
cancer NN Condition
893 CD Size
patients NNS None
with IN None
endocrine-responsive JJ Size
disease NN Size
, , None
and CC None
according VBG None
to TO None
prospectively RB None
defined JJ None
categories NNS None
of IN None
ER NNP None
, , None
age NN None
and CC None
nodal JJ None
status NN None
. . None
postmenopausal JJ Condition
women NNS Condition
with IN None
endocrine-responsive JJ None
breast NN Condition
cancer NN Condition
-DOCSTART- -X- N

multiple JJ Condition
myeloma NN Condition
. . None
newly RB None
diagnosed VBN None
multiple JJ Condition
myeloma NN Condition
524 CD Size
( ( None
90.2 CD None
% NN None
) ) None
of IN None
581 CD Size
patients NNS None
enrolled VBN None
in IN None
the DT None
NMSG NNP None
4/90 CD None
completed VBD None
the DT None
first JJ None
questionnaire NN None
, , None
and CC None
484 CD Size
( ( None
83.3 CD None
% NN None
) ) None
completed VBD None
all DT None
questionnaires NNS None
given VBN None
to TO None
them PRP None
. . None
-DOCSTART- -X- N

HIV NNP Condition
seropositive JJ Condition
subjects NNS None
with IN None
elevated JJ None
TNF NNP None
. . None
HIV-seropositive JJ Condition
patients NNS None
persons NNS None
with IN None
elevated JJ None
TNF-alpha NNP None
. . None
Six NNP Size
HIV-seropositive JJ Condition
subjects NNS None
with IN None
elevated JJ None
amounts NNS None
of IN None
TNF-alpha NNP None
in IN None
plasma NN None
at IN None
least JJS None
at IN None
two CD None
occasions NNS None
-DOCSTART- -X- N

hepatocellular JJ Condition
carcinoma NN Condition
. . None
patients NNS None
with IN None
curative JJ None
resection NN None
of IN None
HCC NNP Condition
; : None
818 CD None
days NNS None
, , None
21 CD Size
patients NNS None
received VBD None
one CD None
dose NN None
and CC None
19 CD Size
received VBD None
four CD None
doses NNS None
, , None
with IN None
10 CD None
( ( None
47.6 CD None
% NN None
) ) None
and CC None
eight CD None
( ( None
42.1 CD None
% NN None
) ) None
recurrences NNS None
, , None
respectively RB None
. . None
two CD None
groups NNS None
. . None
-DOCSTART- -X- N

50 CD Size
patients NNS None
allocated VBD None
randomly RB None
to TO None
undergo VB None
anaesthesia NN None
with IN None
either DT None
artificial JJ None
ventilation NN None
with IN None
isoflurane NN None
and CC None
nitrous JJ None
oxide NN None
in IN None
oxygen NN None
and CC None
atracurium NN None
( ( None
group NN None
A NNP None
) ) None
or CC None
spontaneous JJ None
ventilation NN None
with IN None
isoflurane NN None
and CC None
nitrous JJ None
oxide NN None
in IN None
oxygen NN None
( ( None
group NN None
B NNP None
) ) None
. . None
-DOCSTART- -X- N

after IN None
lumbar JJ Condition
disk NN Condition
surgery NN Condition
: : None
patient JJ None
outcome NN None
after IN Condition
lumbar NN Condition
disk NN Condition
surgery NN Condition
. . None
Departments NNS None
of IN None
physical JJ None
medicine NN None
and CC None
rehabilitation NN None
and CC None
orthopedics NNS None
at IN None
a DT None
Finnish JJ None
hospital NN None
. . None
Patients NNPS None
( ( None
N=126 NNP Size
) ) None
were VBD None
randomized VBN None
-DOCSTART- -X- N

patients NNS None
with IN None
periarthritis NN Condition
pain NN None
of IN None
the DT None
shoulder NN None
previously RB None
unsuccessfully RB None
treated VBN None
with IN None
nonsteroidal JJ None
anti-inflammatory JJ None
drugs NNS None
other JJ None
than IN None
diclofenac NNS None
and CC None
oxaprozin NN None
. . None
eligible JJ None
patients NNS None
with IN None
periarthritis NN Condition
of IN None
the DT None
shoulder NN None
patient-assessed JJ None
shoulder NN Condition
pain NN Condition
patient-assessed JJ None
quality NN None
of IN None
life NN None
on IN None
the DT None
Short-Form-36 NNP Size
( ( None
SF-36 NNP Size
) ) None
Acute NNP None
Health NNP None
Survey NNP None
Patients NNS None
also RB None
assessed VBD None
the DT None
overall JJ None
efficacy NN None
of IN None
oxaprozin NN None
as IN None
superior JJ None
to TO None
that DT None
of IN None
diclofenac NN None
patients NNS None
with IN None
periarthritis NN Condition
of IN None
the DT None
shoulder NN None
refractory NN None
-DOCSTART- -X- N

primary JJ Condition
coronary JJ Condition
intervention NN Condition
: : Condition
Fifty NNP Size
consecutive JJ None
patients NNS None
entered VBD None
the DT None
myocardial JJ None
contrast NN None
echocardiography NN None
( ( None
MCE NNP None
) ) None
substudy NN None
of IN None
the DT None
REMEDIA NNP None
( ( None
Randomized NNP None
Evaluation NNP None
of IN None
the DT None
Effect NNP None
of IN None
Mechanical NNP None
Reduction NNP None
of IN None
Distal NNP None
Embolization NNP None
by IN None
Thrombus NNP None
Aspiration NNP None
in IN None
Primary NNP None
and CC None
Rescue NNP None
Angioplasty NNP None
) ) None
trial NN None
total NN None
of IN None
25 CD Size
patients NNS None
were VBD None
randomized VBN None
to TO None
be VB None
pretreated VBN None
with IN None
thrombus JJ None
aspiration NN None
before IN None
PCI NNP None
of IN None
the DT None
culprit NN None
lesion NN None
and CC None
25 CD Size
received JJ None
standard JJ None
PCI NNP None
. . None
-DOCSTART- -X- N

women NNS None
with IN None
suspected JJ None
coronary JJ None
artery NN None
disease NN None
: : None
women NNS None
with IN None
suspected JJ None
coronary JJ None
artery NN None
disease NN None
( ( None
CAD NNP None
) ) None
. . None
women NNS None
with IN None
suspected JJ None
CAD NNP None
. . None
symptomatic JJ None
women NNS None
with IN None
suspected JJ None
CAD NNP None
, , None
an DT None
interpretable JJ None
ECG NNP None
, , None
and CC None
?5 NNP None
metabolic JJ None
equivalents NNS None
on IN None
the DT None
Duke NNP None
Activity NNP None
Status NNP None
Index NNP None
to TO None
total NN None
of IN None
824 CD None
women NNS None
were VBD None
symptomatic JJ None
women NNS None
with IN None
suspected JJ None
CAD NNP None
. . None
-DOCSTART- -X- N

ADHD NNP Condition
children NNS Condition
: : Condition
17 CD None
boys NNS None
( ( None
ages IN Age
7.8-9.9 CD Age
years NNS Age
) ) Age
with IN None
attention NN None
deficit NN None
hyperactivity NN None
disorder NN None
( ( None
ADHD NNP None
) ) None
-DOCSTART- -X- N

autistic JJ Condition
behavior NN Condition
. . Condition
Eight NNP Age
young JJ Age
adults NNS Age
who WP Age
were VBD Age
diagnosed VBN Age
with IN Age
autism NN Age
-DOCSTART- -X- N

symptomatic JJ Condition
atrial JJ Condition
fibrillation NN Condition
. . None
atrial JJ Condition
fibrillation NN Condition
( ( Condition
AF NNP Condition
) ) None
Patients NNS None
with IN None
symptomatic JJ Condition
paroxysmal NN Condition
or CC None
persistent JJ Condition
AF NNP Condition
who WP None
had VBD None
converted VBN None
to TO None
sinus VB Condition
rhythm NN Condition
( ( Condition
SR NNP Condition
) ) None
Of IN None
the DT None
141 CD Size
patients NNS None
from IN None
36 CD Size
participating VBG None
centers NNS None
, , None
47 CD Size
were VBD Size
given VBN Size
aprindine NN Size
, , None
47 CD Size
digoxin NN Size
, , None
and CC None
47 CD Size
were VBD Size
on IN Size
placebo NN Size
. . None
-DOCSTART- -X- N

intubation NN None
patient NN None
who WP None
may MD None
have VB None
a DT None
cervical JJ None
( ( None
C NNP None
) ) None
-spine VBP None
injury NN None
Thirty-six NNP None
healthy JJ None
patients NNS None
were VBD None
randomized VBN None
to TO None
participate VB None
in IN None
a DT None
crossover JJ None
trial NN None
-DOCSTART- -X- N

pre-school JJ None
children NNS None
with IN None
autism NN None
. . None
autism NN None
against IN None
ordinary JJ None
care NN None
, , None
with IN None
28 CD None
children NNS None
aged VBN None
2-5 CD None
years NNS None
-DOCSTART- -X- N

Thirty NNP Size
patients NNS Condition
undergoing VBG Condition
primary JJ Condition
ICD NNP Condition
implantation NN Condition
or CC Condition
pulse JJ Condition
generator NN Condition
replacement NN Condition
14 CD Size
patients NNS None
-DOCSTART- -X- N

renal JJ Condition
transplant NN Condition
recipients NNS None
with IN None
Renin-Angiotensin NNP Condition
system NN Condition
polymorphisms NN Condition
. . None
renal JJ Condition
transplant NN Condition
recipients NNS None
with IN None
RAS NNP Condition
polymorphisms NNS Condition
. . Condition
76 CD Size
recipients NNS None
were VBD None
recruited VBN None
randomly RB None
-DOCSTART- -X- N

advanced JJ None
chronic JJ None
venous JJ None
insufficiency NN None
( ( None
CVI NNP None
) ) None
832 CD None
patients NNS None
stratified VBN None
by IN None
CEAP NNP None
classification NN None
. . None
300 CD None
patients NNS None
with IN None
C4 NNP None
CVI NNP None
, , None
119 CD None
patients NNS None
with IN None
C5 NNP None
CVI NNP None
, , None
and CC None
413 CD None
patients NNS None
with IN None
C6 NNP None
CVI NNP None
. . None
92 CD None
patients NNS None
with IN None
C4 NNP None
disease NN None
92 CD None
randomized VBD None
patients NNS None
with IN None
C4 NNP None
disease NN None
832 CD None
patients NNS None
-DOCSTART- -X- N

polyarteritis NN None
nodosa NN None
and CC None
Churg-Strauss NNP None
syndrome NN None
patients NNS None
with IN None
factors NNS None
predicting VBG None
poor JJ None
prognosis NN None
. . None
sixty-two JJ None
patients NNS None
. . None
severe JJ Condition
polyarteritis NN Condition
nodosa NN Condition
( ( Condition
PAN NNP Condition
) ) Condition
and CC Condition
Churg-Strauss JJ Condition
syndrome NN Condition
( ( Condition
CSS NNP Condition
) ) Condition
62 CD Size
patients NNS Size
were VBD None
randomly RB None
assigned VBN None
to TO None
receive VB None
either DT None
prednisone NN None
plus CC None
cyclophosphamide NN None
( ( None
intravenous JJ None
bolus NN None
) ) None
( ( None
group NN None
A NNP None
; : None
n JJ None
= NNP None
28 CD None
) ) None
or CC None
prednisone JJ None
plus CC None
cyclophosphamide JJ None
( ( None
intravenous JJ None
bolus NN None
) ) None
plus CC None
plasma JJ None
exchanges NNS None
( ( None
group NN None
B NNP None
; : None
n CC None
= VB None
34 CD None
) ) None
as IN None
first-line JJ None
treatment NN None
for IN None
severe JJ None
PAN NNP None
or CC None
CSS NNP None
. . None
-DOCSTART- -X- N

Asian JJ None
males NNS None
with IN None
erectile JJ Condition
dysfunction NN Condition
and CC None
cardiovascular JJ Condition
risk NN Condition
. . None
Asian JJ None
males NNS None
with IN None
erectile JJ Condition
dysfunction NN Condition
( ( None
ED NNP Condition
) ) None
and CC None
one CD None
or CC None
more JJR None
of IN None
the DT None
co-morbidities NNS None
, , None
mild-to-moderate JJ None
hypertension NN Condition
, , None
dyslipidemia NN Condition
, , None
and CC None
diabetes NNS Condition
. . None
One CD Size
hundred CD Size
and CC Size
fifty VB Size
five CD Size
male JJ Size
subjects NNS None
-DOCSTART- -X- N

Fifteen JJ Condition
males NNS Condition
with IN Condition
angiographic JJ Condition
evidence NN Condition
of IN Condition
coronary JJ Condition
heart NN Condition
disease NN Condition
and CC Condition
stable JJ Condition
, , Condition
exercise-induced JJ Condition
angina NN Condition
pectoris NN Condition
-DOCSTART- -X- N

nine CD None
normal JJ None
students NNS None
with IN None
and CC None
without IN None
the DT None
anticonvulsant JJ None
drug NN None
phenytoin NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
small-cell JJ None
lung NN None
cancer NN None
( ( None
SCLC NNP None
) ) None
SCLC NNP None
patients NNS None
with IN None
brain NN None
metastases NNS None
One CD None
hundred VBD None
twenty NN None
eligible JJ None
patients NNS None
-DOCSTART- -X- N

acute JJ None
anterior JJ None
ST-elevation NNP None
myocardial JJ None
infarction NN None
. . None
patients NNS None
with IN None
acute JJ None
anterior JJ None
STEMI NNP None
receiving VBG None
thrombolytic JJ None
treatment NN None
( ( None
TLT NNP None
) ) None
. . None
101 CD None
patients NNS None
with IN None
acute JJ None
anterior JJ None
STEMI NNP None
who WP None
were VBD None
candidate NN None
for IN None
TLT NNP None
-DOCSTART- -X- N

eclampsia NN None
: : None
Between NNP None
January NNP None
and CC None
June NNP None
2011 CD None
, , None
98 CD None
eclamptic JJ None
mothers NNS None
presenting VBG None
at IN None
the DT None
labour JJ None
ward NN None
of IN None
the DT None
University NNP None
of IN None
Maiduguri NNP None
Teaching NNP None
Hospital NNP None
-DOCSTART- -X- N

labor NN None
analgesia NN None
: : None
parturients NNS None
undergoing VBG None
labor NN None
during IN None
epidural JJ None
analgesia NN None
. . None
Sixty-one JJ None
parturients NNS None
undergoing VBG None
labor NN None
selected VBN None
for IN None
delivery NN None
with IN None
epidural JJ None
analgesia NNS None
-DOCSTART- -X- N

15 CD Size
healthy JJ None
volunteers NNS None
. . None
subjects NNS None
wore VBP None
from IN None
0900 CD None
to TO None
1700 CD None
h NN None
an DT None
upper JJ None
removable JJ None
acrylic JJ None
appliance NN None
holding VBG None
one CD None
polished JJ None
enamel NN None
and CC None
one CD None
polished VBN None
dentine NN None
specimen NNS None
. . None
-DOCSTART- -X- N

presyncopal JJ Condition
symptom NN Condition
limited VBD Condition
lower JJR Condition
body NN Condition
negative JJ Condition
pressure NN Condition
exposures NNS None
. . None
11 CD Size
subjects NNS None
were VBD None
exposed VBN None
to TO None
4 CD None
PSL-LBNP JJ Condition
tests NNS None
; : None
nine CD Size
subjects NNS None
-DOCSTART- -X- N

severely RB None
malnourished VBN None
head NN Condition
and CC Condition
neck NN Condition
cancer NN Condition
patients NNS None
: : None
malnourished VBN None
head NN Condition
and CC Condition
neck NN Condition
cancer NN Condition
patients NNS None
undergoing VBG None
surgery NN None
. . None
49 CD Size
Malnourished NNP None
( ( None
weight JJ None
loss NN None
> VBZ None
10 CD None
% NN None
) ) None
head NN Condition
and CC Condition
neck NN Condition
cancer NN Condition
patients NNS None
who WP None
were VBD None
included VBN None
in IN None
a DT None
nutrition NN None
intervention NN None
trial NN None
patients NNS None
-DOCSTART- -X- N

the DT None
third JJ None
trimester NN None
of IN None
pregnancy NN None
in IN None
diabetic JJ Condition
and CC None
non-diabetic JJ Condition
women NNS Sex
. . Sex
ten JJ Size
non-diabetic JJ Condition
, , None
ten JJ Size
chemical JJ Condition
diabetic NN Condition
and CC None
five CD Size
juvenile NN Condition
diabetic JJ Condition
women NNS Sex
in IN None
late JJ None
pregnancy NN None
. . None
None NN None
of IN None
the DT None
women NNS Sex
had VBD None
been VBN None
treated VBN None
with IN None
beta-sympathomimetic JJ None
drugs NNS None
earlier RBR None
in IN None
their PRP$ None
pregnancy NN None
. . None
juvenile NN Condition
diabetic NN Condition
non-diabetic JJ Condition
chemical JJ Condition
diabetic JJ Condition
women NNS Sex
. . None
patients NNS None
showing VBG None
criteria NNS None
of IN None
potential JJ None
diabetes NNS Condition
. . None
-DOCSTART- -X- N

zirconia NN Condition
copings NNS Condition
Zirconia NNP None
cores NNS None
zirconia NN None
copings NNS None
single JJ None
crowns NNS None
9 CD Size
stone NN None
cast NN None
replicas NN None
were VBD None
fabricated VBN None
, , None
numbered VBN None
, , None
and CC None
distributed VBD None
into IN None
8 CD None
ceramic JJ None
ZrO NNP None
( ( None
2 CD None
) ) None
CAD/CAM NNP None
system NN None
groups NNS None
( ( None
Lava NNP None
Frame NNP None
0.3 CD None
and CC None
0.5 CD None
, , None
IPS NNP None
e.max VBZ None
ZirCAD NNP None
, , None
VITA NNP None
YZ NNP None
, , None
Procera NNP None
AllZircon NNP None
, , None
Digizon NNP None
, , None
DC NNP None
Zircon NNP None
, , None
and CC None
Cercon NNP None
Base NNP None
) ) None
and CC None
to TO None
a DT None
lithium NN None
disilicate JJ None
glass-ceramic JJ None
control NN None
group NN None
( ( None
IPS NNP None
e.max RB None
Press NNP None
) ) None
using VBG None
a DT None
simple JJ None
computer-generated JJ None
randomization NN None
method NN None
. . None
ZrO NNP None
( ( None
2 CD None
) ) None
copings NNS None
zirconia NN None
copings NNS None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
isolated JJ Condition
hypertriglyceridemia NN Condition
patients NNS Condition
with IN Condition
isolated JJ Condition
hypertriglyceridemia NN Condition
39 CD None
patients NNS None
with IN None
elevated JJ None
triglyceride NN None
levels NNS None
and CC None
peripheral JJ None
artery NN None
sclerosis NN None
patients NNS None
with IN None
isolated JJ None
hypertriglyceridemia NN None
patients NNS None
with IN None
elevated JJ None
triglyceride NN None
levels NNS None
-DOCSTART- -X- N

peripheral JJ None
stage NN None
IA NNP None
non-small NN None
cell NN None
lung NN None
cancer NN None
: : None
patients NNS None
with IN None
operable JJ None
stage NN None
IA NNP None
lung NN None
cancer NN None
. . None
a DT None
planning NN None
study NN None
was VBD None
performed VBN None
in IN None
26 CD None
stage NN None
I PRP None
patients NNS None
, , None
of IN None
which WDT None
22 CD None
were VBD None
stage NN None
1A CD None
-DOCSTART- -X- N

patients NNS None
with IN None
HCV NNP Condition
genotype NN Condition
1 CD Condition
infection NN None
treated VBN None
with IN None
peginterferon NN None
alpha-2a JJ None
plus CC None
ribavirin JJ None
. . None
patients NNS None
with IN None
chronic JJ Condition
hepatitis NN Condition
C NNP Condition
treatment-naive JJ None
patients NNS None
with IN None
HCV NNP None
genotype NN None
1 CD None
infection NN None
enrolled VBN None
in IN None
a DT None
large JJ None
expanded JJ None
access NN None
programme NN None
. . None
Eight NNP Size
hundred VBD Size
and CC Size
ninety-one JJ Size
patients NNS None
treated VBD None
for IN None
48 CD None
weeks NNS None
with IN None
an DT None
initial JJ None
ribavirin NN None
dose NN None
of IN None
800 CD None
or CC None
1000/1200 CD None
mg/day NNS None
genotype JJ None
1 CD None
patients NNS None
. . None
-DOCSTART- -X- N

depressed JJ None
, , None
distensible JJ None
acne NN None
scars NNS None
moderate JJ None
to TO None
severe VB None
, , None
depressed JJ None
, , None
distensible JJ None
facial JJ None
acne NN None
scars NNS None
subjects NNS None
with IN None
bilateral JJ None
moderate NN None
to TO None
severe VB None
acne JJ None
scarring NN None
; : None
subjects NNS None
Subjects NNS Size
( ( Size
n JJ Size
= NNP Size
99 CD Size
) ) Size
-DOCSTART- -X- N

pre-school JJ Condition
children NNS Condition
with IN Condition
autism NN Condition
. . None
pre-school JJ None
children NNS None
with IN None
autism NN None
. . None
Twenty-four CD None
children NNS None
meeting VBG None
ICD-10 NNP None
criteria NNS None
for IN None
childhood NN None
autism NN None
( ( Age
mean JJ Age
age NN Age
= VBD Age
23 CD Age
months NNS Age
) ) Age
parent NN None
training NN None
group NN None
three CD None
parents NNS None
in IN None
the DT None
local JJ None
services NNS None
group NN None
pre-school JJ None
children NNS None
with IN None
autism NN None
-DOCSTART- -X- N

among IN None
individuals NNS None
with IN None
heart NN Condition
failure NN Condition
Boston NNP None
, , None
Massachusetts NNP None
individuals NNS None
with IN None
stable JJ Condition
heart NN Condition
failure NN Condition
. . None
100 CD Size
patients NNS None
Among IN None
patients NNS None
undergoing VBG None
treatment NN None
for IN None
heart NN None
failure NN None
, , None
-DOCSTART- -X- N

human JJ Condition
essential JJ Condition
hypertension NN Condition
. . Condition
human JJ Condition
subjects NNS Condition
with IN Condition
essential JJ Condition
hypertension NN Condition
. . Condition
Twenty NNP Condition
male NN Condition
, , Condition
white JJ Condition
patients NNS Condition
( ( Condition
27 CD Condition
+/- JJ Condition
1 CD Condition
years NNS Condition
) ) Condition
with IN Condition
mild JJ Condition
essential JJ Condition
hypertension NN Condition
( ( Condition
143 CD Condition
+/- JJ Condition
11/95 CD Condition
+/- JJ Condition
6 CD Condition
mm NN Condition
Hg NNP Condition
) ) Condition
-DOCSTART- -X- N

randomized JJ None
multicenter NN None
study NN None
SAKK NNP None
40/81 CD None
: : None
curatively RB Condition
resected VBN Condition
colorectal JJ Condition
cancer NN Condition
] NN None
Between JJ None
1981 CD None
and CC None
1987 CD None
, , None
533 CD Size
patients NNS None
from IN None
9 CD None
institutions NNS None
have VBP None
been VBN None
entered VBN None
in IN None
a DT None
randomized JJ None
trial NN None
469 CD None
evaluable JJ None
patients NNS None
at IN None
a DT None
median JJ None
follow-up NN None
of IN None
5.8 CD None
years NNS None
revealed VBD None
110 CD None
recurrences NNS None
in IN None
the DT None
control NN None
and CC None
94 CD None
recurrences NNS None
in IN None
the DT None
infusion NN None
group NN None
. . None
-DOCSTART- -X- N

young JJ Condition
autistic JJ Condition
children NNS Condition
. . Condition
23 CD None
autistic JJ None
children NNS None
-DOCSTART- -X- N

functional JJ Condition
dyspepsia NN Condition
: : None
patients NNS None
with IN None
functional JJ Condition
dyspepsia NN Condition
, , None
supporting VBG None
the DT None
use NN None
of IN None
prokinetic JJ None
drugs NNS None
for IN None
treatment NN None
of IN None
dyspeptic JJ Condition
symptoms NNS Condition
. . None
1298 CD Size
patients NNS None
were VBD None
enrolled VBN None
in IN None
a DT None
double-blind JJ None
multicentric NN None
study NN None
carried VBD None
out IN None
in IN None
45 CD None
Italian JJ None
Gastroenterology NNP None
Departments NNP None
. . None
Patients NNS None
were VBD None
selected VBN None
on IN None
the DT None
basis NN None
of IN None
: : None
a DT None
) ) None
occurrence NN None
in IN None
the DT None
last JJ None
4 CD None
weeks NNS None
of IN None
at IN None
least JJS None
5/10 CD None
selected VBN None
symptoms NNS None
( ( None
anorexia NN Condition
, , None
nausea NN Condition
, , None
vomiting VBG Condition
, , None
upper JJ Condition
abdominal JJ Condition
pain NN Condition
, , None
postprandial JJ Condition
bloating NN Condition
, , None
abdominal JJ Condition
fullness NN Condition
, , None
early JJ Condition
satiety NN Condition
, , None
belching NN Condition
, , None
heartburn NN Condition
, , None
regurgitation NN Condition
) ) None
, , None
severity NN None
of IN None
which WDT None
should MD None
reach/exceed VB None
a DT None
total JJ None
score NN None
of IN None
8 CD None
, , None
as IN None
assessed VBN None
by IN None
a DT None
specific JJ None
scale NN None
ranging VBG None
from IN None
0 CD None
( ( None
absent NN None
) ) None
to TO None
3 CD None
( ( None
severe JJ None
) ) None
; : None
b VBN None
) ) None
normal JJ None
results NNS None
of IN None
routine JJ None
biochemical NN None
, , None
ultrasound NN None
and CC None
endoscopic JJ None
examinations NNS None
. . None
-DOCSTART- -X- N

autism NN Condition
children NNS Condition
: : Condition
autism NN None
children NNS None
. . None
Sixty NNP None
qualified VBD None
autism NN None
children NNS None
autism NN None
children NNS None
autism NN None
children NNS None
-DOCSTART- -X- N

Fifty-six NNP Size
consecutive JJ None
patients NNS None
scheduled VBN Condition
for IN Condition
knee NN Condition
arthroscopy NN Condition
thirty-one JJ Size
female NN Sex
patients NNS Size
and CC Size
twenty-five JJ Size
male NN Sex
patients NNS Size
with IN None
a DT None
combined JJ None
average JJ Age
age NN Age
of IN Age
fifty JJ Age
years NNS Age
and CC None
an DT None
average JJ None
body NN None
mass NN None
index NN None
of IN None
30.9 CD None
. . None
-DOCSTART- -X- N

normal JJ Condition
pregnancy NN Condition
. . None
several JJ None
mammalian JJ None
species NNS None
. . None
pregnant JJ Condition
women NNS Sex
pregnant JJ Condition
women NNS Sex
with IN None
abnormally RB None
increased VBN Condition
3-HIA JJ Condition
excretion NN Condition
. . None
Twenty-six NNP Size
pregnant JJ Condition
women NNS Sex
with IN None
increased JJ Condition
3-HIA JJ Condition
excretion NN Condition
were VBD None
studied VBN None
in IN None
a DT None
randomized JJ None
, , None
placebo-controlled JJ None
trial NN None
; : None
normal JJ None
pregnancy NN None
-DOCSTART- -X- N

blood NN Condition
pressure NN Condition
taking VBG Condition
randomized VBD None
162 CD Size
first-year JJ Age
medical JJ Age
students NNS Age
into IN None
four CD None
groups NNS None
that WDT None
received VBD None
different JJ None
lead-in JJ None
statements NNS None
before IN None
measuring VBG Condition
blood NN Condition
pressure NN Condition
on IN None
a DT None
manikin JJ None
simulator NN None
. . None
Student NNP Age
-DOCSTART- -X- N

patients NNS None
with IN None
diabetes NNS Condition
mellitus NNS Condition
in IN None
the DT None
LIFE-study NNP None
] NNP None
patients NNS None
with IN None
hypertension NN None
and CC None
diabetes VBZ None
diabetic JJ None
patients NNS None
. . None
A NNP None
total NN None
of IN None
1195 CD Size
patients NNS None
in IN None
the DT None
LIFE-study NNP None
had VBD None
diabetes NNS None
patients NNS None
had VBD None
ECG-verified JJ None
left JJ None
ventricular NN None
hypertrophy NN None
, , None
mean JJ None
age NN None
67 CD Age
years NNS None
, , None
blood NN None
pressure NN None
177/96 CD None
mmHg NN None
after IN None
two CD None
weeks NNS None
placebo JJ None
run-in JJ None
period NN None
. . None
Patients NNS None
were VBD None
followed VBN None
for IN None
at IN None
least JJS None
four CD None
years NNS None
( ( None
mean JJ None
4.7 CD None
years NNS None
) ) None
. . None
patients NNS None
with IN None
hypertension NN Condition
and CC None
diabetes NNS None
. . None
-DOCSTART- -X- N

retinopathy NN Condition
of IN Condition
prematurity NN Condition
( ( None
ROP NNP None
) ) None
40 CD Size
preterm JJ None
infants NNS Age
undergoing VBG None
ROP NNP Condition
screening NN None
. . None
neonatal JJ None
intensive JJ None
units NNS None
for IN None
infants NNS None
undergoing VBG None
routine JJ None
ROP NNP None
screening VBG None
exams NNS None
. . None
RESULT NNP None
Forty NNP None
preterm NN None
infants NNS None
were VBD None
included VBN None
in IN None
the DT None
study NN None
. . None
in IN None
preterm JJ None
infants NNS None
of IN None
-DOCSTART- -X- N

stroke NN Condition
: : None
Tinzaparin NNP None
in IN None
Acute NNP Condition
Ischaemic NNP Condition
Stroke NNP Condition
Trial NNP None
( ( None
TAIST NNP None
) ) None
. . None
High NNP Condition
blood NN Condition
pressure NN Condition
( ( None
BP NNP None
) ) None
in IN None
acute JJ Condition
stroke NN Condition
using VBG None
data NNS None
from IN None
TAIST NNP None
trial NN None
. . None
high JJ None
systolic JJ None
BP NNP None
, , None
mean JJ None
arterial JJ None
pressure NN None
, , None
pulse JJ None
pressure NN None
, , None
and CC None
BP NNP None
variability NN None
. . None
acute JJ Condition
ischemic JJ Condition
stroke NN Condition
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
hepatitis JJ Condition
C NNP Condition
virus-related JJ Condition
chronic JJ Condition
liver NN Condition
disease NN Condition
. . None
101 CD Size
patients NNS None
with IN None
hepatitis JJ Condition
C NNP Condition
virus-related JJ Condition
chronic JJ Condition
liver NN Condition
disease NN Condition
. . None
Forty-nine JJ None
patients NNS None
were VBD None
assigned VBN None
to TO None
receive VB None
UDCA NNP None
( ( None
450 CD None
mg/day NN None
) ) None
over IN None
a DT None
period NN None
of IN None
6 CD None
months NNS None
and CC None
52 CD None
to TO None
receive VB None
no DT None
treatment NN None
. . None
patients NNS None
who WP None
fail VBP None
to TO None
respond VB None
to TO None
interferon VB None
therapy NN None
. . None
-DOCSTART- -X- N

autism NN None
. . None
autistic JJ None
adults NNS None
Twenty NNP None
typical JJ None
and CC None
19 CD None
autistic JJ None
adults NNS None
donated VBD None
to TO None
charity NN None
and CC None
to TO None
a DT None
person NN None
, , None
both DT None
when WRB None
alone RB None
that IN None
autistic JJ None
adults NNS None
did VBD None
autistic JJ None
individuals NNS None
. . None
while IN None
individuals NNS None
with IN None
autism NN None
may MD None
-DOCSTART- -X- N

patients NNS None
insufficiently RB Condition
controlled VBN Condition
on IN None
timolol NN None
patients NNS None
with IN None
open JJ None
angle NN Condition
glaucoma NN Condition
or CC Condition
ocular JJ Condition
hypertension NN Condition
where WRB None
IOP NNP None
is VBZ None
not RB None
adequately RB None
controlled VBN None
with IN None
timolol NN None
53 CD Size
patients NNS None
with IN None
primary JJ Condition
open JJ Condition
angle NN Condition
glaucoma NN Condition
, , None
capsular JJ Condition
glaucoma NN Condition
, , None
or CC None
ocular JJ Condition
hypertension NN Condition
with IN None
an DT None
IOP NNP None
of IN None
at IN None
least JJS None
21 CD None
mmHg NN None
on IN None
current JJ None
therapy NN None
-DOCSTART- -X- N

patients NNS None
presenting VBG None
with IN None
acute JJ Condition
myocardial JJ Condition
infarction NN Condition
ST-elevation NNP None
acute JJ None
myocardial JJ None
infarction NN None
( ( None
AMI NNP Condition
) ) None
. . None
Patients NNS None
with IN None
ischemic JJ Condition
chest NN Condition
pain NN Condition
with IN None
duration NN None
< NN None
or CC None
=12 NN None
hours NNS None
and CC None
no DT None
contraindication NN None
for IN None
thrombolytic JJ None
therapy NN None
were VBD None
included VBN None
. . None
Between NNP None
October NNP None
1993 CD None
and CC None
August NNP None
1995 CD None
, , None
58 CD Size
patients NNS None
were VBD None
randomly RB None
assigned VBN None
to TO None
streptokinase VB None
( ( None
SK NNP None
) ) None
and CC None
54 CD Size
patients NNS None
to TO None
primary JJ None
PCI NNP None
. . None
Median JJ None
age NN None
( ( None
interquartile JJ None
range NN None
) ) None
was VBD None
68 CD Age
( ( None
58 CD None
, , None
75 CD None
) ) None
years NNS None
, , None
29 CD None
% NN None
were VBD None
women NNS Sex
, , None
and CC None
78 CD None
% NN None
of IN None
the DT None
patients NNS None
met VBD None
at IN None
least JJS None
one CD None
criterion NN None
for IN None
not RB None
low JJ None
risk NN None
AMI NNP None
( ( None
anterior JJ None
location NN None
, , None
age NN None
> VBD Age
70 CD Age
years NNS Age
old JJ None
, , None
previous JJ None
MI NNP None
, , None
systolic JJ None
blood NN None
pressure NN None
< VBZ None
100 CD None
mm NN None
Hg NNP None
, , None
and/or JJ None
heart NN None
rate NN None
> VBD None
100 CD None
bpm NN None
) ) None
. . None
-DOCSTART- -X- N

migraine NN Condition
. . None
acute JJ None
migraine NN None
attacks NNS None
acute JJ None
migraine NN None
attacks NNS None
in IN None
ten JJ None
patients NNS None
. . None
60 CD None
attacks NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
low JJ Condition
back RB Condition
pain NN Condition
: : None
low JJ Condition
back RB Condition
pain NN Condition
in IN None
managed VBN None
care NN None
patients NNS None
receiving VBG None
medical JJ None
or CC None
chiropractic JJ None
care NN None
. . None
low VB Condition
back RB Condition
pain NN Condition
patients NNS None
A NNP None
total NN None
of IN None
681 CD Size
low JJ Condition
back RB Condition
pain NN Condition
patients NNS None
presenting VBG None
to TO None
a DT None
managed-care JJ None
facility NN None
681 CD Size
patients NNS None
, , None
610 CD Size
( ( None
89.6 CD None
% NN None
) ) None
were VBD None
followed VBN None
through IN None
18 CD None
months NNS None
. . None
-DOCSTART- -X- N

commercial JJ None
beef NN None
cattle NNS None
at IN None
housing NN None
. . None
commercial JJ None
beef NN None
cattle NNS None
with IN None
three CD None
fluke NNS None
and CC None
worm VB None
combination NN None
products NNS None
with IN None
different JJ None
administration NN None
profiles NNS None
. . None
Young NNP None
beef NN None
cattle NNS None
( ( None
n JJ None
= NNP None
270 CD None
) ) None
weighing VBG None
approximately RB None
400 CD None
kg NNS None
were VBD None
allocated VBN None
to TO None
batches NNS None
of IN None
five CD None
-DOCSTART- -X- N

major JJ None
burns NNS None
major JJ None
burns NNS None
, , None
patients NNS None
nutritional JJ None
deficiencies NNS None
including VBG None
trace NN None
element NN None
( ( None
TE NNP None
) ) None
deficiencies NNS None
. . None
major JJ None
burns NNS None
. . None
21 CD None
patients NNS None
aged VBD None
35 CD None
+/- JJ None
11 CD None
y NN None
( ( None
x JJ None
+/- NNP None
SD NNP None
) ) None
with IN None
burns NNS None
on IN None
45 CD None
+/- JJ None
21 CD None
% NN None
of IN None
their PRP$ None
body NN None
surface NN None
area NN None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
acute JJ Condition
lymphoblastic JJ Condition
leukemia NN Condition
in IN None
first JJ None
bone NN None
marrow NN None
relapse NN None
. . None
relapsed JJ None
acute NN Condition
lymphoblastic JJ Condition
leukemia NN Condition
( ( None
ALL DT Condition
) ) None
. . None
45 CD Size
patients NNS None
with IN None
ALL NNP None
in IN None
first JJ None
bone NN None
marrow NN None
relapse NN None
enrolled VBD None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ Condition
active JJ Condition
hepatitis NN Condition
C. NNP Condition
85 CD Size
patients NNS None
with IN None
chronic JJ Condition
active JJ Condition
hepatitis NN Condition
C NNP Condition
55 CD Size
patients NNS None
who WP None
responded VBD None
to TO None
interferon VB None
by IN None
normalization NN None
of IN None
alanine JJ None
transaminase NN None
( ( None
ALT NNP None
) ) None
, , None
median JJ None
APC NNP None
before IN None
treatment NN None
was VBD None
0.47 CD None
( ( None
range NN None
, , None
0.12 CD None
to TO None
0.98 CD None
; : None
normal JJ None
range NN None
, , None
0.34 CD None
to TO None
1.02 CD None
mL/min/kg NNS None
body NN None
wt NN None
) ) None
, , None
a DT None
value NN None
that WDT None
was VBD None
significantly RB None
greater JJR None
than IN None
in IN None
30 CD None
nonresponders NNS None
( ( None
0.23 CD None
; : None
0.08 CD None
to TO None
0.67 CD None
mL/min/kg NNS None
body NN None
wt NN None
, , None
P NNP None
< NNP None
.001 NNP None
) ) None
A DT None
second JJ None
, , None
independent JJ None
group NN None
of IN None
43 CD Size
patients NNS None
-DOCSTART- -X- N

human JJ None
tears NNS None
and CC None
saliva NN None
. . None
tears NNS None
and CC None
saliva NN None
of IN None
healthy JJ Condition
individuals NNS None
. . None
The DT None
subjects NNS None
( ( None
n JJ Size
= NNP Size
45 CD Size
) ) None
-DOCSTART- -X- N

pulmonary JJ Condition
arterial JJ Condition
hypertension NN Condition
in IN Condition
children NNS Condition
. . Condition
children NNS Age
. . Age
children NNS Age
with IN Age
PAH NNP Age
. . Age
29 CD None
children NNS None
treated VBN None
with IN None
inhaled JJ None
treprostinil NN None
for IN None
?6 JJ None
weeks NNS None
was VBD None
performed VBN None
. . None
4 CD None
patients NNS None
because IN None
targeted JJ None
PAH NNP None
therapy NN None
in IN None
children NNS None
and CC None
had VBD None
warranted VBN None
in IN None
pediatric JJ None
patients NNS None
with IN None
PAH NNP None
. . None
-DOCSTART- -X- N

diabetes NNS Condition
. . None
60 CD Size
individuals NNS None
with IN None
diabetes NNS Condition
-DOCSTART- -X- N

children NNS None
previously RB None
randomly RB None
assigned VBN None
to TO None
intrathecal JJ None
methotrexate NN None
childhood NN None
acute NN None
lymphoblastic JJ Condition
leukemia NN Condition
. . None
children NNS Age
with IN None
acute JJ Condition
lymphoblastic JJ Condition
leukemia NN Condition
( ( Condition
ALL NNP Condition
) ) Condition
, , None
CNS NNP None
prophylaxis NN None
consists VBZ None
of IN None
either DT None
intrathecal JJ None
( ( None
IT NNP None
) ) None
methotrexate NN None
or CC None
triple VB None
IT NNP None
therapy NN None
( ( None
ie JJ None
, , None
methotrexate NN None
with IN None
both DT None
cytarabine NN None
and CC None
hydrocortisone NN None
) ) None
. . None
171 CD Size
children NNS Age
with IN None
standard-risk JJ None
ALL NNP None
, , None
age NN Age
1 CD Age
to TO Age
9.99 CD Age
years NNS Age
at IN None
diagnosis NN None
, , None
previously RB None
randomly RB None
assigned VBN None
to TO None
IT NNP None
methotrexate NNP None
( ( None
n JJ None
= NNP None
82 CD None
) ) None
or CC None
to TO None
triple VB None
IT NNP None
therapy NN None
( ( None
n JJ None
= NNP None
89 CD None
) ) None
on IN None
CCG NNP None
1952 CD None
, , None
underwent JJ None
neurocognitive JJ None
evaluation NN None
by IN None
a DT None
licensed JJ None
psychologist NN None
at IN None
a DT None
mean NN None
of IN None
5.9 CD None
years NNS None
after IN None
random JJ None
assignment NN None
. . None
Patients NNPS None
who WP None
received VBD None
IT NNP None
methotrexate NNP None
19.5 CD None
% NN None
of IN None
children NNS None
in IN None
the DT None
IT NNP None
methotrexate NNP None
group NN None
sex NN None
or CC None
age NN None
at IN None
diagnosis NN None
. . None
-DOCSTART- -X- N

hypertensive JJ None
non-diabetic JJ None
patients NNS None
. . None
13 CD None
hypertensive JJ None
patients NNS None
. . None
-DOCSTART- -X- N

children NNS None
with IN None
autism NN Condition
: : None
children NNS Age
aged VBD Age
2 CD Age
to TO Age
7 CD Age
years NNS Age
95 CD Size
participants NNS None
children NNS None
with IN None
autism NN None
. . None
children NNS None
with IN None
autism NN None
. . None
-DOCSTART- -X- N

children NNS Sex
with IN None
a DT None
pervasive JJ Condition
development NN Condition
disorder NN Condition
. . None
children NNS Age
with IN None
autism NN Condition
or CC None
a DT None
related JJ Condition
pervasive JJ Condition
developmental NN Condition
disorder NN Condition
( ( Condition
PDD NNP Condition
) ) Condition
children NNS None
with IN None
PDD NNP Condition
-DOCSTART- -X- N

dogs NNS None
. . None
healthy JJ None
dogs NNS None
. . None
Nine NNP None
adult NN None
dogs NNS None
( ( None
beagle NN None
and CC None
beagle NN None
cross NN None
breeds NNS None
) ) None
, , None
four CD None
males NNS None
and CC None
five CD None
females NNS None
. . None
-DOCSTART- -X- N

parent NN Condition
young JJ Condition
children NNS Condition
with IN Condition
autism NN Condition
spectrum NN Condition
disorder NN Condition
. . Condition
parent NN None
32 CD None
young JJ None
children NNS None
with IN None
a DT None
confirmed JJ None
diagnosis NN None
of IN None
autism NN None
spectrum NN None
disorder NN None
( ( None
ASD NNP None
) ) None
. . None
children NNS None
with IN None
ASD NNP None
-DOCSTART- -X- N

patient NN None
's POS None
historical JJ None
triptan NN None
response NN None
. . None
patients NNS None
respond NN None
to TO None
triptans NNS None
and CC None
telcagepant NN None
. . None
migraine NN None
patients NNS None
who WP None
can MD None
not RB None
be VB None
adequately RB None
helped VBN None
with IN None
triptans NNS None
patients NNS None
' POS None
self-reported JJ None
historical JJ None
triptan NN None
response NN None
( ( None
HTR NNP None
) ) None
: : None
( ( None
1 CD None
) ) None
good JJ None
HTR NNP None
( ( None
N NNP None
= NNP None
660 CD None
) ) None
: : None
response NN None
in IN None
75-100 CD None
% NN None
of IN None
attacks NNS None
; : None
( ( None
2 CD None
) ) None
intermediate NN None
HTR NNP None
( ( None
N NNP None
= NNP None
248 CD None
) ) None
: : None
response NN None
in IN None
25-74 JJ None
% NN None
of IN None
attacks NNS None
; : None
( ( None
3 CD None
) ) None
poor JJ None
HTR/no NNP None
use NN None
( ( None
N NNP None
= NNP None
407 CD None
) ) None
: : None
response NN None
in IN None
< JJ None
25 CD None
% NN None
of IN None
attacks NNS None
, , None
or CC None
patient NN None
did VBD None
not RB None
take VB None
triptans NNS None
. . None
the DT None
last JJ None
subgroup NN None
comprised VBD None
mainly RB None
( ( None
91 CD None
% NN None
) ) None
patients NNS None
who WP None
reported VBD None
that IN None
they PRP None
did VBD None
not RB None
take VB None
triptans NNS None
, , None
but CC None
it PRP None
was VBD None
not RB None
known VBN None
whether IN None
these DT None
patients NNS None
were VBD None
triptan-na?ve JJ None
or CC None
had VBD None
previously RB None
used VBN None
triptans NNS None
and CC None
stopped VBD None
taking VBG None
them PRP None
. . None
-DOCSTART- -X- N

chronic JJ Condition
low JJ Condition
back RB Condition
pain NN Condition
: : None
chronic JJ Condition
low JJ Condition
back RB Condition
pain NN Condition
( ( None
CLBP NNP None
) ) None
. . None
Primary NNP None
contact NN None
, , None
college NN None
out-patient JJ None
clinic NN None
. . None
174 CD Size
patients NNS None
aged VBN None
20-60 JJ Age
yr NNS None
-DOCSTART- -X- N

healthy JJ Condition
subjects NNS None
. . None
healthy JJ Condition
subjects NNS None
. . None
healthy JJ Condition
young JJ None
male JJ Sex
subjects NNS None
RESULTS NNP None
Fourteen JJ None
subjects NNS None
were VBD None
enrolled VBN None
and CC None
completed VBN None
the DT None
study NN None
-DOCSTART- -X- N

Participants NNS None
consisted VBD None
of IN None
those DT None
subjects NNS None
in IN None
the DT None
WAIS-III JJ None
standardization NN None
sample NN None
that WDT None
has VBZ None
complete JJ None
demographic JJ None
data NNS None
( ( None
N=2,401 NNP None
) ) None
and CC None
were VBD None
randomly RB None
divided VBN None
into IN None
two CD None
groups NNS None
. . None
patients NNS None
with IN None
known VBN None
or CC None
suspected VBN None
neurological JJ None
dysfunction NN None
-DOCSTART- -X- N

patients NNS None
with IN None
hip JJ Condition
osteoarthritis NN Condition
: : None
patients NNS None
with IN None
hip NN None
osteoarthritis NN None
( ( None
OA NNP Condition
) ) None
. . None
patients NNS None
from IN None
hospitals NNS None
, , None
primary JJ None
health NN None
care NN None
and CC None
advertisement NN None
, , None
Oslo NNP None
, , None
Norway NNP None
. . None
109 CD Size
patients NNS None
with IN None
radiographic JJ None
and CC None
symptomatic JJ None
hip NN None
OA NNP None
with IN None
mild NN None
to TO None
moderate VB None
symptoms NNS None
. . None
-DOCSTART- -X- N

Early-stage JJ None
squamous JJ Condition
cell NN Condition
carcinoma NN Condition
of IN None
the DT None
oropharynx NN None
: : None
oropharyngeal JJ None
squamous JJ None
cell NN None
carcinoma NN None
( ( None
OPSCC NNP Condition
) ) None
comprises NNS None
OPSCC NNP None
patients NNS None
who WP None
would MD None
be VB None
unlikely JJ None
to TO None
require VB None
chemotherapy JJ None
post-resection NN None
: : None
Tumor NN None
stage NN None
T1-T2 NN None
with IN None
likely JJ None
negative JJ None
margins NNS None
at IN None
surgery NN None
; : None
Nodal NNP None
stage NN None
N0-2 NNP None
, , None
?3 NNP None
cm NN None
in IN None
size NN None
, , None
with IN None
no DT None
evidence NN None
of IN None
extranodal JJ None
extension NN None
on IN None
imaging VBG None
. . None
Participants NNS None
A DT None
sample NN None
of IN None
68 CD None
patients NNS None
-DOCSTART- -X- N

40 CD Size
individuals NNS None
were VBD None
randomly RB None
assigned VBN None
-DOCSTART- -X- N

healthy JJ None
subjects NNS None
and CC None
asymptomatic JJ None
carriers NNS None
of IN None
the DT None
acute JJ None
intermittent NN None
porphyria NNS None
gene NN None
who WP None
have VBP None
increased VBN None
porphyrin NN None
precursor NN None
excretion NN None
. . None
healthy JJ None
subjects NNS None
and CC None
asymptomatic JJ None
porphobilinogen NN None
deaminase-deficient JJ None
subjects NNS None
with IN None
high JJ None
concentrations NNS None
of IN None
porphobilinogen NN None
, , None
the DT None
substrate NN None
of IN None
porphobilinogen NN None
deaminase NN None
. . None
Forty NNP None
individuals NNS None
participated VBD None
in IN None
this DT None
two-part JJ None
study NN None
: : None
20 CD None
asymptomatic JJ None
porphobilinogen NN None
deaminase-deficient JJ None
subjects NNS None
( ( None
both DT None
male NN None
and CC None
female NN None
) ) None
with IN None
> NN None
or CC None
=4 JJ None
times NNS None
the DT None
upper JJ None
reference NN None
urinary JJ None
porphobilinogen NN None
level NN None
, , None
and CC None
20 CD None
healthy JJ None
male JJ None
subjects NNS None
. . None
Part VB None
A NNP None
included VBD None
12 CD None
asymptomatic JJ None
porphobilinogen NN None
deaminase-deficient JJ None
subjects NNS None
, , None
and CC None
the DT None
enzyme NN None
was VBD None
administered VBN None
in IN None
an DT None
open-label JJ None
, , None
single-dose JJ None
design NN None
. . None
Part NN None
B NNP None
included VBD None
20 CD None
asymptomatic JJ None
porphobilinogen NN None
deaminase-deficient JJ None
subjects NNS None
and CC None
20 CD None
healthy JJ None
subjects NNS None
. . None
patients NNS None
with IN None
acute JJ None
intermittent NN None
porphyria NN None
. . None
-DOCSTART- -X- N

duodenal JJ Condition
ulcer NN Condition
duodenal JJ Condition
ulcer NN Condition
. . None
171 CD Size
patients NNS None
with IN None
endoscopically RB None
confirmed VBN None
duodenal JJ Condition
ulcers NNS Condition
. . None
two CD None
treatment NN None
groups NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
cancer NN Condition
. . None
opioid-tolerant JJ None
patients NNS None
with IN None
cancer NN None
. . None
conducted VBN None
in IN None
opioid-tolerant JJ None
male NN Sex
and CC Sex
female JJ Sex
patients NNS None
( ( None
aged VBN None
> NN Age
or CC Age
=17 CD Age
years NNS None
) ) None
with IN None
BTcP NNP None
. . None
131 CD Size
patients NNS None
entered VBD None
the DT None
titration NN None
phase NN None
, , None
of IN None
whom WP None
61 CD Size
were VBD None
included VBN None
in IN None
the DT None
primary JJ None
efficacy NN None
analysis NN None
. . None
opioid-tolerant JJ None
patients NNS None
with IN None
cancer NN None
. . None
-DOCSTART- -X- N

eyes NNS None
with IN None
severe JJ None
proliferative JJ Condition
vitreoretinopathy NN Condition
. . None
117 CD Size
of IN None
404 CD Size
eyes NNS None
( ( None
29 CD None
% NN None
) ) None
with IN None
severe JJ None
proliferative JJ Condition
vitreoretinopathy NN Condition
( ( None
> CD None
or CC None
= VB None
C-3 NNP None
, , None
full-thickness JJ None
retinal JJ None
folds NNS None
in IN None
three CD None
or CC None
more JJR None
quadrants NNS None
) ) None
Forty-six JJ Size
eyes NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
advanced JJ None
non-small-cell JJ None
lung NN None
cancer NN None
. . None
patients NNS None
with IN None
advanced JJ None
non-small-cell JJ None
lung NN None
cancer NN None
( ( None
NSCLC NNP None
) ) None
. . None
Between NNP None
January NNP None
1995 CD None
and CC None
April NNP None
1996 CD None
, , None
414 CD None
patients NNS None
with IN None
stage NN None
IIIB NNP None
or CC None
IV NNP None
NSCLC NNP None
were VBD None
randomized VBN None
to TO None
received VB None
either RB None
a DT None
control NN None
arm NN None
of IN None
high-dose JJ None
cisplatin NN None
( ( None
100 CD None
mg/m NN None
( ( None
2 CD None
) ) None
) ) None
or CC None
a DT None
combination NN None
of IN None
paclitaxel NN None
( ( None
175 CD None
mg/m NN None
( ( None
2 CD None
) ) None
, , None
3-hour JJ None
infusion NN None
) ) None
and CC None
cisplatin NN None
( ( None
80 CD None
mg/m NN None
( ( None
2 CD None
) ) None
) ) None
every DT None
21 CD None
days NNS None
. . None
-DOCSTART- -X- N

six CD None
umbilical JJ None
cord NN None
care NN None
regimens VBZ None
. . None
Two CD None
hundred VBD None
and CC None
seventy VB None
one CD None
infants NNS None
were VBD None
enrolled VBN None
in IN None
a DT None
study NN None
to TO None
compare VB None
six CD None
different JJ None
methods NNS None
of IN None
treating VBG None
the DT None
umbilical JJ None
cord NN None
. . None
-DOCSTART- -X- N

infants NNS None
. . None
40 CD None
children NNS None
younger JJR None
than IN None
4 CD None
yr NNS None
having VBG None
elective JJ None
abdominal JJ None
surgery NN None
under IN None
general JJ None
anaesthesia NN None
supplemented VBN None
with IN None
either DT None
systemic JJ None
opioids NNS None
or CC None
extradural JJ None
bupivacaine NN None
. . None
-DOCSTART- -X- N

of IN None
ulcerative JJ None
colitis NN None
. . None
Overall NNP None
, , None
826 CD None
patients NNS None
were VBD None
randomized VBN None
and CC None
dosed VBN None
. . None
-DOCSTART- -X- N

antiretroviral JJ Condition
initiation NN Condition
A5224s NNP None
was VBD None
a DT None
sub-study NN None
of IN None
A5202 NNP None
, , None
a DT None
prospective JJ None
trial NN None
of IN None
1857 CD None
ART-naive JJ None
participants NNS None
randomized VBN None
to TO None
blinded VBN None
abacavir-lamivudine NN None
( ( None
ABC/3TC NNP None
) ) None
or CC None
tenofovir JJ None
DF-emtricitabine NNP None
( ( None
TDF/FTC NNP None
) ) None
with IN None
open-label JJ None
efavirenz NN None
( ( None
EFV NNP None
) ) None
or CC None
atazanavir-ritonavir JJ None
( ( None
ATV/r NNP None
) ) None
. . None
269 CD None
participants NNS None
: : None
85 CD None
% NN None
men NNS None
, , None
47 CD None
% NN None
white JJ None
non-Hispanic JJ None
, , None
median JJ None
age NN None
38 CD None
years NNS None
, , None
HIV-1 NNP None
RNA NNP None
4.6 CD None
log10 NN None
copies/ml NN None
, , None
and CC None
CD4 NNP None
cell VBP None
count NN None
233 CD None
cells/?l NN None
. . None
-DOCSTART- -X- N

15 CD Size
hypertensive JJ Condition
patients NNS None
-DOCSTART- -X- N

polycythemia NN Condition
vera NN Condition
and CC None
the DT None
other JJ None
myeloproliferative JJ Condition
diseases NNS Condition
to TO None
accumulate VB None
well RB Size
over IN Size
1,000 CD Size
patients NNS None
with IN None
these DT None
various JJ None
disorders NNS None
-DOCSTART- -X- N

Siriraj NNP None
Asthma NNP Condition
Control NNP None
Siriraj NNP None
Hospital NNP None
. . None
20 CD Size
randomized JJ None
asthmatic JJ Condition
patients NNS None
in IN None
the DT None
clinic NN None
including VBG None
the DT None
record NN None
of IN None
3 CD None
visits NNS None
for IN None
each DT None
subject NN None
. . None
20 CD None
patients NNS None
with IN None
age NN None
29-73 CD Age
years NNS None
Thai NNP None
asthmatic JJ Condition
patients NNS None
. . None
-DOCSTART- -X- N

acute JJ Condition
myeloid NN Condition
leukaemia NN Condition
. . None
Thirty-two JJ Size
adults NNS None
with IN None
acute JJ None
myeloid NN None
leukaemia NN None
( ( None
AML NNP None
) ) None
-DOCSTART- -X- N

colorectal JJ Condition
adenoma NN Condition
recurrence NN Condition
colorectal JJ Condition
neoplasms NNS Condition
in IN None
some DT None
human JJ None
studies NNS None
. . None
1,859 CD None
participants NNS None
of IN None
the DT None
Polyp NNP None
Prevention NNP None
Trial NNP None
. . None
in IN None
women NNS Sex
. . Sex
-DOCSTART- -X- N

serum NN Condition
retinol JJ Condition
concentration NN Condition
of IN None
Filipino NNP None
children NNS None
4-7 CD Age
years NNS None
old JJ None
. . None
542 CD Size
Filipino NNP None
children NNS None
aged VBD None
4 CD Age
to TO Age
7 CD Age
years NNS None
-DOCSTART- -X- N

autism NN Condition
. . None
METHODS NNP None
A NNP None
sample NN None
of IN None
14 CD None
high-functioning JJ None
adolescent NN None
and CC None
adult NN None
participants NNS None
with IN None
autism NN None
and CC None
14 CD None
matched VBN None
controls NNS None
RESULTS JJ None
Participants NNS None
with IN None
autism NN None
autism NN None
participants NNS None
. . None
-DOCSTART- -X- N

early JJ None
stage NN None
cancer NN None
of IN None
the DT None
esophagus NN None
. . None
100 CD None
consecutive JJ None
endoscopic NN None
resections NNS None
were VBD None
performed VBN None
in IN None
72 CD Size
patients NNS Size
with IN None
early JJ Condition
stage NN Condition
esophageal JJ Condition
cancer NN Condition
. . None
patients NNS None
who WP None
had VBD None
prior JJ Condition
endoscopic NN Condition
treatment NN Condition
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
pervasive JJ Condition
developmental NN Condition
disorders NNS Condition
-DOCSTART- -X- N

human JJ None
oocytes NNS None
274 CD None
oocytes NNS None
obtained VBN None
from IN None
46 CD Size
couples NNS None
undergoing JJ None
infertility NN Condition
treatment NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
bulimia JJ Condition
nervosa NN Condition
. . None
patients NNS None
with IN None
bulimia JJ Condition
nervosa NNS Condition
The DT None
study NN None
included VBD None
93 CD Size
patients NNS None
. . None
-DOCSTART- -X- N

CABG NNP Condition
patients NNS None
. . None
CABG NNP Condition
patients NNS None
Forty-three JJ Size
CABG NNP Condition
patients NNS None
-DOCSTART- -X- N

40 CD Size
subjects NNS None
20 CD Size
subjects NNS None
served VBD None
as IN None
a DT None
control NN None
group NN None
supportive JJ None
periodontal NN None
care NN None
SPT NNP None
20 CD Size
subjects NNS None
-DOCSTART- -X- N

advanced-stage JJ Condition
idiopathic JJ Condition
Parkinson NNP Condition
disease NN Condition
: : None
2 CD None
groups NNS None
of IN None
patients NNS None
with IN None
advanced JJ Condition
stage NN Condition
Parkinson NNP Condition
Disease NNP Condition
. . None
-DOCSTART- -X- N

in IN None
children NNS Age
with IN None
standard-risk JJ Condition
acute JJ Condition
lymphoblastic JJ Condition
leukemia NN Condition
: : None
Children NNP None
's POS None
Cancer NNP None
Group NNP None
1952 CD None
( ( None
CCG-1952 NNP None
) ) None
standard-risk JJ Condition
acute JJ Condition
lymphoblastic JJ Condition
leukemia NN Condition
. . None
After IN None
remission NN None
induction NN None
, , None
2027 CD Size
patients NNS None
257 CD Size
patients NNS None
-DOCSTART- -X- N

Eight NNP Size
healthy JJ Condition
subjects NNS None
underwent JJ None
esophageal JJ Condition
manometry NN Condition
using VBG None
a DT None
10-lumen JJ None
sleeve NN None
assembly NN None
during IN None
placebo NN None
or CC None
loxiglumide NN None
( ( None
10 CD None
mg/kg/h NN None
) ) None
in IN None
-DOCSTART- -X- N

implants NNS Condition
in IN Condition
the DT Condition
anterior JJ Condition
maxilla NN Condition
: : None
prosthodontic JJ Condition
and CC None
aesthetic JJ Condition
peri-implant JJ Condition
immediately RB None
restored VBN None
, , None
Southern JJ Condition
single-tapered JJ Condition
implants NNS Condition
in IN Condition
the DT Condition
anterior JJ Condition
maxilla NN Condition
after IN None
1 CD None
year NN None
. . None
Participants NNP None
( ( None
mean JJ None
age NN None
: : None
43.25 CD None
years NNS None
; : None
range NN None
: : None
23-71 JJ None
years NNS None
) ) None
satisfying VBG None
specified VBN None
inclusion NN None
criteria NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
differentiated JJ None
papillary JJ None
thyroid NN None
carcinoma NN None
undergoing JJ None
total JJ None
thyroidectomy NN None
plus CC None
central JJ None
neck NN None
dissection NN None
. . None
patients NNS None
undergoing VBG None
thyroidectomy JJ None
plus JJ None
central JJ None
neck NN None
dissection NN None
( ( None
CND NNP None
) ) None
. . None
197 CD None
patients NNS None
with IN None
differentiated JJ None
papillary JJ None
thyroid NN None
carcinoma NN None
-DOCSTART- -X- N

functional JJ None
ovarian JJ Condition
cysts NNS Condition
: : None
formed VBN None
functional JJ None
ovarian JJ Condition
cysts NNS Condition
. . None
Eighty NNP Size
patients NNS None
in IN None
whom WP None
ultrasonography NN None
revealed VBD None
unilateral JJ Condition
, , Condition
mobile JJ Condition
, , Condition
unilocular JJ Condition
, , Condition
thin-walled JJ Condition
ovarian JJ Condition
cysts NNS Condition
without IN Condition
internal JJ Condition
echoes NNS Condition
and CC Condition
greater JJR Condition
than IN Condition
30 CD Condition
mm NNS Condition
but CC Condition
not RB Condition
exceeding VBG Condition
60 CD Condition
mm NN Condition
in IN Condition
diameter NN Condition
were VBD None
enrolled VBN None
into IN None
the DT None
study NN None
. . None
functional JJ Condition
ovarian JJ Condition
cysts NNS Condition
functional JJ None
ovarian JJ Condition
cysts NNS Condition
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
: : None
children NNS Age
with IN None
Autism NNP Condition
Spectrum NNP Condition
Disorders NNP Condition
( ( Condition
ASD NNP Condition
) ) Condition
8-13 JJ None
year NN None
old JJ None
children NNS None
with IN None
ASD NNP None
and CC None
normal JJ None
IQs NNP None
( ( None
n JJ None
= NNP None
40 CD None
) ) None
. . None
The DT None
-DOCSTART- -X- N

mild JJ None
asthma JJ None
patients NNS None
: : None
mite-allergic JJ None
asthma NN None
. . None
mite JJ None
monosensitive NN None
, , None
mild JJ None
asthma NN None
patients NNS None
. . None
26 CD None
asthma JJ None
patients NNS None
who WP None
randomly VBP None
received VBN None
vaccination NN None
or CC None
placebo NN None
for IN None
1 CD None
year NN None
. . None
mild JJ None
asthma JJ None
patients NNS None
-DOCSTART- -X- N

uterine JJ Condition
myoma NN Condition
regression NN Condition
. . None
This DT None
study NN None
took VBD None
place NN None
in IN None
the DT None
Department NNP None
of IN None
Obstetrics NNP None
and CC None
Gynecology NNP None
of IN None
Tabriz NNP None
University NNP None
of IN None
Medical NNP None
Sciences NNPS None
, , None
Tabriz NNP None
, , None
Iran NNP None
from IN None
July NNP None
2004 CD None
to TO None
December NNP None
2005 CD None
. . None
Fifty NNP Condition
women NNS Condition
with IN None
uterine JJ Condition
myoma NN Condition
, , None
who WP None
met VBD None
the DT None
criteria NNS None
of IN None
the DT None
study NN None
thoroughly RB None
-DOCSTART- -X- N

patients NNS None
with IN None
hormone-refractory JJ Condition
prostate NN Condition
cancer NN Condition
. . None
hormone-refractory JJ Condition
prostate NN Condition
cancer NN Condition
( ( Condition
HRPC NNP Condition
) ) Condition
380 CD Condition
patients NNS None
was VBD None
initiated VBN None
in IN None
men NNS Age
with IN None
HRPC NNP Condition
. . Condition
50 CD Size
randomized JJ None
patients NNS None
prostate NN None
cancer NN None
-DOCSTART- -X- N

of IN None
healthy JJ None
adults NNS None
. . None
74 CD None
healthy JJ None
men NNS None
and CC None
women NNS None
. . None
-DOCSTART- -X- N

chronic JJ Condition
suppurative JJ Condition
otitis NN Condition
media NNS Condition
. . None
Active NNP Condition
chronic JJ Condition
suppurative NN Condition
otitis NN Condition
media NNS Condition
patients NNS None
are VBP None
being VBG None
considered VBN None
for IN None
surgical JJ None
treatment NN None
. . None
discharging VBG Condition
ears NNS Condition
. . None
Fifty-two JJ Size
patients NNS None
were VBD None
selected VBN None
chronic JJ Condition
suppurative NN Condition
otitis NN Condition
media NNS Condition
. . None
active JJ None
chronic JJ None
suppurative NN None
otitis NN None
media NNS None
-DOCSTART- -X- N

total JJ None
knee NN None
arthroplasty NN None
( ( None
TKA NNP None
) ) None
61 CD Size
ASA NNP Condition
physical JJ Condition
status NN Condition
I-III NNP Condition
patients NNS Condition
scheduled VBN None
for IN None
elective JJ None
unilateral JJ None
total NN None
knee NN None
arthroplasty NN None
( ( None
TKA NNP None
) ) None
under IN None
spinal JJ None
anesthesia NN None
( ( None
SA NNP None
) ) None
-DOCSTART- -X- N

Hungarian JJ None
asthmatics NNS Condition
. . None
119 CD Size
asthmatics NNS None
were VBD None
randomized VBN None
the DT None
subjects NNS None
were VBD None
regularly RB None
controlled VBN None
asthmatics NNS None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
hairy JJ Condition
cell NN Condition
leukemia NN Condition
: : Condition
a DT Condition
multicenter NN Condition
phase NN Condition
III NNP Condition
trial NN Condition
( ( Condition
SAKK NNP Condition
32/98 CD Condition
) ) Condition
. . Condition
One CD None
hundred VBD None
patients NNS None
-DOCSTART- -X- N

obesity NN Condition
treatment NN None
140 CD Condition
patients NNS Condition
( ( None
36 CD Condition
men NNS Condition
, , None
104 CD Condition
women NNS Condition
) ) None
, , None
aged VBN None
18-60 CD Age
years NNS None
and CC None
body NN None
mass NN None
index NN None
> VBD None
30 CD None
kg/m NN None
( ( None
2 CD None
) ) None
were VBD None
randomized VBN None
and CC None
93 CD Condition
patients NNS Condition
( ( None
27 CD Condition
men NNS Condition
, , None
66 CD Condition
women NNS Condition
) ) None
completed VBD None
the DT None
study NN None
. . None
-DOCSTART- -X- N

prostatic JJ None
cancer NN None
previously RB Condition
untreated JJ Condition
patients NNS Size
with IN Size
prostatic JJ Size
cancer NN Size
patients NNS Size
with IN Size
advanced JJ Condition
disease NN Condition
no RB Condition
longer RBR Condition
responsive VB Condition
to TO Condition
hormonal JJ Condition
treatment NN Condition
-DOCSTART- -X- N

severe JJ Condition
bronchiectasis NN Condition
Twenty-four CD Size
patients NNS Size
( ( None
12 CD Sex
female NN Sex
; : None
mean JJ Age
age NN Age
51 CD Age
yr NN Age
) ) None
bronchiectasis NN Condition
-DOCSTART- -X- N

autism NN Condition
spectrum NN Condition
disorders NNS Condition
. . None
brains NNS None
of IN None
patients NNS None
with IN None
autism NN None
. . None
METHOD NNP None
exploration NN None
. . None
Twenty NNP None
children NNS None
with IN None
autism NN None
spectrum NN None
disorder NN None
age NN None
4-12 CD None
years NNS None
were VBD None
RESULTS NNP None
Eighteen JJ None
participants NNS None
( ( None
10 CD None
mecamylamine NN None
, , None
8 CD None
placebo NN None
) ) None
completed VBD None
the DT None
study NN None
. . None
All DT None
-DOCSTART- -X- N

neonatal JJ None
respiratory NN None
distress NN None
syndrome NN None
. . None
Three CD None
hundred VBD None
and CC None
eighty JJ None
six CD None
preterm JJ None
infants NNS None
with IN None
birthweights NNS None
from IN None
1000 CD None
to TO None
2000 CD None
g NN None
, , None
and CC None
requiring VBG None
ventilation NN None
for IN None
respiratory JJ None
distress JJ None
syndrome NN None
within IN None
24 CD None
hours NNS None
of IN None
birth NN None
preterm JJ None
infants NNS None
with IN None
respiratory JJ None
distress JJ None
syndrome NN None
-DOCSTART- -X- N

adolescent JJ None
basketball NN None
players NNS None
. . None
young JJ None
basketball NN None
players NNS None
. . None
Twenty-seven JJ None
adolescent JJ None
basketball NN None
players NNS None
( ( None
14.7+/-0.5 CD None
years NNS None
; : None
Tanner NNP None
stage NN None
: : None
3.5+/-0.5 JJ None
) ) None
-DOCSTART- -X- N

Delta NNP None
Research NNP None
Group NNP None
. . None
various JJ None
demographic JJ None
groups NNS None
. . None
103 CD Condition
healthy JJ None
men NNS Condition
and CC None
women NNS Condition
aged VBD None
22 CD None
to TO None
67 CD None
years NNS None
at IN None
4 CD None
field NN None
centers NNS None
. . None
-DOCSTART- -X- N

carcinoma NN None
in IN None
situ NN None
of IN None
the DT None
bladder NN None
. . None
Forty-two JJ None
patients NNS None
with IN None
carcinoma NN None
in IN None
situ NN None
of IN None
the DT None
bladder NN None
Of IN None
the DT None
patients NNS None
, , None
27 CD None
had VBD None
grade VBN None
2 CD None
and CC None
15 CD None
had VBD None
grade VBN None
3 CD None
cancer NN None
. . None
-DOCSTART- -X- N

preterm JJ Condition
neonates NNS Condition
: : None
preterm NN Condition
neonates NNS Age
preterm JJ None
neonates NNS None
. . None
Preterm NNP Condition
neonates NNS Age
without IN None
other JJ None
risk NN None
factors NNS None
for IN None
infection NN None
admitted VBN None
in IN None
the DT None
first JJ None
12h CD None
of IN None
life NN None
low JJ None
risk NN None
preterm NN None
neonates VBZ None
-DOCSTART- -X- N

49 CD Size
patients NNS None
with IN None
non-insulin-dependent JJ Condition
diabetes NNS Condition
mellitus NNS Condition
-DOCSTART- -X- N

trial NN None
in IN None
Bangladesh NNP None
. . None
Populations NNPS None
in IN None
South NNP None
and CC None
East NNP None
Asia NNP None
and CC None
many JJ None
other JJ None
regions NNS None
of IN None
the DT None
world NN None
are VBP None
chronically RB Condition
exposed VBN Condition
to TO Condition
arsenic-contaminated JJ Condition
drinking NN Condition
water NN Condition
. . None
arsenic-exposed JJ None
adults NNS None
Two CD Size
hundred VBD Size
adults NNS None
in IN None
a DT None
rural JJ None
region NN None
of IN None
Bangladesh NNP None
, , None
previously RB None
found VBN None
to TO None
have VB None
low JJ Condition
plasma JJ Condition
concentrations NNS Condition
of IN Condition
folate NN Condition
( ( Condition
< JJ Condition
/=9 NNP Condition
nmol/L NN Condition
) ) Condition
participants NNS None
with IN None
low JJ Condition
plasma NN Condition
folate NN Condition
-DOCSTART- -X- N

students NNS Condition
with IN Condition
an DT Condition
ASD NNP Condition
children NNS None
with IN None
Autism NNP None
Spectrum NNP None
Disorders NNP None
( ( None
ASD NNP None
) ) None
. . None
study NN None
( ( None
N NNP None
= NNP None
49 CD None
) ) None
indicates VBZ None
providing VBG None
children NNS None
with IN None
low-functioning JJ None
autism NN None
( ( None
LFA NNP None
) ) None
and CC None
high JJ None
functioning NN None
autism NN None
( ( None
HFA NNP None
) ) None
opportunities VBZ None
-DOCSTART- -X- N

136 CD Size
postmenopausal JJ Condition
women NNS Sex
-DOCSTART- -X- N

preschool JJ Age
children NNS Age
who WP None
have VBP None
intellectual JJ Condition
disabilities NNS Condition
preschool NN None
children NNS None
with IN None
intellectual JJ Condition
disabilities NNS Condition
( ( Condition
IDs NNP Condition
) ) Condition
, , None
including VBG None
children NNS None
with IN None
Down NNP Condition
syndrome NN Condition
and CC None
children NNS None
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
Seventy-seven JJ Size
children NNS None
preschool JJ Age
children NNS Age
who WP None
have VBP None
ID NNP None
and CC None
significant JJ None
language NN None
impairments NNS None
-DOCSTART- -X- N

autistic JJ Condition
disorder NN Condition
: : None
autism NN Condition
Individuals NNS None
with IN None
a DT None
DSM-IV JJ None
diagnosis NN None
of IN None
autistic JJ Condition
disorder NN Condition
( ( None
mean JJ None
age NN None
, , None
16.3 CD None
years NNS None
; : None
range NN None
, , None
10-36 JJ None
years NNS None
) ) None
were VBD None
randomly RB None
assigned VBN None
, , None
by IN None
using VBG None
a DT None
Latin NNP None
square NN None
design NN None
, , None
to TO None
the DT None
following JJ None
7-week JJ None
trials NNS None
: : None
placebo NN None
, , None
clomipramine NN Condition
( ( None
mean JJ None
daily RB None
dose RB None
, , None
128.4 CD None
mg NN None
; : None
range NN None
, , None
100-150 JJ None
mg NN None
) ) None
, , None
or CC None
haloperidol NN None
( ( None
mean JJ None
daily RB None
dose RB None
, , None
1.3 CD None
mg NN None
; : None
range NN None
, , None
1-1.5 JJ None
mg NN None
) ) None
. . None
Data NNP None
on IN None
36 CD Size
subjects NNS None
were VBD None
analyzed VBN None
-DOCSTART- -X- N

during IN None
general JJ Condition
anesthesia NN Condition
. . None
general JJ Condition
propofol-sufentanil JJ Condition
anesthesia NN Condition
in IN None
58 CD Size
patients NNS None
undergoing JJ None
day-case JJ Condition
arthroscopic NN Condition
surgery NN Condition
. . None
( ( None
Group NNP Size
A NNP Size
, , Size
29 CD Size
patients NNS None
) ) None
( ( None
GRoup NNP Size
B NNP Size
, , Size
29 CD Size
patients NNS None
) ) None
. . None
under IN None
general JJ Condition
anesthesia NN Condition
-DOCSTART- -X- N

postoperative JJ None
pain NN None
. . None
moderate JJ None
or CC None
severe JJ None
postoperative JJ None
pain NN None
. . None
A DT None
final JJ None
patient NN None
population NN None
of IN None
149 CD None
subjects NNS None
Sixty CD None
patients NNS None
patients NNS None
with IN None
postoperative JJ None
pain NN None
. . None
-DOCSTART- -X- N

toddlers NNS Age
with IN None
autism NN Condition
: : None
Seventy-five JJ None
toddlers NNS None
with IN None
autism NN None
spectrum NN None
disorder NN None
( ( None
65 CD None
autism NN None
, , None
10 CD None
PDD-NOS NN None
, , None
mean JJ None
age NN None
= VBD None
34.4 CD None
months NNS None
, , None
SD NNP None
= NNP None
6.2 CD None
) ) None
were VBD None
of IN None
67 CD None
children NNS None
( ( None
lost VBN None
-DOCSTART- -X- N

patients NNS None
with IN None
early JJ None
breast NN None
cancer NN None
patients NNS None
with IN None
early JJ None
breast NN None
cancer NN None
-DOCSTART- -X- N

Endophthalmitis NNP Condition
Vitrectomy NNP Condition
Study NNP None
( ( None
EVS NNP None
) ) None
. . None
420 CD Size
EVS NNP Condition
patients NNS None
with IN None
postoperative JJ Condition
endophthalmitis NN Condition
, , None
201 CD Size
received VBD None
immediate JJ None
vitreous JJ None
tap NN None
or CC None
biopsy NN Condition
( ( None
without IN None
pars NNS None
plana VBP None
vitrectomy NN None
) ) None
193 CD Size
201 CD Size
patients NNS None
undergoing JJ None
tap NN None
or CC None
biopsy NN Condition
, , None
70 CD Size
( ( None
35 CD None
% NN None
) ) None
had VBD None
needle JJ Condition
tap NN Condition
, , None
127 CD Size
( ( None
63 CD None
% NN None
) ) None
had VBD None
mechanized VBN Condition
biopsy NN Condition
, , None
and CC None
4 CD Size
( ( None
2 CD None
% NN None
) ) None
had VBD None
initial JJ None
needle JJ Condition
tap NN Condition
-DOCSTART- -X- N

stroke-free JJ None
individuals NNS None
over IN None
2 CD None
years NNS None
. . None
total NN None
of IN None
227 CD None
subjects NNS None
227 CD None
randomized JJ None
subjects NNS None
, , None
33 CD None
( ( None
14.5 CD None
% NN None
) ) None
had VBD None
SBI VBN None
at IN None
baseline NN None
. . None
-DOCSTART- -X- N

preschoolers NNS Age
with IN None
autism NN Condition
. . None
children NNS Age
with IN None
an DT None
autism NN Condition
spectrum NN Condition
disorder NN Condition
( ( Condition
ASD NNP Condition
) ) Condition
attend VBP None
public JJ None
preschools NNS None
public JJ Condition
preschool NN Condition
teachers NNS Condition
Sixteen NNP Size
dyads NNS None
( ( None
preschoolers NNS Age
with IN None
ASD NNP Condition
and CC None
the DT None
public JJ None
school NN None
teachers NNS None
who WP None
worked VBD None
in IN None
the DT None
child NN None
's POS None
classroom NN None
) ) None
teachers NNS Condition
children NNS Age
with IN None
ASD NNP Condition
in IN None
a DT None
public JJ Condition
preschool NN Condition
-DOCSTART- -X- N

hypertension NN None
. . None
the DT None
patients NNS None
-DOCSTART- -X- N

healthy JJ None
adults NNS None
?60 CD None
years NNS None
of IN None
age NN None
210 CD None
subjects NNS None
?60 CD None
years NNS None
old JJ None
-DOCSTART- -X- N

healthy JJ None
volunteers NNS None
and CC None
in IN None
patients NNS None
with IN None
primary JJ Condition
hypothyroidism NN Condition
. . None
8 CD Size
healthy JJ None
volunteers NNS None
, , None
and CC None
6 CD Size
women NNS Sex
with IN None
untreated JJ None
primary JJ Condition
hypothyroidism NN Condition
healthy JJ None
volunteers NNS None
patients NNS None
with IN None
hypothyroidism NN Condition
normal JJ None
subjects NNS None
and CC None
in IN None
patients NNS None
with IN None
primary JJ None
hypothyroidism NN Condition
-DOCSTART- -X- N

heart NN Condition
failure NN Condition
outpatients NNS Condition
: : None
patients NNS None
under IN None
cardiologists NNS None
' POS None
care NN None
over IN None
long-term JJ None
follow-up NN None
One CD Condition
hundred VBD Condition
seventeen JJ Condition
patients NNS None
were VBD None
randomized VBN None
to TO None
usual JJ None
care NN None
, , None
and CC None
233 CD Condition
to TO None
additional JJ None
intervention NN None
. . None
patients NNS None
under IN None
the DT None
supervision NN None
of IN None
a DT None
cardiologist NN None
-DOCSTART- -X- N

patients NNS None
with IN None
extensive JJ None
non-small NN None
cell NN None
lung NN None
cancer NN None
. . None
87 CD Size
patients NNS None
with IN None
inoperable JJ None
, , None
extensive JJ None
non-small NN None
cell NN None
lung NN Condition
cancer NN Condition
( ( None
NSCLC NNP None
) ) None
-DOCSTART- -X- N

metastatic JJ Condition
breast NN Condition
cancer NN Condition
: : None
67 CD Size
patients NNS None
with IN None
systemic JJ Condition
breast NN Condition
cancer NN Condition
treated VBN Condition
by IN Condition
chemotherapy NN Condition
; : None
55 CD Size
were VBD None
assessable JJ Condition
by IN Condition
UICC NNP Condition
criteria NNS Condition
and CC None
the DT None
response NN None
index NN None
( ( None
96 CD None
% NN None
of IN None
all DT None
UICC NNP None
assessable JJ None
patients NNS None
) ) None
. . None
patients NNS None
-DOCSTART- -X- N

behavioral JJ None
parent NN None
training NN None
in IN None
children NNS None
with IN None
ADHD NNP Condition
: : None
children NNS None
with IN None
attention NN Condition
deficit/hyperactivity NN Condition
disorder NN Condition
( ( Condition
ADHD NNP Condition
) ) Condition
Study NNP None
subjects NNS None
were VBD None
a DT None
subsample NN None
( ( None
n JJ None
= NN None
50 CD Size
, , None
for IN None
whom WP None
DAT1 NNP None
genotypes NNS None
were VBD None
available JJ None
) ) None
of IN None
a DT None
randomized VBN None
controlled VBN None
BPT NNP None
effectiveness NN None
study NN None
( ( None
N NNP None
= NNP None
94 CD Size
) ) None
comparing VBG None
BPT NNP None
plus CC None
ongoing JJ None
routine JJ None
clinical JJ None
care NN None
( ( None
RCC NNP None
) ) None
versus NN None
RCC NNP None
alone RB None
in IN None
referred JJ None
children NNS None
( ( None
4-12 CD None
years NNS None
old JJ None
) ) None
with IN None
ADHD NNP Condition
. . None
-DOCSTART- -X- N

adults NNS None
with IN None
common JJ None
variable JJ None
immunodeficiency NN Condition
. . None
The DT None
setting NN None
was VBD None
at IN None
University NNP None
Hospital NNP None
, , None
Out-patient NNP None
Clinic NNP None
. . None
patients NNS None
were VBD None
twenty-one JJ Size
adult NN None
patients NNS None
with IN None
common JJ Condition
variable JJ Condition
immunodeficiency NN Condition
. . None
-DOCSTART- -X- N

neuromuscular JJ Condition
block NN Condition
at IN None
the DT None
laryngeal NN None
muscles NNS None
surface NN None
laryngeal NN None
electromyography NN None
neuromuscular JJ None
block NN None
neuromuscular JJ None
block NN None
neuromuscular JJ None
block NN None
at IN None
the DT None
larynx NN None
. . None
-DOCSTART- -X- N

4 CD None
clients NNS None
. . None
2 CD None
clients NNS None
clients NNS None
with IN None
severe JJ None
to TO None
profound VB None
disabilities NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
acute JJ Condition
respiratory NN Condition
distress NN Condition
syndrome NN Condition
. . None
patients NNS None
with IN None
acute JJ None
respiratory NN None
distress NN None
syndrome NN None
( ( None
ARDS NNP Condition
) ) None
patients NNS None
with IN None
ARDS NNP None
. . None
12 CD Size
patients NNS None
with IN None
ARDS NNP None
-DOCSTART- -X- N

single-implant JJ None
crown JJ None
single-implant JJ None
crown NN None
restorations NNS None
METHODS NNP None
Altogether NNP None
, , None
35 CD None
consecutive JJ None
patients NNS None
were VBD None
provided VBN None
with IN None
41 CD None
turned VBD None
single JJ None
Br?nemark NNP None
System NNP None
implants NNS None
( ( None
Nobel NNP None
Biocare NNP None
AB NNP None
) ) None
in IN None
the DT None
partially RB None
edentulous JJ None
upper JJ None
jaw NN None
. . None
By IN None
random NN None
, , None
15 CD None
and CC None
20 CD None
patients NNS None
were VBD None
provided VBN None
with IN None
18 CD None
test NN None
and CC None
23 CD None
control NN None
implant JJ None
crowns NNS None
, , None
respectively RB None
. . None
-DOCSTART- -X- N

schizophrenia NN None
: : None
schizophrenia NN None
. . None
chronic JJ None
schizophrenic JJ None
patients NNS None
six CD None
double-blind JJ None
trials NNS None
combined JJ None
patient JJ None
population NN None
-DOCSTART- -X- N

3-5 JJ Condition
year NN Condition
old JJ Condition
children NNS Condition
attending VBG Condition
long RB Condition
day NN Condition
care NN Condition
services NNS Condition
: : Condition
Young NNP None
children NNS None
young JJ None
children NNS None
children NNS None
attending VBG None
long RB None
day NN None
care NN None
services NNS None
. . None
Three CD None
hundred VBD None
children NNS None
aged VBN None
between IN None
3-5 CD None
years NNS None
from IN None
twenty NN None
randomly RB None
selected VBN None
long RB None
day NN None
care NN None
services NNS None
in IN None
the DT None
Hunter NNP None
Region NNP None
of IN None
New NNP None
South NNP None
Wales NNP None
, , None
Australia NNP None
young JJ None
children NNS None
in IN None
long JJ None
day NN None
care NN None
settings NNS None
. . None
Australian NNP None
New NNP None
Zealand NNP None
Clinical NNP None
Trials NNP None
Registry NNP None
-DOCSTART- -X- N

HIV-infected JJ None
women NNS None
. . None
HIV-infected JJ None
women NNS None
. . None
in IN None
sexually RB None
abstinent JJ None
and CC None
active JJ None
HIV-infected JJ None
women NNS None
. . None
Fifty-nine JJ None
HIV-infected JJ None
women NNS None
Sexually NNP None
abstinent JJ None
women NNS None
HIV-infected JJ None
women NNS None
and CC None
their PRP$ None
male JJ None
partners NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ Condition
fatigue NN Condition
syndrome NN Condition
. . None
Forty-nine NNP Size
patients NNS None
( ( None
40 CD Size
with IN None
abnormal JJ Condition
cell-mediated JJ Condition
immunity NN Condition
) ) None
participated VBD None
-DOCSTART- -X- N

32 CD None
subjects NNS None
. . None
-DOCSTART- -X- N

parasite JJ Condition
burden NN Condition
finishing VBG None
heifers NNS None
1,862 CD Size
yearling VBG None
heifers NNS None
feedlot NN None
heifers NNS None
-DOCSTART- -X- N

Upper NNP Condition
gastrointestinal JJ Condition
endoscopy NN Condition
( ( None
UGIE NNP None
) ) None
Eight NNP Size
normal JJ None
male NN Sex
volunteers NNS None
undergoing VBG None
UGIE NNP None
with IN None
sedation NN None
( ( None
0.1 CD None
mg/kg NN None
of IN None
midazolam NN None
) ) None
and CC None
without IN None
it PRP None
( ( None
two CD None
endoscopies NNS None
per IN None
volunteer NN None
in IN None
random JJ None
order NN None
) ) None
-DOCSTART- -X- N

55 CD None
premature NN None
infants NNS None
weighing VBG None
less JJR None
than IN None
1501 CD None
g NN None
at IN None
birth NN None
were VBD None
selected VBN None
randomly RB None
at IN None
their PRP$ None
initial JJ None
eye NN None
examination NN None
. . None
42 CD None
patients NNS None
. . None
premature JJ None
infants NNS None
. . None
-DOCSTART- -X- N

110 CD Size
patients NNS None
suffering VBG None
from IN None
hay NN Condition
fever NN Condition
( ( None
confirmed VBN None
by IN None
skin NN None
tests NNS None
) ) None
-DOCSTART- -X- N

mild JJ Condition
acute JJ Condition
pancreatitis NN Condition
. . Condition
Patients NNPS None
recovering VBG None
from IN None
mild JJ Condition
acute JJ Condition
pancreatitis NN Condition
Patients NNS None
with IN None
mild JJ Condition
pancreatitis NNS Condition
121 CD Size
patients NNS Size
: : None
66 CD Size
to TO None
CLD NNP None
and CC None
55 CD Size
to TO None
LFSD NNP None
. . None
-DOCSTART- -X- N

prospective JJ Condition
blood NN Condition
donors NNS Condition
: : None
Participants NNS None
were VBD None
randomly RB None
assigned VBN None
-DOCSTART- -X- N

postoperative JJ Condition
pain NN Condition
after IN None
vaginal JJ Condition
hysterectomy NN Condition
. . None
animals NNS None
and CC None
volunteers NNS None
humans NNS None
) ) None
patients NNS None
undergoing VBG None
elective JJ None
vaginal JJ None
hysterectomy NN None
-DOCSTART- -X- N

church-attending JJ None
African-American JJ None
men NNS Sex
. . None
among IN None
African-American JJ None
men NNS Sex
; : None
African-American JJ None
men NNS Sex
who WP None
attend VBP None
church NN None
Churches NNP None
-DOCSTART- -X- N

anxiety NN Condition
in IN Condition
children NNS Condition
with IN Condition
autism NN Condition
spectrum NN Condition
disorders NNS Condition
: : Condition
Children NNP None
with IN None
autism NN None
spectrum NN None
disorders NNS None
comorbid NN None
anxiety NN None
disorders NNS None
that WDT None
cause VBP None
significant JJ None
functional JJ None
impairment NN None
. . None
children NNS None
with IN None
ASD NNP None
Forty NNP None
children NNS None
( ( None
7-11 CD None
years NNS None
old JJ None
) ) None
were VBD None
randomly RB None
assigned VBN None
-DOCSTART- -X- N

391 CD Size
medical JJ Condition
student NN Condition
volunteers NNS Condition
during IN None
the DT None
influenza JJ None
A2 NNP None
Hong NNP None
Kong NNP None
epidemic VBP None
in IN None
Helsinki NNP None
in IN None
the DT None
winter NN None
of IN None
1969 CD None
-DOCSTART- -X- N

cytological JJ Condition
cervical JJ Condition
diagnosis NN Condition
: : None
cervical JJ Condition
cancer NN Condition
screening NN None
. . None
In IN None
18 CD Size
healthy JJ Condition
women NNS Sex
, , None
two CD None
ecto-endocervical JJ None
samples NNS None
, , None
obtained VBN None
by IN None
two CD None
different JJ None
methods NNS None
, , None
were VBD None
obtained VBN None
at IN None
a DT None
three-month JJ None
interval NN None
. . None
-DOCSTART- -X- N

One CD None
hundred VBD None
patients NNS None
scheduled VBN None
for IN None
lobectomy NN None
-DOCSTART- -X- N

One CD Size
hundred VBD Size
maxillary JJ None
premolar JJ None
teeth NNS None
ten VB None
groups NNS None
. . None
Each DT None
group NN None
-DOCSTART- -X- N

infants NNS None
fed VBN None
iron-fortified JJ None
beikost NN None
with IN None
meat NN None
. . None
two CD None
groups NNS None
of IN None
healthy JJ None
term NN None
infants NNS None
who WP None
received VBD None
meat-containing JJ None
baby NN None
foods NNS None
fortified VBN None
with IN None
ferrous JJ None
sulphate NN None
( ( None
2 CD None
mg NN None
Fe/100 NNP None
g NN None
) ) None
. . None
healthy JJ None
term NN None
infants NNS None
-DOCSTART- -X- N

AIDS-affected JJ None
children NNS None
living VBG None
in IN None
AIDS-impacted JJ None
communities NNS None
: : None
southwestern JJ None
Uganda NNP None
. . None
AIDS-affected JJ None
children NNS None
in IN None
communities NNS None
heavily RB None
impacted VBN None
by IN None
HIV/AIDS NNP None
in IN None
Uganda NNP None
. . None
a DT None
treatment NN None
condition NN None
( ( None
n=179 JJ None
) ) None
and CC None
a DT None
control NN None
condition NN None
( ( None
n=118 JJ None
) ) None
children NNS None
with IN None
poor JJ None
mental JJ None
health NN None
functioning VBG None
living NN None
in IN None
communities NNS None
affected VBN None
by IN None
HIV/AIDS NNP None
children NNS None
living VBG None
in IN None
resource JJ None
poor JJ None
AIDS-impacted JJ None
communities NNS None
. . None
-DOCSTART- -X- N

children NNS Age
with IN Age
autism NN Condition
: : None
Twenty-four JJ Size
children NNS Age
with IN None
autism NN Condition
assigned VBN None
to TO None
a DT None
clinic-directed JJ None
group NN None
or CC None
to TO None
a DT None
parent-directed JJ None
group NN None
-DOCSTART- -X- N

patients NNS None
undergoing JJ None
noncardiac JJ None
surgery NN None
. . None
patients NNS None
undergoing JJ None
noncardiac JJ None
surgery NN None
patients NNS None
who WP None
are VBP None
already RB None
on IN None
an DT None
aspirin JJ None
regimen NNS None
and CC None
among IN None
those DT None
who WP None
are VBP None
not RB None
. . None
10,010 CD None
patients NNS None
who WP None
were VBD None
preparing VBG None
to TO None
undergo VB None
noncardiac JJ None
surgery NN None
and CC None
were VBD None
at IN None
risk NN None
for IN None
vascular JJ None
complications NNS None
-DOCSTART- -X- N

type NN Condition
2 CD Condition
diabetic JJ Condition
patients NNS None
with IN None
late JJ Condition
failure NN Condition
of IN None
sulphonylurea JJ Condition
therapy NN Condition
. . None
patients NNS None
with IN None
type JJ Condition
2 CD Condition
diabetes NNS Condition
receiving VBG None
exogenous JJ Condition
insulin NN Condition
due JJ None
to TO None
secondary JJ None
failure NN Condition
of IN None
maximum NN None
dose JJ None
sulphonylurea JJ Condition
therapy NN Condition
. . None
48 CD Size
type NN Condition
2 CD Condition
diabetic JJ Condition
patients NNS None
with IN None
late-term JJ Condition
failure NN Condition
following VBG None
at IN None
least JJS None
3 CD None
years NNS None
of IN None
sulphonylurea JJ Condition
therapy NN Condition
requiring VBG None
additional JJ None
insulin NN Condition
therapy NN Condition
to TO None
determine VB None
the DT None
impact NN None
of IN None
acarbose NN None
on IN None
glycaemic JJ None
control NN None
and CC None
insulin NN None
requirements NNS None
. . None
type NN Condition
2 CD Condition
diabetic JJ Condition
patients NNS None
. . None
-DOCSTART- -X- N

Twenty-nine JJ Size
patients NNS None
undergoing VBG None
cholecystectomy NN None
because IN None
of IN None
chronic JJ Condition
calculous JJ Condition
cholecystitis NN Condition
were VBD None
randomised VBN None
to TO None
receive VB None
phenylbutazone NN None
10 CD None
mg/kg NN None
intramuscularly RB None
or CC None
a DT None
control NN None
injection NN None
-DOCSTART- -X- N

pre-core NN None
mutant NN None
chronic JJ None
hepatitis NN None
B NNP None
infection NN None
pre-core JJ None
mutant NN None
of IN None
hepatitis NN None
B NNP None
virus NN None
( ( None
HBV NNP None
) ) None
infection NN None
Mediterranean NNP None
Europe NNP None
and CC None
in IN None
Asia NNP None
. . None
pre-core JJ None
mutant NN None
HBV NNP None
patients NNS None
with IN None
this DT None
variant NN None
patients NNS Condition
with IN Condition
pre-core JJ Condition
mutant NN Condition
hepatitis NN Condition
B NNP Condition
. . None
patients NNS Condition
with IN Condition
chronic JJ Condition
hepatitis NN Condition
B NNP Condition
, , Condition
including VBG Condition
those DT Condition
with IN Condition
pre-core JJ Condition
mutant JJ Condition
HBV NNP Condition
infection NN Condition
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ Condition
obstructive JJ Condition
pulmonary JJ Condition
disease NN Condition
: : None
435 CD Size
adults NNS Age
with IN None
stable JJ Condition
, , Condition
symptomatic JJ Condition
, , Condition
smoking-related JJ Condition
COPD NNP Condition
were VBD None
randomized VBN None
79 CD Size
patients NNS None
with IN None
serious JJ Condition
adverse JJ Condition
events NNS Condition
( ( None
SAEs NNP Condition
) ) None
, , None
43 CD Size
( ( None
14.8 CD None
% NN None
) ) None
in IN None
the DT None
sibenadet NN Condition
pMDI NN Condition
group NN None
and CC None
36 CD Size
( ( None
24.8 CD None
% NN None
) ) None
in IN None
the DT None
placebo NN Condition
group NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
ST-segment-elevation NNP Condition
myocardial JJ Condition
infarction NN Condition
. . None
patients NNS None
with IN None
acute JJ None
myocardial JJ None
infarction NN None
. . None
368 CD Size
patients NNS None
with IN None
first JJ None
ST-segment-elevation NNP None
myocardial JJ None
infarction NN None
undergoing VBG None
percutaneous JJ Condition
coronary JJ Condition
intervention NN Condition
( ( None
PCI NNP Condition
) ) None
. . None
patients NNS None
with IN None
ST-segment-elevation NNP None
myocardial JJ None
infarction NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
metastatic JJ Condition
malignant JJ Condition
melanoma NN Condition
. . None
patients NNS None
with IN None
malignant JJ Condition
melanoma NN Condition
53 CD Size
patients NNS None
were VBD None
stratified VBN None
according VBG None
to TO None
performance NN None
status NN None
patients NNS None
with IN None
malignant JJ Condition
melanoma NN Condition
patients NNS None
with IN None
malignant JJ Condition
melanoma NN Condition
-DOCSTART- -X- N

autism NN Condition
. . None
children NNS Age
with IN None
autism NN Condition
addition NN None
of IN None
a DT None
web-based JJ None
group NN None
. . None
Forty-nine JJ Size
teacher-child JJ None
dyads NNS None
child NN Age
. . None
young JJ None
children NNS Age
with IN None
autism NN Condition
. . None
-DOCSTART- -X- N

Abstinence NN None
or CC None
controlled VBN None
drinking NN None
excessive JJ None
drinkers NNS None
46 CD Size
clients NNS None
of IN None
a DT None
clinical JJ None
psychology NN None
alcohol NN None
problems NNS None
service NN None
( ( None
30 CD Size
men NNS Size
, , None
16 CD Size
women NNS Size
) ) None
Those DT None
with IN None
dependence NN None
indicators NNS None
for IN None
abstinence NN None
-DOCSTART- -X- N

vitamin JJ Condition
D-deficient JJ Condition
non-western JJ None
immigrants NNS None
: : None
non-western JJ None
immigrants NNS None
. . None
trial NN None
in IN None
11 CD None
general JJ None
practices NNS None
in IN None
The DT None
Netherlands NNP None
. . None
Non-western JJ None
immigrants NNS None
, , None
aged VBN None
18-65 CD None
years NNS None
( ( None
n JJ None
= NNP None
232 CD None
) ) None
and CC None
serum $ None
25 CD None
( ( None
OH NNP None
) ) None
D NNP None
< $ None
25 CD None
nmol/l NN None
were VBD None
included VBD None
211 CD None
persons NNS None
deficiency NN None
in IN None
non-western JJ None
immigrants NNS None
. . None
-DOCSTART- -X- N

Eighty-four JJ Size
cases NNS None
were VBD None
randomly RB None
divided VBN None
into IN None
3 CD None
groups NNS None
, , None
28 CD Size
cases NNS None
in IN None
each DT None
group NN None
. . None
-DOCSTART- -X- N

=2 VB None
month-old JJ None
children NNS None
. . None
1200 CD Size
healthy JJ None
children NNS Age
of IN None
2-5 JJ Age
months NNS Age
old JJ Age
in IN None
Jiangsu NNP None
province NN None
were VBD None
administered VBN None
OPV NNP Condition
( ( Condition
HDC NNP Condition
) ) Condition
vaccine NN Condition
and CC None
control NN None
vaccines NNS None
. . None
the DT None
children NNS None
> VBP None
or CC None
=2 JJ None
months NNS None
old JJ None
. . None
-DOCSTART- -X- N

pigs NNS None
with IN Condition
and CC Condition
without IN Condition
passively RB Condition
acquired VBN Condition
maternal JJ Condition
antibody NN Condition
Pigs NNS None
pigs NNS None
inoculated VBD None
with IN None
strain NN None
Bartha NNP None
or CC None
with IN None
the DT None
inactivated JJ None
vaccine NN None
-DOCSTART- -X- N

patients NNS None
with IN None
non-small JJ None
cell NN None
lung NN Condition
cancer NN Condition
: : None
non-small JJ None
cell NN None
lung NN Condition
cancer NN Condition
( ( None
NSCLC NNP None
) ) None
381 CD Size
patients NNS None
were VBD None
randomised VBN None
to TO None
chemotherapy VB None
( ( None
C NNP None
, , None
192 CD Size
patients NNS None
) ) None
or CC None
no DT None
chemotherapy NN None
( ( None
NoC NNP None
, , None
189 CD Size
patients NNS None
) ) None
. . None
-DOCSTART- -X- N

May NNP None
2008 CD None
to TO None
July NNP None
2010 CD None
, , None
78 CD Condition
patients NNS None
with IN None
knee JJ Condition
osteoarthritis NN Condition
42 CD Size
patients NNS None
in IN None
the DT None
experimental JJ None
group NN None
, , None
including VBG None
16 CD Size
males NNS None
and CC None
26 CD Size
females NNS None
, , None
ranging VBG None
in IN None
age NN None
from IN None
41 CD None
to TO None
63 CD None
years NNS None
, , None
with IN None
an DT None
average NN None
of IN None
( ( None
53.62 CD None
+/- JJ None
6.53 CD None
) ) None
years NNS None
; : None
the DT None
disease NN None
course NN None
ranged VBD None
from IN None
8 CD None
to TO None
24 CD None
months NNS None
, , None
with IN None
an DT None
average NN None
of IN None
( ( None
10.35 CD None
+/- JJ None
6.42 CD None
) ) None
months NNS None
. . None
36 CD Size
patients NNS None
in IN None
the DT None
control NN None
group NN None
, , None
including VBG None
14 CD Size
males NNS None
and CC None
22 CD Size
females NNS None
, , None
ranging VBG None
in IN None
age NN None
from IN None
40 CD None
to TO None
62 CD None
years NNS None
, , None
with IN None
an DT None
average NN None
of IN None
( ( None
54.34 CD None
+/- JJ None
7.67 CD None
) ) None
years NNS None
; : None
the DT None
disease NN None
course NN None
ranged VBD None
from IN None
6 CD None
to TO None
25 CD None
months NNS None
, , None
with IN None
an DT None
average NN None
of IN None
( ( None
11.94 CD None
+/- JJ None
5.13 CD None
) ) None
months NNS None
. . None
with IN None
knee JJ Condition
osteoarthritis NN Condition
-DOCSTART- -X- N

acute JJ Condition
ischaemic JJ Condition
stroke NN Condition
. . None
within IN None
the DT None
first JJ None
6 CD None
hours NNS None
of IN None
acute JJ Condition
ischaemic JJ Condition
stroke NN Condition
. . None
Patients NNS None
fulfilling VBG None
the DT None
selection NN None
criteria NNS None
Fourteen CD Size
patients NNS None
were VBD None
given VBN None
IVF NNP None
and CC None
13 CD Size
IAF NNP None
. . None
27 CD Size
patients NNS None
had VBD None
been VBN None
included VBN None
because IN None
of IN None
the DT None
mortality NN None
rate NN None
. . None
-DOCSTART- -X- N

chronic JJ None
bronchitis NN None
and CC None
emphysema NN None
: : None
patients NNS None
disabled VBN None
by IN None
chronic JJ None
obstructive JJ None
airways NNS None
disease NN None
giving VBG None
rise NN None
to TO None
dyspnoea VB None
. . None
Forty-three JJ Size
men NNS None
and CC Size
22 CD Size
women NNS None
with IN None
severe JJ Condition
COAD NNP Condition
-DOCSTART- -X- N

perennial JJ Condition
allergic JJ Condition
rhinitis NN Condition
. . None
patients NNS None
with IN None
allergic JJ Condition
rhinitis NN Condition
32 CD Size
subjects NNS None
with IN None
perennial JJ Condition
allergic JJ Condition
rhinitis NN Condition
and CC None
randomized VBD None
them PRP None
in IN None
a DT None
double-blinded JJ None
, , None
cross-over JJ None
fashion NN None
patients NNS None
with IN None
perennial JJ Condition
allergic JJ Condition
rhinitis NN Condition
-DOCSTART- -X- N

anemic JJ None
critically RB None
ill JJ None
patients NNS None
without IN None
acute JJ None
blood NN None
loss NN None
. . None
anemic JJ None
critically RB None
ill JJ None
patients NNS None
. . None
Ten CD None
centers NNS None
in IN None
the DT None
United NNP None
States NNPS None
. . None
Adult NNP None
( ( None
age NN None
> VBN None
or=18 CD None
years NNS None
) ) None
critically RB None
ill JJ None
patients NNS None
with IN None
hemoglobin JJ None
< NNP None
or=12 NN None
g/dL NN None
, , None
expected VBN None
hospitalization NN None
of IN None
> NNP None
or=7 NNP None
days NNS None
, , None
with IN None
no DT None
ongoing VBG None
acute RB None
blood NN None
loss NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
treated JJ None
HIV NNP Condition
infection NN Condition
: : None
Thirty-one JJ None
subjects NNS None
with IN None
an DT None
ART-suppressed JJ None
plasma NN None
HIV NNP None
RNA NNP None
level NN None
of IN None
< $ None
40 CD None
copies/mL NN None
and CC None
a DT None
CD4 NNP None
( ( None
+ NNP None
) ) None
T-cell NNP None
count NN None
of IN None
?350 NNP None
cells/mm NN None
( ( None
3 CD None
) ) None
for IN None
?1 JJ None
year NN None
were VBD None
among IN None
patients NNS None
receiving VBG None
treatment NN None
for IN None
HIV NNP None
infection NN None
. . None
-DOCSTART- -X- N

antimony-unresponsive JJ Condition
kala-azar NN Condition
. . None
120 CD Size
uncomplicated JJ None
and CC None
parasitologically RB None
confirmed VBN None
cases NNS None
of IN None
antimony-unresponsive JJ Condition
kala-azar NN Condition
. . None
-DOCSTART- -X- N

abomasal JJ None
emptying VBG None
rate NN None
in IN None
suckling VBG None
calves NNS None
. . None
Five CD None
male JJ None
Holstein-Friesian JJ None
calves NNS None
( ( None
8-15 JJ None
days NNS None
of IN None
age NN None
) ) None
. . None
dairy NN None
calves NNS None
-DOCSTART- -X- N

postmenopausal JJ Condition
women NNS Sex
stratified VBN None
by IN None
Helicobacter NNP Condition
pylori NN Condition
status NN None
. . None
healthy JJ Condition
postmenopausal NN Condition
women NNS Sex
stratified VBN None
by IN None
Helicobacter NNP Condition
pylori NN Condition
status NN None
. . None
-DOCSTART- -X- N

90 CD Size
medical JJ Condition
students NNS None
without IN None
previous JJ None
experience NN None
in IN None
laparoscopic NN None
techniques NNS None
were VBD None
randomly RB None
assigned VBN None
to TO None
undergo VB None
one CD None
of IN None
three CD None
procedures NNS None
: : None
CLS NNP None
, , None
SPLS NNP None
using VBG None
two CD None
pre-bent JJ None
instruments NNS None
( ( None
SPLS-pp NNP None
) ) None
, , None
or CC None
SPLS NNP None
using VBG None
one CD None
pre-bent NN None
and CC None
one CD None
straight NN None
laparoscopic NN None
instrument NN None
( ( None
SPLS-ps NNP None
) ) None
. . None
-DOCSTART- -X- N

three-year-old JJ Condition
children NNS Condition
in IN Condition
relation NN Condition
to TO Condition
otitis VB Condition
media NNS Condition
in IN Condition
their PRP$ Condition
first JJ Condition
three CD Condition
years NNS Condition
of IN Condition
life NN Condition
. . Condition
We PRP None
enrolled VBD None
6350 CD None
healthy JJ None
infants NNS None
by IN None
2 CD None
months NNS None
of IN None
age NN None
who WP None
presented VBD None
for IN None
primary JJ None
care NN None
at IN None
1 CD None
of IN None
2 CD None
urban JJ None
hospitals NNS None
or CC None
1 CD None
of IN None
2 CD None
small JJ None
town/rural JJ None
and CC None
4 CD None
suburban JJ None
private JJ None
pediatric JJ None
practices NNS None
. . None
Children NNP None
who WP None
met VBD None
specified VBN None
minimum JJ None
criteria NNS None
regarding VBG None
the DT None
persistence NN None
of IN None
MEE NNP None
became VBD None
eligible JJ None
for IN None
a DT None
clinical JJ None
trial NN None
From IN None
among IN None
those DT None
remaining VBG None
, , None
we PRP None
selected VBD None
randomly RB None
, , None
within IN None
sociodemographic JJ None
strata NNS None
, , None
a DT None
sample NN None
of IN None
241 CD None
children NNS None
who WP None
represented VBD None
a DT None
spectrum NN None
of IN None
MEE NNP None
experience NN None
from IN None
having VBG None
no DT None
MEE NNP None
to TO None
having VBG None
MEE NNP None
whose WP$ None
cumulative JJ None
duration NN None
fell VBD None
just RB None
short RB None
of IN None
meeting VBG None
randomization NN None
criteria NNS None
. . None
In IN None
subjects NNS None
so RB None
selected VBN None
, , None
the DT None
estimated JJ None
duration NN None
of IN None
MEE NNP None
ranged VBD None
from IN None
none NN None
to TO None
65.6 CD None
% NN None
of IN None
the DT None
first JJ None
year NN None
of IN None
life NN None
and CC None
44.8 CD None
% NN None
of IN None
the DT None
first JJ None
3 CD None
years NNS None
of IN None
life NN None
. . None
241 CD None
children NNS None
persistent JJ None
early-life JJ None
MEE NNP None
-DOCSTART- -X- N

Nurses NNS Condition
without IN None
prior JJ Condition
experience NN Condition
in IN Condition
the DT Condition
use NN Condition
of IN Condition
the DT Condition
laryngeal JJ Condition
mask NN Condition
airway NN Condition
( ( Condition
LMA NNP Condition
) ) Condition
Group NNP None
A NNP None
( ( None
32 CD Size
nurses NNS Condition
) ) None
were VBD None
trained VBN None
only RB None
on IN None
a DT None
manikin NN None
and CC None
group NN None
B NNP None
( ( None
20 CD Size
nurses NNS Condition
) ) None
were VBD None
trained VBN None
on IN None
a DT None
manikin NN None
and CC None
with IN None
live JJ None
anaesthetised VBN None
patient JJ None
practice NN None
in IN None
theatre NN None
( ( None
five CD None
successful JJ None
insertions NNS None
) ) None
. . None
live JJ None
patient NN None
in IN None
theatre JJ None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
advanced JJ Condition
cancer NN Condition
: : Condition
advanced JJ None
cancer NN None
. . None
Patients NNP None
with IN None
advanced JJ None
cancer NN None
with IN None
a DT None
fatigue NN None
score NN None
of IN None
? . None
4 CD None
out IN None
of IN None
10 CD None
on IN None
the DT None
Edmonton NNP None
Symptom NNP None
Assessment NNP None
Scale NNP None
( ( None
ESAS NNP None
) ) None
were VBD None
RESULTS VB None
One CD None
hundred JJ None
forty-one JJ None
patients NNS None
were VBD None
evaluable JJ None
. . None
-DOCSTART- -X- N

neurosurgery NN None
. . None
trepanations NNS None
patients NNS None
undergoing VBG None
major JJ None
craniotomies NNS None
. . None
Only JJ None
clean JJ None
or CC None
clean JJ None
contaminated VBN None
cases NNS None
were VBD None
included VBN None
. . None
Excluded VBN None
were VBD None
contaminated VBN None
cases NNS None
, , None
operations NNS None
with IN None
a DT None
transnasal-transsphenoidal JJ None
approach NN None
, , None
shunt-operations NNS None
and CC None
patients NNS None
with IN None
any DT None
other JJ None
preoperative JJ None
infection NN None
or CC None
antibiotic JJ None
therapy NN None
. . None
Outpatients NNS None
were VBD None
excluded VBN None
due JJ None
to TO None
difficulties NNS None
in IN None
obtaining VBG None
sufficient JJ None
clinical JJ None
information NN None
. . None
From NNP None
originally RB None
918 CD Size
consecutive JJ None
patients NNS None
operated VBN None
on IN None
711 CD Size
fulfilled VBD None
the DT None
entry NN None
criteria NNS None
. . None
With IN None
regard NN None
to TO None
age NN None
, , None
sex NN None
, , None
diagnosis NN None
and CC None
the DT None
site NN None
of IN None
te JJ None
trepanation NN None
, , None
control NN None
patients NNS None
( ( None
n JJ None
= NNP None
355 CD Size
) ) None
and CC None
cefotiam $ None
treated VBN None
patients NNS None
( ( None
n JJ None
= NNP None
356 CD Size
) ) None
were VBD None
shown VBN None
to TO None
be VB None
comparable JJ None
. . None
different JJ None
primary JJ None
diagnoses NNS None
, , None
concomitant JJ None
steroidal NN None
therapy NN None
concomitant NN None
severe JJ None
internal JJ None
medical JJ None
diseases NNS None
-DOCSTART- -X- N

Three CD Size
individuals NNS None
with IN None
mental JJ Condition
retardation NN Condition
exhibited VBD None
stimulus JJ None
overselectivity NN None
in IN None
a DT None
delayed JJ None
matching-to-sample NN None
task NN None
-DOCSTART- -X- N

individuals NNS Condition
considering VBG Condition
genetic JJ Condition
testing NN Condition
for IN Condition
hereditary JJ Condition
nonpolyposis NN Condition
colorectal NN Condition
cancer NN Condition
risk NN Condition
. . Condition
153 CD None
individuals NNS None
men NNS Condition
women NNS Condition
-DOCSTART- -X- N

young JJ Age
children NNS Age
with IN None
autism NN Condition
: : None
young JJ Age
children NNS Age
with IN None
autism NN Condition
. . None
Participants NNPS None
were VBD None
58 CD Size
children NNS Age
with IN None
autism NN Condition
aged VBN None
3 CD Age
and CC Age
4 CD Age
years NNS Age
( ( None
46 CD Size
boys NNS Sex
) ) None
. . None
young JJ None
children NNS None
with IN None
autism NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
generalized JJ None
osteoarthritis NN None
: : None
patients NNS None
with IN None
generalized JJ None
osteoarthritis NN None
( ( None
GOA NNP None
) ) None
. . None
patients NNS None
with IN None
GOA NNP None
. . None
we PRP None
aim VBP None
to TO None
include VB None
170 CD None
patients NNS None
with IN None
GOA NNP None
. . None
patients NNS None
with IN None
GOA NNP None
. . None
-DOCSTART- -X- N

second JJ Condition
intention NN Condition
wound IN Condition
healing VBG Condition
in IN None
horses NNS None
. . None
horses NNS None
. . None
four CD Size
horses NNS None
, , None
each DT None
with IN None
wounds NNS None
Four CD None
adult NN None
Standardbred NNP None
geldings NNS None
. . None
four CD None
horses NNS None
, , None
giving VBG None
a DT None
total NN None
of IN None
64 CD None
wounds NNS None
. . None
horses NNS None
. . None
-DOCSTART- -X- N

healthy JJ None
men NNS Condition
and CC None
women NNS Condition
. . None
Sixteen NNP None
healthy JJ None
volunteers NNS None
( ( None
10 CD None
men NNS None
, , None
age NN None
43 CD None
? . None
19 CD None
years NNS None
; : None
mean VB None
? . None
SD NNP None
) ) None
were VBD None
-DOCSTART- -X- N

nine CD Size
healthy JJ Condition
subjects NNS None
. . None
wearers NNS None
-DOCSTART- -X- N

patients NNS None
and CC None
their PRP$ None
partners NNS None
with IN None
bacterial JJ None
vaginosis NN None
. . None
male JJ None
partners NNS None
of IN None
women NNS None
with IN None
bacterial JJ None
vaginosis NN None
patients NNS None
with IN None
bacterial JJ None
vaginosis NN None
. . None
sexual JJ None
partner NN None
of IN None
women NNS None
with IN None
bacterial JJ None
vaginosis NN None
-DOCSTART- -X- N

the DT None
elderly JJ Age
. . None
after IN None
upper JJ None
abdominal JJ None
surgery NN None
. . None
20 CD None
patients NNS None
aged VBD Age
61 CD Age
to TO Age
78 CD Age
years NNS Age
. . None
elderly JJ None
patients NNS None
undergoing VBG Condition
upper JJ Condition
abdominal JJ Condition
surgery NN Condition
-DOCSTART- -X- N

patients NNS None
with IN None
congestive JJ None
heart NN None
failure NN None
. . None
patients NNS None
with IN None
congestive JJ None
heart NN None
failure NN None
. . None
patients NNS None
with IN None
congestive JJ None
heart NN None
failure NN None
. . None
13 CD None
patients NNS None
with IN None
congestive JJ None
heart NN None
failure NN None
long-term JJ None
treatment NN None
of IN None
patients NNS None
having VBG None
congestive JJ None
heart NN None
failure NN None
patients NNS None
with IN None
ischemic JJ None
heart NN None
disease NN None
patients NNS None
with IN None
congestive JJ None
heart NN None
failure NN None
. . None
-DOCSTART- -X- N

postprandial JJ Condition
esophageal JJ Condition
acid NN None
exposure NN None
. . None
gastroesophageal NN Condition
reflux NN Condition
( ( None
GER NNP Condition
) ) None
. . None
10 CD Size
normal JJ None
subjects NNS None
and CC None
10 CD Size
GER NNP None
patients NNS None
following VBG None
low JJ None
and CC None
high JJ None
fat NN None
meals NNS None
eaten VBP None
in IN None
two CD None
body NN None
positions NNS None
. . None
-DOCSTART- -X- N

patients NNS Condition
undergoing VBG Condition
surgical JJ Condition
myocardial JJ Condition
revascularisation NN Condition
. . Condition
40 CD None
patients NNS None
who WP None
underwent VBP None
myocardial JJ None
revascularisation NN None
using VBG None
extracorporeal JJ None
circulation NN None
. . None
-DOCSTART- -X- N

infants NNS Age
born VBN None
to TO None
anemic JJ Condition
mothers NNS None
: : None
infants NNS None
born VBN None
to TO None
anemic VB None
mothers NNS None
at IN None
3 CD None
months NNS None
of IN None
age NN None
. . None
Teaching NNP None
hospital NN None
. . None
Infants NNPS None
born VBN None
to TO None
mothers NNS None
with IN None
hemoglobin NN None
( ( None
Hb NNP None
) ) None
< VBD None
100 CD None
g/L NNS None
102 CD None
neonates NNS None
neonates NNS None
born VBN None
to TO None
anemic VB None
mothers NNS None
-DOCSTART- -X- N

21 CD Size
healthy JJ Condition
subjects NNS Condition
with IN None
different JJ None
fitness NN Condition
levels NNS Condition
. . None
-DOCSTART- -X- N

Chomsky NNP None
's POS None
principle NN None
of IN None
Full NNP None
Interpretation NNP None
. . None
88 CD Size
adult JJ Age
Japanese JJ None
speakers NNS None
-DOCSTART- -X- N

patients NNS None
' POS None
well-being NN None
in IN None
a DT None
radiation NN None
therapy NN None
department NN None
. . None
patients NNS None
' POS None
well-being JJ None
. . None
Fifty-five JJ None
subjects NNS None
undergoing VBG None
radiation NN None
therapy NN None
for IN None
cure NN None
and CC None
who WP None
were VBD None
able JJ None
to TO None
communicate VB None
by IN None
telephone NN None
comprised VBD None
the DT None
sample NN None
. . None
control NN None
group NN None
, , None
who WP None
received VBD None
the DT None
usual JJ None
care NN None
or CC None
to TO None
an DT None
experimental JJ None
group NN None
-DOCSTART- -X- N

moderate JJ Condition
acne NN Condition
vulgaris NN Condition
. . None
patients NNS None
with IN None
acne NN Condition
Two CD Size
hundred VBD Size
fifty-seven RB Size
healthy JJ Condition
female NN Sex
subjects NNS None
, , None
15 CD Age
to TO Age
49 CD Age
years NNS Age
of IN None
age NN None
with IN None
moderate JJ Condition
acne NNS Condition
vulgaris NN Condition
160 CD Size
subjects NNS None
placebo NN None
group NN None
in IN None
women NNS Sex
with IN None
no DT None
known VBN None
contraindication NN None
to TO None
OC NNP None
therapy NN None
. . None
-DOCSTART- -X- N

healthy JJ Condition
subjects NNS None
. . None
10 CD Size
adult NN Age
healthy JJ Condition
subjects NNS None
-DOCSTART- -X- N

beneficiaries NNS None
with IN None
mental JJ None
illness NN None
: : None
Cash NNP None
and CC None
Counseling NNP None
Demonstration NNP None
and CC None
Evaluation NNP None
( ( None
CCDE NNP None
) ) None
programs NNS None
in IN None
New NNP None
Jersey NNP None
, , None
Arkansas NNP None
, , None
and CC None
Florida NNP None
those DT None
with IN None
a DT None
diagnosis NN None
of IN None
mental JJ None
illness NN None
. . None
nonelderly RB None
Medicaid NNP None
beneficiaries NNS None
in IN None
New NNP None
Jersey NNP None
with IN None
a DT None
diagnosis NN None
of IN None
mental JJ None
illness NN None
and CC None
compared VBN None
and CC None
contrasted VBN None
the DT None
experiences NNS None
of IN None
those DT None
in IN None
New NNP None
Jersey NNP None
's POS None
CCDE NNP None
program NN None
( ( None
N=109 NNP None
) ) None
and CC None
those DT None
who WP None
received VBD None
services NNS None
provided VBN None
by IN None
an DT None
agency NN None
( ( None
N=119 NNP None
) ) None
. . None
persons NNS None
with IN None
a DT None
diagnosis NN None
of IN None
mental JJ None
illness NN None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
: : None
pediatric JJ Age
patients NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
Thirty-six JJ Size
children NNS Age
with IN None
an DT None
autism NN Condition
spectrum NN Condition
disorder NN Condition
( ( None
5-17 JJ Age
years NNS None
old JJ None
) ) None
accompanied VBN None
by IN None
severe JJ None
tantrums NNS None
, , None
aggression NN None
, , None
or CC None
self-injurious JJ None
behavior NN None
children NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
. . None
-DOCSTART- -X- N

hookworm NN Condition
, , None
Ascaris NNP Condition
and CC None
Trichuris NNP Condition
infection NN Condition
340 CD Size
cases NNS None
of IN None
hookworm NN Condition
infection NN Condition
, , None
196 CD Size
cases NNS None
of IN None
ascariasis NN None
and CC None
178 CD Size
cases NNS None
of IN None
trichuriasis NN None
were VBD None
treated VBN None
with IN None
an DT None
anthelmintic JJ None
, , None
oxibendazole JJ None
, , None
15mg/kg.d CD None
x JJ None
3d CD None
; : None
102 CD None
, , None
70 CD None
and CC None
66 CD None
cases NNS None
of IN None
respective JJ None
infections NNS None
were VBD None
treated VBN None
with IN None
pyrantel NN None
10mg/kg.d CD None
x NN None
3d CD None
and CC None
108 CD None
, , None
74 CD None
and CC None
63 CD None
cases NNS None
took VBD None
placebo NN None
-DOCSTART- -X- N

hospital NN None
emergency NN None
department NN None
. . None
patients NNS None
in IN None
a DT None
hospital NN None
emergency NN None
department NN None
. . None
Twenty-five JJ Size
patients NNS None
were VBD None
allocated VBN None
randomly RB None
either DT None
to TO None
a DT None
TAMS NNP None
group NN None
or CC None
to TO None
an DT None
on-scene JJ None
directed NN None
( ( None
OSD NNP None
) ) None
group NN None
. . None
12 CD Size
were VBD None
intubated VBN None
-DOCSTART- -X- N

in IN None
patients NNS None
with IN None
a DT None
body NN None
mass NN None
index NN None
( ( None
BMI NNP None
) ) None
< VBD None
23.0 CD None
kg/m NN None
( ( None
2 CD None
) ) None
. . None
One CD Size
hundred CD Size
and CC Size
twenty JJ Size
consecutive JJ None
patients NNS None
with IN None
a DT None
BMI NNP None
< NNP None
23.0 CD None
kg/m NN None
( ( None
2 CD None
) ) None
and CC None
a DT None
low JJ None
calcium NN None
load NN None
undergoing VBG None
retrospective JJ None
electrocardiogram NN None
( ( None
ECG NNP None
) ) None
-gated VBD None
dual-source JJ None
CCTA NNP Condition
in IN None
patients NNS None
with IN None
a DT None
low JJ None
BMI NNP None
< NN None
23.0 CD None
kg/m NN None
( ( None
2 CD None
) ) None
and CC None
a DT None
low JJ None
calcium NN None
load NN None
-DOCSTART- -X- N

online NN None
continuing VBG None
medical JJ None
education NN None
seminars NNS None
: : None
evidence NN None
for IN None
improving VBG None
clinical JJ None
practices NNS None
. . None
Primary NNP None
care NN None
physicians NNS None
( ( None
113 CD None
) ) None
participated VBN None
in IN None
a DT None
randomized NN None
controlled VBN None
trial NN None
to TO None
evaluate VB None
an DT None
online NN None
CME NNP None
series NN None
. . None
Physicians NNPS None
physicians NNS None
physician JJ None
clinical JJ None
practice NN None
. . None
-DOCSTART- -X- N

post-hemorrhoidectomy JJ None
status NN None
: : None
chronic JJ None
venous JJ None
insufficiency NN None
. . None
non-surgical JJ None
patients NNS None
with IN None
acute JJ Condition
uncomplicated JJ Condition
hemorrhoids NNS Condition
. . None
post-hemorrhoidectomy JJ Condition
patients NNS None
. . None
30 CD Size
patients NNS None
were VBD None
randomized VBN None
-DOCSTART- -X- N

healthy JJ Condition
young JJ Age
adults NNS Age
. . None
Sixty-five JJ Size
healthy JJ Condition
adults NNS Age
aged VBD None
18-29yrs JJ Age
-DOCSTART- -X- N

Stage NN Condition
II NNP Condition
carcinoma NN Condition
of IN Condition
the DT Condition
ovary JJ Condition
: : None
Ninety-three JJ Size
women NNS Sex
with IN None
FIGO NNP Condition
stage NN Condition
II NNP Condition
epithelial JJ Condition
ovarian JJ Condition
carcinoma NN Condition
forty-five JJ Size
women NNS Sex
treated VBN None
with IN None
melphalan NN None
forty-eight JJ Size
women NNS Sex
treated VBN None
with IN None
intraperitoneal JJ None
phosphorus NN None
-DOCSTART- -X- N

patients NNS None
with IN None
hepatitis NN Condition
B NNP Condition
e VBZ Condition
antigen-negative JJ Condition
chronic JJ Condition
hepatitis NN Condition
B NNP Condition
. . None
chronic JJ Condition
hepatitis NN Condition
B NNP Condition
( ( None
CHB NNP Condition
) ) None
. . None
Thirteen NNP Size
patients NNS None
with IN None
HBeAg-negative JJ None
CHB NNP None
HBeAg-negative JJ Condition
CHB NNP Condition
-DOCSTART- -X- N

older JJR Age
adults NNS Age
: : None
older JJR Age
adults NNS Age
who WP None
are VBP None
inexperienced VBN None
wheelchair JJ None
users NNS None
. . None
Participants NNS None
( ( None
N=20 NNP Size
) ) None
who WP None
were VBD None
community-living JJ None
older JJR Age
adults NNS Age
at IN None
least JJS None
65 CD Age
years NNS Age
old JJ Age
( ( None
mean JJ None
age NN None
, , None
70y CD Age
) ) None
, , None
50 CD None
% NN None
women NNS Sex
, , None
and CC None
who WP None
had VBD None
no DT None
experience NN None
of IN None
using VBG None
a DT None
wheelchair NN None
among IN None
older JJR None
adults NNS None
who WP None
are VBP None
inexperienced VBN None
wheelchair JJ None
users NNS None
. . None
-DOCSTART- -X- N

408 CD None
subjects NNS None
were VBD None
stratified VBN None
by IN None
age NN None
( ( None
18-59 JJ None
and CC None
> JJ None
60 CD None
years NNS None
) ) None
-DOCSTART- -X- N

paroxysmal JJ None
atrial JJ None
fibrillation NN None
or CC None
flutter NN None
to TO None
sinus VB Condition
rhythm NN Condition
. . None
40 CD Size
patients NNS None
with IN None
paroxysmal JJ Condition
atrial JJ Condition
fibrillation NN Condition
( ( None
AF NNP None
) ) None
or CC None
atrial JJ None
flutter NN None
( ( None
AFI NNP None
) ) None
. . None
20 CD Size
patients NNS None
receiving VBG None
flecainide RB None
, , None
14 CD Size
of IN None
17 CD Size
( ( None
82 CD None
% NN None
) ) None
with IN None
AF NNP None
converted VBD None
to TO None
sinus VB Condition
rhythm NN Condition
, , None
but CC None
in IN None
3 CD None
patients NNS None
with IN None
AFI NNP None
flecainide NN None
failed VBD None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
hepatocellular JJ Condition
carcinoma NN Condition
. . None
Forty-five JJ None
patients NNS None
with IN None
cured JJ None
or CC None
possibly RB None
cured VBN None
HCC NNP Condition
-DOCSTART- -X- N

small-cell JJ Condition
lung NN Condition
cancer NN Condition
. . None
small-cell JJ None
lung NN None
cancer NN None
( ( None
SCLC NNP None
) ) None
patients NNS None
who WP None
responded VBD None
to TO None
six CD None
courses NNS None
of IN None
induction NN None
chemotherapy NN None
with IN None
ifosfamide NN None
, , None
etoposide RB None
, , None
and CC None
an DT None
anthracycline NN None
( ( None
doxorubicin NN None
or CC None
epirubicin NN None
) ) None
. . None
Among IN None
235 CD Size
eligible JJ None
patients NNS None
initially RB None
registered VBD None
, , None
91 CD Size
were VBD None
randomized VBN None
to TO None
receive VB None
maintenance NN None
therapy NN None
, , None
including VBG None
seven CD Size
patients NNS None
who WP None
were VBD None
no RB None
longer RBR None
responding VBG None
. . None
-DOCSTART- -X- N

breast NN Condition
cancer NN Condition
patients NNS None
. . None
191 CD Size
patients NNS None
with IN None
T2-4 NNP Condition
N0-1 NNP Condition
breast NN Condition
cancer NN Condition
enrolled VBN None
in IN None
a DT None
randomized JJ None
trial NN None
-DOCSTART- -X- N

bleeding VBG Condition
from IN Condition
esophageal JJ Condition
varices NNS Condition
. . None
bleeding VBG Condition
esophageal JJ Condition
varices NNS Condition
in IN Condition
patients NNS Condition
who WP Condition
did VBD Condition
not RB Condition
respond VB Condition
to TO Condition
blood VB Condition
transfusion NN Condition
and CC Condition
vasoactive JJ Condition
drugs NNS Condition
. . None
101 CD None
patients NNS None
with IN Condition
cirrhosis NN Condition
of IN Condition
the DT Condition
liver NN Condition
and CC Condition
bleeding VBG Condition
esophageal JJ Condition
varices NNS Condition
-DOCSTART- -X- N

standard-risk JJ None
acute JJ None
lymphoblastic JJ Condition
leukemia NN Condition
in IN None
childhood NN Age
( ( None
JCCLSG-S811 NNP None
) ) None
. . None
Japanese JJ None
Children NNP None
's POS None
Cancer NNP None
and CC None
Leukemia NNP None
Study NNP None
Group NNP None
. . None
1981 CD None
to TO None
1983 CD None
, , None
131 CD None
previously RB None
untreated JJ None
patients NNS None
with IN None
acute JJ None
lymphoblastic JJ None
leukemia NN None
( ( None
ALL DT None
) ) None
standard-risk JJ None
group NN None
119 CD Size
eligible JJ None
patients NNS None
-DOCSTART- -X- N

ventricular JJ Condition
tachycardia NN Condition
: : None
124 CD Size
consecutive JJ None
patients NNS None
referred VBD None
for IN None
treatment NN None
of IN None
symptomatic JJ None
ventricular NN None
tachyarrhythmias NN None
, , None
57 CD Size
consenting NN None
patients NNS None
were VBD None
eligible JJ None
to TO None
have VB None
drug NN None
therapy NN None
selected VBN None
by IN None
either DT None
noninvasive JJ None
or CC None
invasive JJ None
approaches NNS None
. . None
-DOCSTART- -X- N

in IN None
naive JJ Condition
and CC Condition
pre-immunized JJ Condition
subjects NNS None
. . None
A DT None
total NN None
of IN None
86 CD Size
healthy JJ Condition
subjects NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
mild-to-moderate JJ None
essential JJ None
hypertension NN None
. . None
205 CD None
patients NNS None
from IN None
16 CD None
investigators NNS None
. . None
-DOCSTART- -X- N

children NNS Age
after IN None
birth NN Condition
asphyxia NN Condition
resuscitated JJ Condition
children NNS Age
. . None
parallel JJ None
group NN None
infants NNS Age
unresponsive JJ None
to TO None
stimulation NN None
who WP None
received VBD None
bag NN None
and CC None
mask NN None
ventilation NN None
as IN None
part NN None
of IN None
their PRP$ None
resuscitation NN None
at IN None
birth NN None
and CC None
infants NNS Age
who WP None
did VBD None
not RB None
require VB None
any DT None
resuscitation NN None
born VBN None
in IN None
rural JJ None
communities NNS None
in IN None
India NNP None
, , None
Pakistan NNP None
, , None
and CC None
Zambia NNP None
. . None
Intervention NN None
infants NNS Age
in IN None
children NNS None
resuscitated VBN None
at IN None
birth NN None
provides VBZ None
evidence NN None
and CC None
resuscitated JJ None
infants NNS None
-DOCSTART- -X- N

palatal-anterior JJ None
superior JJ None
alveolar JJ None
injection NN None
40 CD Size
subjects NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
hepatitis NN Condition
B NNP Condition
chronic NN Condition
liver NN Condition
disease NN Condition
. . None
26 CD Size
patients NNS Size
with IN None
chronic JJ None
hepatitis NN None
B NNP None
liver NN None
disease NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
advanced-stage JJ None
Hodgkin NNP Condition
's POS Condition
lymphoma NN Condition
: : None
German JJ None
advanced-stage JJ None
Hodgkin NNP None
's POS None
disease NN None
( ( None
HD NNP Condition
) ) None
. . None
The DT None
randomized VBN None
, , None
three-arm JJ None
trial NN None
recruited VBD None
patients NNS None
in IN None
stages NNS None
IIB NNP None
and CC None
IIIA NNP None
with IN None
risk NN None
factors NNS None
and CC None
stages NNS None
IIIB NNP None
and CC None
IV NNP None
. . None
505 CD Size
assessable JJ None
patients NNS None
-DOCSTART- -X- N

liver-transplant JJ Condition
recipients NNS None
. . None
orthotopic NN None
liver JJ None
transplantation NN None
. . None
Between NNP None
December NNP None
, , None
1993 CD None
, , None
and CC None
April NNP None
, , None
1995 CD None
, , None
304 CD Size
liver-transplant JJ None
recipients NNS None
Seronegative JJ None
recipients NNS None
of IN None
seronegative JJ Condition
livers NNS Condition
orthotopic NN None
liver NN Condition
transplantation NN Condition
. . None
-DOCSTART- -X- N

after IN Condition
autologous JJ Condition
marrow NN Condition
transplantation NN Condition
. . None
Eighteen JJ Size
patients NNS None
six CD Size
concurrent NN None
control NN None
and CC None
65 CD Size
historical JJ None
control NN None
patients NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
IBS NNP Condition
and CC None
a DT None
study NN None
conducted VBN None
in IN None
healthy JJ Condition
male JJ Sex
subjects NNS None
. . None
2516 CD Size
IBS NNP Condition
patients NNS None
with IN None
symptoms NNS None
of IN None
abdominal JJ Condition
pain NN Condition
and CC None
constipation NN Condition
tegaserod JJ None
In IN None
an DT None
additional JJ None
study NN None
, , None
36 CD Size
healthy JJ Condition
male NN Sex
subjects NNS None
received VBD None
iv NN None
. . None
single JJ None
doses NNS None
of IN None
tegaserod NN None
( ( None
0.8 CD None
mg NN None
to TO None
20 CD None
mg NN None
) ) None
or CC None
placebo NN None
. . None
healthy JJ Condition
volunteers NNS None
-DOCSTART- -X- N

dyspnoea NN Condition
in IN None
primary JJ None
care NN None
. . None
heart NN None
failure NN None
in IN None
primary JJ None
care NN None
B-type NNP None
natriuretic JJ None
peptide NN None
( ( None
BNP NNP None
) ) None
levels NNS None
. . None
Twenty-nine JJ Size
primary JJ None
care NN None
physicians NNS None
in IN None
Switzerland NNP None
and CC None
Germany NNP None
coordinated VBN None
by IN None
the DT None
University NNP None
Hospital NNP None
Basel NNP None
, , None
Switzerland NNP None
. . None
total NN None
of IN None
323 CD Size
consecutive JJ None
patients NNS None
presenting VBG None
with IN None
dyspnoea NN Condition
. . None
-DOCSTART- -X- N

More JJR None
than IN None
50 CD None
% NN None
of IN None
patients NNS None
with IN None
Crohn NNP None
's POS None
disease NN None
Patients NNPS None
with IN None
steroid-dependent JJ None
Crohn NNP None
's POS None
disease NN None
( ( None
n JJ None
= NNP None
271 CD None
) ) None
were VBD None
enrolled VBN None
Steroid JJ None
dependence NN None
was VBD None
defined VBN None
as IN None
use NN None
of IN None
prednisolone NN None
or CC None
prednisone NN None
( ( None
15-40 JJ None
mg/day NN None
) ) None
or CC None
budesonide NN None
( ( None
9 CD None
mg/day NN None
) ) None
for IN None
> NN None
or CC None
=8 JJ None
weeks NNS None
, , None
a DT None
previous JJ None
failed JJ None
attempt NN None
to TO None
decrease VB None
or CC None
discontinue VB None
steroids NNS None
within IN None
8 CD None
weeks NNS None
of IN None
screening NN None
, , None
and CC None
a DT None
Crohn NNP None
's POS None
Disease NNP None
Activity NNP None
Index NNP None
score NN None
of IN None
< NN None
or CC None
=150 JJ None
points NNS None
. . None
patients NNS None
with IN None
steroid JJ None
sparing NN None
patients NNS None
with IN None
steroid-dependent JJ None
Crohn NNP None
's POS None
disease NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
active JJ None
rheumatoid NN None
arthritis NN None
and CC None
an DT None
inadequate JJ None
response NN None
to TO None
methotrexate VB None
alone RB None
. . None
active JJ None
rheumatoid NN None
arthritis NN None
( ( None
RA NNP None
) ) None
in IN None
patients NNS None
receiving VBG None
a DT None
stable JJ None
background NN None
regimen NNS None
of IN None
methotrexate NN None
( ( None
MTX NNP None
) ) None
who WP None
have VBP None
an DT None
inadequate JJ None
response NN None
to TO None
MTX NNP None
monotherapy NN None
. . None
patients NNS None
with IN None
active JJ None
RA NNP None
( ( None
n JJ None
= NNP None
507 CD None
) ) None
CONCLUSION NNP None
In IN None
patients NNS None
with IN None
active JJ None
RA NNP None
in IN None
whom WP None
the DT None
response NN None
to TO None
MTX NNP None
has VBZ None
been VBN None
inadequate JJ None
, , None
the DT None
-DOCSTART- -X- N

Fifteen NNP Size
atopic NN Condition
asthmatics NNS Condition
were VBD None
randomized VBN None
in IN None
double-blind NN None
, , None
cross-over JJ None
fashion NN None
to TO None
receive VB None
for IN None
1 CD None
week NN None
either CC None
levocetirizine JJ None
5 CD None
mg NN None
or CC None
placebo NN None
. . None
-DOCSTART- -X- N

multicenter NN None
, , None
double-blind NN None
, , None
randomized VBN None
, , None
parallel-group JJ None
study NN None
. . None
cisplatin NN None
chemotherapy NN None
( ( None
> CD None
or CC None
= VB None
60 CD None
mg/m2 NN None
) ) None
. . None
40 CD None
% NN None
and CC None
49 CD None
% NN None
of IN None
patients NNS None
in IN None
Cycles NNP None
2 CD None
and CC None
3 CD None
, , None
respectively RB None
, , None
for IN None
the DT None
10 CD None
micrograms/kg NN None
group NN None
, , None
and CC None
in IN None
42 CD None
% NN None
and CC None
38 CD None
% NN None
of IN None
patients NNS None
in IN None
Cycles NNP None
2 CD None
and CC None
3 CD None
, , None
respectively RB None
, , None
for IN None
the DT None
40 CD None
micrograms/kg NN None
group NN None
. . None
high-dose JJ None
cisplatin-based JJ None
chemotherapy NN None
. . None
-DOCSTART- -X- N

contemporary JJ Condition
coronary JJ Condition
stent NN Condition
trials NNS Condition
: : Condition
The DT None
Resolute NNP None
'All-Comers NNS None
' POS None
stent JJ None
trial NN None
. . None
after IN None
the DT None
assigned JJ None
percutaneous JJ None
coronary JJ None
intervention NN None
or CC None
at IN None
discharge NN None
. . None
2121/2292 CD None
patients NNS None
( ( None
92.5 CD None
% NN None
) ) None
had VBD None
an DT None
analysable JJ None
dataset NN None
for IN None
either DT None
biomarker NN None
. . None
890/2121 CD None
patients NNS None
267/890 CD None
patients NNS None
-DOCSTART- -X- N

young JJ Condition
asthmatics NNS Condition
] VBP Condition
Nineteen JJ None
asthmatics NNS None
aged VBD None
6 CD None
to TO None
12 CD None
years NNS None
young JJ None
asthmatics NNS None
patients NNS None
who WP None
have VBP None
difficulty NN None
in IN None
swallowing VBG None
large JJ None
dosage NN None
forms NNS None
. . None
-DOCSTART- -X- N

low-birth-weight JJ Condition
infants NNS Age
. . None
appropriate-for-gestational JJ Age
age NN Age
, , None
low-birth-weight JJ Condition
infants NNS Age
-DOCSTART- -X- N

children NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
. . None
Thirty-four JJ None
children NNS None
, , None
with IN None
autism NN None
spectrum NN None
disorders NNS None
, , None
ages VBZ None
4-14 CD None
years NNS None
-DOCSTART- -X- N

participants NNS None
participants NNS None
Eyes NNP None
All DT None
eyes NNS None
Participants NNS None
with IN None
2 CD None
study NN None
eyes NNS None
423 CD Size
participants NNS None
with IN None
1 CD None
study NN None
eye NN None
112 CD Size
participants NNS None
with IN None
2 CD None
study NN None
eyes NNS None
-DOCSTART- -X- N

Japanese JJ None
elderly JJ None
hypertensive JJ None
patients NNS None
( ( None
JATOS NNP None
) ) None
elderly JJ None
hypertension NN None
elderly JJ None
hypertensive JJ None
patients NNS None
. . None
Patients NNS None
with IN None
essential JJ None
hypertension NN None
( ( None
65-85 CD None
years NNS None
old JJ None
, , None
with IN None
a DT None
pretreatment JJ None
systolic JJ None
blood NN None
pressure NN None
of IN None
above IN None
160 CD None
mmHg NNS None
) ) None
54 CD None
in IN None
the DT None
strict-treatment JJ None
group NN None
vs. FW None
42 CD None
in IN None
the DT None
mild-treatment JJ None
group NN None
( ( None
p=0.22 NN None
) ) None
, , None
and CC None
treatment NN None
was VBD None
withdrawn VBN None
because IN None
of IN None
adverse JJ None
events NNS None
in IN None
36 CD None
patients NNS None
in IN None
each DT None
group NN None
( ( None
p=0.99 NN None
) ) None
. . None
hypertension NN None
in IN None
the DT None
elderly JJ None
. . None
-DOCSTART- -X- N

implant-retained JJ None
mandibular JJ None
overdentures NNS None
. . None
patients NNS None
with IN None
implant-retained JJ None
overdentures NNS None
. . None
-DOCSTART- -X- N

Oscillatory NN Condition
potentials NNS None
, , None
retinopathy NN Condition
, , None
and CC None
long-term JJ None
glucose NN None
control NN None
in IN None
insulin-dependent JJ Condition
diabetes NNS Condition
. . None
insulin-dependent JJ None
diabetes NNS None
. . None
45 CD Size
patients NNS None
Oslo NNP None
-DOCSTART- -X- N

oral JJ None
cancer NN None
screening NN None
in IN None
the DT None
developing NN None
world NN None
population-based JJ None
screening NN None
project NN None
in IN None
India NNP None
. . None
oral JJ None
cancer NN None
mortality NN None
in IN None
high-risk JJ None
individuals NNS None
in IN None
India NNP None
. . None
96,517 CD None
eligible JJ None
subjects NNS None
, , None
87,655 CD None
were VBD None
screened VBN None
, , None
8688 CD None
individuals NNS None
never RB None
received VBD None
the DT None
invitation NN None
and CC None
174 CD None
refused VBD None
screening NN None
. . None
5143 CD None
screen-positives NNS None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
severe JJ Condition
Raynaud NNP Condition
's POS Condition
syndrome NN Condition
: : Condition
Patients NNPS None
with IN None
Raynaud NNP None
's POS None
syndrome NN None
healthy JJ None
volunteers NNS None
and CC None
patients NNS None
with IN None
primary JJ None
Raynaud NNP None
's POS None
syndrome NN None
. . None
20 CD None
patients NNS None
with IN None
severe JJ None
Raynaud NNP None
's POS None
syndrome NN None
, , None
and CC None
ten RB None
healthy JJ None
volunteers NNS None
. . None
primary JJ None
Raynaud NNP None
's POS None
syndrome NN None
-DOCSTART- -X- N

transurethral JJ None
prostate NN None
surgery NN None
: : None
101 CD Size
men NNS Sex
with IN None
benign JJ Condition
prostatic JJ Condition
hyperplasia NN Condition
96 CD Size
patients NNS None
with IN None
a DT None
mean JJ Age
age NN Age
+/- JJ Age
SD NNP Age
of IN Age
69.1 CD Age
+/- JJ Age
6.1 CD Age
years NNS Age
was VBD None
available JJ None
-DOCSTART- -X- N

children NNS Condition
with IN Condition
high-functioning JJ Condition
autism NN Condition
spectrum NN Condition
disorders NNS Condition
and CC Condition
anxiety NN Condition
Children NNP None
anxiety NN None
in IN None
children NNS None
with IN None
ASD NNP None
Fifty NNP None
children NNS None
with IN None
high-functioning JJ None
ASD NNP None
and CC None
anxiety NN None
Forty-seven JJ None
children NNS None
-DOCSTART- -X- N

20 CD Size
patients NNS None
, , None
ASA NNP None
I-II NNP None
, , None
aged VBD None
20-54 JJ Age
, , None
both DT Condition
sexes NNS Condition
, , None
scheduled VBN None
for IN None
abdominal JJ Condition
surgery NN Condition
. . None
-DOCSTART- -X- N

patients NNS None
who WP Condition
require VBP Condition
long-term JJ Condition
ventilation NN Condition
in IN Condition
the DT Condition
Intensive NNP Condition
Care NNP Condition
Unit NNP Condition
. . None
Twenty-four CD None
patients NNS None
predicted VBN None
to TO None
require VB Condition
artificial JJ Condition
ventilation NN Condition
for IN Condition
at IN Condition
least JJS Condition
48 CD Condition
h NNS Condition
-DOCSTART- -X- N

new JJ None
admissions NNS None
. . None
individuals NNS None
in IN None
the DT None
transitional JJ None
period NN None
following VBG None
a DT None
return NN None
to TO None
the DT None
community NN None
. . None
individuals NNS None
newly RB None
admitted VBN None
to TO None
nursing VBG Condition
homes NNS Condition
and CC None
worked VBD None
with IN None
a DT None
family NN None
caregiver NN None
to TO None
develop VB None
and CC None
implement VB None
a DT None
nursing NN None
home NN None
discharge NN None
plan NN None
. . None
intervention NN None
group NN None
( ( None
n JJ None
= NNP None
33 CD Size
) ) None
control NN None
group NN None
( ( None
n JJ None
= NNP None
29 CD Size
) ) None
-DOCSTART- -X- N

finishing VBG None
steers NNS None
. . None
A DT None
total NN None
of IN None
4,178 CD None
steers NNS None
( ( None
mean JJ None
initial JJ None
BW NNP None
= NN None
403.9 CD None
? . None
16.04 CD None
kg NN None
) ) None
were VBD None
used VBN None
to TO None
test VB None
-DOCSTART- -X- N

severe JJ Condition
pediatric JJ Condition
head NN Condition
injury NN Condition
. . Condition
24 CD None
children NNS None
with IN None
severe JJ None
head NN None
injury NN None
, , None
urinary JJ None
free JJ None
cortisol NN None
Twelve CD None
patients NNS None
12 CD None
( ( None
group NN None
2 CD None
) ) None
-DOCSTART- -X- N

children NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
: : None
children NNS None
with IN None
Autism NNP None
Spectrum NNP None
Disorders NNP None
( ( None
ASD NNP None
) ) None
. . None
Seventy JJ None
children NNS None
( ( None
9-16 CD None
years NNS None
old JJ None
) ) None
children NNS None
and CC None
adolescents NNS None
with IN None
ASD NNP None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
advanced JJ None
human JJ None
immunodeficiency NN None
virus NN None
disease NN None
: : None
patients NNS None
with IN None
human JJ None
immunodeficiency NN None
virus NN None
( ( None
HIV NNP None
) ) None
disease NN None
, , None
absolute JJ None
CD4 NNP None
lymphocyte NN None
count NN None
of IN None
< $ None
200/microL CD None
( ( None
or CC None
prior RB None
AIDS-defining NNP None
opportunistic JJ None
infection NN None
) ) None
, , None
and CC None
the DT None
presence NN None
of IN None
serum NN None
IgG NNP None
to TO None
Toxoplasma NNP None
gondii NN None
. . None
218 CD None
patients NNS None
taking VBG None
trimethoprim-sulfamethoxazole JJ None
117 CD None
taking VBG None
aerosolized JJ None
pentamidine NN None
HIV-infected JJ None
patients NNS None
-DOCSTART- -X- N

patients NNS None
undergoing VBG None
ACL NNP Condition
reconstruction NN Condition
. . None
107 CD Size
American JJ None
Society NNP None
of IN None
Anaesthesiologists NNP None
physical JJ None
status NN None
grade NN None
I PRP None
and CC None
II NNP None
patients NNS None
between IN None
18 CD Age
and CC Age
65 CD Age
years NNS None
of IN None
age NN None
who WP None
were VBD None
scheduled VBN None
to TO None
undergo VB None
elective JJ Condition
anterior JJ Condition
crucial JJ Condition
ligament NN Condition
( ( Condition
ACL NNP Condition
) ) Condition
reconstruction NN Condition
with IN None
hamstring VBG None
autografts NNS None
were VBD None
enrolled VBN None
in IN None
the DT None
study NN None
. . None
-DOCSTART- -X- N

in IN None
China NNP None
. . None
non-erosive JJ None
reflux NN None
disease NN None
( ( None
NERD NNP None
) ) None
. . None
Patients NNS None
who WP None
had VBD None
complete JJ None
symptom NN None
relief NN None
in IN None
the DT None
initial JJ None
therapy NN None
398 CD None
patients NNS None
were VBD None
recruited VBN None
in IN None
the DT None
initial JJ None
therapy NN None
group NN None
, , None
among IN None
whom WP None
253 CD None
were VBD None
included VBN None
in IN None
on-demand JJ None
therapy NN None
, , None
with IN None
127 CD None
patients NNS None
in IN None
the DT None
hydrotalcite NN None
group NN None
and CC None
the DT None
remaining VBG None
126 CD None
in IN None
the DT None
esomeprazole JJ None
group NN None
. . None
NERD NNP None
patients NNS None
due JJ None
-DOCSTART- -X- N

Two CD None
hundred VBD None
twenty-eight JJ None
first-admission NN None
schizophrenic JJ None
patients NNS None
-DOCSTART- -X- N

postmenopausal JJ Condition
women NNS Condition
. . Condition
three CD None
groups NNS None
of IN None
postmenopausal JJ None
women NNS None
given VBN None
0.025 CD None
mg NNS None
, , None
0.05 CD None
mg NN None
, , None
or CC None
0.1 CD None
mg NNS None
transdermal JJ None
oestradiol JJ None
daily RB None
. . None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
persistent JJ Condition
arm NN Condition
pain NN Condition
. . Condition
placebo NN None
controls NNS None
. . None
270 CD None
adults NNS None
with IN None
arm NN None
pain NN None
due JJ None
to TO None
repetitive VB None
use NN None
that WDT None
had VBD None
lasted VBN None
at IN None
least JJS None
three CD None
months NNS None
despite IN None
treatment NN None
and CC None
who WP None
scored VBD None
> NNP None
or CC None
=3 VBN None
on IN None
a DT None
10 CD None
point NN None
pain NN None
scale NN None
. . None
-DOCSTART- -X- N

autism NN None
spectrum NN None
disorders NNS None
. . None
patients NNS None
diagnosed VBN None
with IN None
an DT None
autism NN None
spectrum NN None
disorder NN None
Thirty NNP None
subjects NNS None
diagnosed VBD None
with IN None
an DT None
ASD NNP None
-DOCSTART- -X- N

rhinorrhea NN Condition
in IN None
the DT None
laryngectomized JJ Condition
patient NN Condition
: : None
Participants NNS None
were VBD None
selected VBN None
if IN None
they PRP None
had VBD None
a DT None
total JJ Condition
laryngectomy NN Condition
and CC None
complained VBD None
of IN None
rhinorrhea NN Condition
. . None
Six CD Size
patients NNS None
entered VBD None
and CC None
completed VBD None
the DT None
study NN None
. . None
-DOCSTART- -X- N

discoid JJ None
lupus NN None
erythematosus NN None
. . None
patients NNS None
with IN None
therapy-resistant JJ None
discoid NN None
lupus NN None
erythematosus NN None
( ( None
DLE NNP None
) ) None
. . None
Thirty-seven JJ None
patients NNS None
with IN None
at IN None
least JJS None
one CD None
newly RB None
developed VBN None
DLE NNP None
lesion NN None
-DOCSTART- -X- N

advanced JJ None
gastric JJ Condition
carcinoma NN Condition
( ( None
stage JJ None
IV NNP None
) ) None
: : None
Forty-six JJ Condition
patients NNS None
with IN None
advanced JJ None
gastric JJ Condition
carcinoma NN Condition
( ( None
Stage NNP None
IV NNP None
) ) None
were VBD None
evaluated VBN None
Thirty-three JJ Size
patients NNS None
had VBD None
measurable JJ Condition
disease NN Condition
and CC None
thirteen NN Size
had VBD None
only RB None
microscopic JJ None
residual JJ Condition
disease NN Condition
in IN None
the DT None
resection NN None
margins NNS None
. . None
Thirteen JJ Size
patients NNS None
-DOCSTART- -X- N

breastfeeding NN None
among IN None
Vietnamese JJ Condition
women NNS Sex
in IN None
Sydney NNP None
. . None
immigrant JJ Condition
Vietnamese JJ Condition
women NNS Sex
in IN None
Western JJ None
countries NNS None
The DT None
sample NN None
consisted VBD None
of IN None
182 CD Size
prenatal JJ Condition
Vietnamese JJ Condition
women NNS Sex
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
osteoarthritis NN None
. . None
patients NNS None
with IN None
osteoarthritis NN None
( ( None
OA NNP None
) ) None
. . None
male NN None
and CC None
female JJ None
patients NNS None
( ( None
aged VBN None
at IN None
least JJS None
40 CD None
years NNS None
) ) None
with IN None
symptomatic JJ None
primary JJ None
OA NNP None
of IN None
the DT None
hip NN None
, , None
knee NN None
, , None
hand NN None
or CC None
spine NN None
patients NNS None
with IN None
OA NNP None
. . None
-DOCSTART- -X- N

autistic JJ None
children NNS None
: : None
20 CD None
autistic JJ None
children NNS None
received VBD None
40 CD None
mg/day NN None
of IN None
the DT None
neuropeptide NN None
ORG NNP None
2766 CD None
, , None
a DT None
synthetic JJ None
analog NN None
of IN None
ACTH NNP None
( ( None
4-9 JJ None
) ) None
, , None
for IN None
8 CD None
weeks NNS None
. . None
-DOCSTART- -X- N

primary JJ Condition
biliary JJ Condition
cirrhosis NN Condition
: : None
Primary JJ Condition
biliary JJ Condition
cirrhosis NN Condition
( ( Condition
PBC NNP Condition
) ) Condition
is VBZ None
a DT None
chronic JJ None
, , None
progressive JJ None
, , None
cholestatic JJ None
liver NN Condition
disease NN Condition
. . None
from IN None
42 CD Size
patients NNS None
with IN None
PBC NNP Condition
-DOCSTART- -X- N

patients NNS None
with IN None
seasonal JJ Condition
allergic JJ Condition
conjunctivitis NN Condition
. . None
A DT None
total NN None
of IN None
135 CD Size
patients NNS None
with IN None
signs NNS None
and CC None
symptoms NNS None
of IN None
seasonal JJ Condition
allergic JJ Condition
conjunctivitis NN Condition
participated VBD None
. . None
-DOCSTART- -X- N

advanced JJ Condition
colorectal JJ Condition
cancer NN Condition
. . None
patients NNS None
with IN None
unresectable JJ None
, , None
advanced JJ Condition
colorectal JJ Condition
carcinoma NN Condition
. . None
Forty-nine JJ Size
chemotherapy-naive JJ Condition
patients NNS None
were VBD None
randomized VBN None
-DOCSTART- -X- N

patients NNS None
with IN None
knee JJ None
osteoarthritis NN None
. . None
patients NNS None
with IN None
tibiofemoral JJ None
( ( None
TF NNP None
) ) None
osteoarthritis NN None
( ( None
OA NNP None
) ) None
. . None
167 CD None
patients NNS None
with IN None
knee JJ None
OA NNP None
. . None
-DOCSTART- -X- N

severe JJ Condition
traumatic JJ Condition
brain NN Condition
injury NN Condition
patients NNS Condition
: : Condition
severe JJ Condition
traumatic JJ Condition
brain NN Condition
injury NN Condition
( ( Condition
TBI NNP Condition
) ) Condition
patients NNS Condition
. . Condition
240 CD None
patients NNS None
with IN None
severe JJ None
TBI NNP None
( ( None
GCS NNP None
score RB None
3-8 JJ None
) ) None
admitted VBD None
to TO None
NICU NNP None
gender NN None
( ( None
66 CD None
% NN None
vs. FW None
67 CD None
% NN None
male NN None
) ) None
, , None
age NN None
( ( None
46+/-11 CD None
years NNS None
vs. IN None
45+/-10 CD None
years NNS None
) ) None
, , None
APACHE NNP None
II NNP None
score NN None
( ( None
30 CD None
vs. FW None
29 CD None
) ) None
, , None
TISS-28 NNP None
score NN None
( ( None
47 CD None
vs. FW None
46 CD None
) ) None
, , None
and CC None
Glasgow NNP None
Coma NNP None
Score NNP None
( ( None
GCS NNP None
, , None
5.3 CD None
vs. FW None
5.3 CD None
) ) None
patients NNS Condition
with IN Condition
severe JJ Condition
TBI NNP Condition
. . Condition
severe JJ Condition
TBI NNP Condition
patients NNS Condition
. . Condition
-DOCSTART- -X- N

chemo-na?ve JJ None
patients NNS None
with IN None
advanced JJ None
non-small JJ None
cell NN None
lung NN None
cancer NN None
chemo-na?ve JJ None
non-small JJ None
cell NN None
lung NN None
cancer NN None
patients NNS None
Patients NNPS None
with IN None
chemo-na?ve JJ None
stage NN None
IIIB/IV NNP None
non-small NN None
cell NN None
lung NN None
cancer NN None
A DT None
total NN None
of IN None
80 CD None
patients NNS None
were VBD None
entered VBN None
in IN None
this DT None
trial NN None
. . None
-DOCSTART- -X- N

children NNS Age
suffering VBG None
from IN None
severe JJ Condition
protein-energy JJ Condition
malnutrition NN Condition
. . None
hospital NN None
of IN None
children NNS None
suffering VBG None
from IN None
severe JJ None
protein-energy JJ None
malnutrition NN None
( ( None
PEM NNP Condition
) ) None
. . None
group NN None
( ( None
short- JJ None
versus IN None
long-stay NN None
) ) None
and CC None
one CD None
repeated VBN None
measures NNS None
factor NN None
( ( None
admission NN None
, , None
then RB None
12 CD None
, , None
18 CD None
, , None
24 CD None
, , None
30 CD None
and CC None
36 CD None
months NNS None
post-admission NN None
) ) None
SETTING NNP None
Primary NNP None
health NN None
care NN None
, , None
Kingston NNP None
, , None
Jamaica NNP None
. . None
SUBJECTS NNP None
n JJ None
= NNP None
81 CD Size
; : None
mean JJ None
age NN None
11 CD Age
months NNS Age
; : None
79 CD None
contribute VBP None
longitudinal JJ None
data NNS None
; : None
44 CD None
every DT None
measurement NN None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
autism NN None
in IN None
children NNS None
. . None
Children NNP None
with IN None
core NN Condition
autism NN Condition
( ( None
aged VBN None
2 CD Age
years NNS Age
to TO Age
4 CD Age
years NNS Age
and CC Age
11 CD Age
months NNS Age
) ) None
were VBD None
randomly RB None
assigned VBN None
in IN None
a DT None
one-to-one JJ None
ratio NN None
to TO None
a DT None
parent-mediated JJ None
communication-focused JJ None
was VBD None
by IN None
use NN None
of IN None
minimisation NN None
of IN None
probability NN None
in IN None
the DT None
marginal JJ None
distribution NN None
of IN None
treatment NN None
centre NN None
, , None
age NN None
( ( None
< JJ None
/=42 NNP None
months NNS None
or CC None
> $ None
42 CD None
months NNS None
) ) None
, , None
and CC None
autism NN None
severity NN None
( ( None
Autism NNP None
Diagnostic NNP None
Observation NNP None
Schedule-Generic NNP None
[ NNP None
ADOS-G NNP None
] NNP None
algorithm VBZ None
score RB None
12-17 JJ None
or CC None
18-24 JJ None
) ) None
parent-child JJ None
152 CD Size
children NNS None
were VBD None
recruited VBN None
. . None
77 CD Size
were VBD None
assigned VBN None
to TO None
PACT NNP None
( ( None
London NNP None
[ NNP None
n=26 MD None
] VB None
, , None
Manchester NNP None
[ NNP None
n=26 MD None
] VB None
, , None
and CC None
Newcastle NNP None
[ NNP None
n=25 FW None
] NNP None
) ) None
; : None
and CC None
75 CD Size
to TO None
treatment NN None
as IN None
usual JJ None
( ( None
London NNP None
[ NNP None
n=26 MD None
] VB None
, , None
Manchester NNP None
[ NNP None
n=26 MD None
] VB None
, , None
and CC None
Newcastle NNP None
[ NNP None
n=23 FW None
] NNP None
) ) None
. . None
-DOCSTART- -X- N

healthy JJ None
men NNS Sex
and CC None
women NNS Sex
from IN None
five CD None
European JJ None
countries NNS None
: : None
France NNP None
, , None
Ireland NNP None
, , None
The DT None
Netherlands NNP None
, , None
Spain NNP None
, , None
and CC None
the DT None
U.K NNP None
. . None
Volunteers NNS None
, , None
aged VBD None
25 CD Age
45 CD Age
, , None
all DT None
nonsmokers NNS None
-DOCSTART- -X- N

diastolic JJ None
versus NN None
systolic JJ None
heart NN None
failure NN None
. . None
patients NNS None
with IN None
heart NN None
failure NN None
( ( None
HF NNP None
) ) None
with IN None
normal JJ None
left JJ None
ventricular NN None
( ( None
LV NNP None
) ) None
ejection NN None
fractions NNS None
( ( None
EFs NNP None
) ) None
patients NNS None
with IN None
HF NNP None
with IN None
normal JJ None
EFs NNP None
( ( None
> VB None
50 CD None
% NN None
; : None
i.e. CC None
diastolic JJ None
HF NNP None
) ) None
185 CD None
patients NNS None
with IN None
systolic JJ None
HF NNP None
( ( None
79 CD None
% NN None
men NNS None
, , None
mean JJ None
age NN None
62.6 CD None
+/- JJ None
10.9 CD None
years NNS None
) ) None
and CC None
43 CD None
with IN None
diastolic JJ None
HF NNP None
( ( None
54 CD None
% NN None
men NNS None
, , None
mean JJ None
age NN None
67.4 CD None
+/- JJ None
9.8 CD None
years NNS None
) ) None
enrolled VBD None
in IN None
a DT None
phase NN None
II NNP None
multicenter NN None
clinical JJ None
trial NN None
. . None
Patients NNS None
in IN None
the DT None
diastolic JJ None
HF NNP None
group NN None
tended VBD None
to TO None
be VB None
older JJR None
( ( None
p JJ None
< NNP None
0.08 CD None
) ) None
, , None
with IN None
more JJR None
women NNS None
( ( None
p JJ None
< NNP None
0.006 CD None
) ) None
and CC None
with IN None
greater JJR None
body NN None
mass NN None
indexes NNS None
( ( None
p JJ None
-DOCSTART- -X- N

patients NNS None
with IN None
advanced JJ Condition
breast NN Condition
cancer NN Condition
: : None
in IN None
patients NNS None
with IN None
breast JJ Condition
cancer NN Condition
with IN Condition
bone NN Condition
metastases NNS Condition
. . None
placebo NN None
( ( None
n JJ None
= NNP None
1,026 CD None
) ) None
placebo NN None
( ( None
n JJ None
= NNP None
1,020 CD None
) ) None
in IN None
patients NNS None
with IN None
breast JJ None
cancer NN None
metastatic NN None
to TO None
bone NN None
for IN None
patients NNS None
with IN None
bone NN None
metastases NNS None
. . None
-DOCSTART- -X- N

patients NNS None
operated VBN None
on IN None
for IN None
hip NN None
prosthesis NN None
] NNP None
211 CD None
patients NNS None
of IN None
both DT None
sexes NNS None
candidates NNS None
to TO None
receive VB None
total JJ None
hip NN None
arthroplasty NN None
and CC None
presenting NN None
at IN None
least JJS None
one CD None
major JJ None
thromboembolic NN None
risk NN None
factor NN None
patients NNS None
undergoing VBG None
major JJ None
orthopaedic JJ None
surgery NN None
. . None
-DOCSTART- -X- N

after IN None
carotid JJ Condition
endarterectomy NN Condition
: : None
Ninety-five JJ None
consecutive JJ None
primary JJ None
carotid NN None
endarterectomies NNS None
were VBD None
performed VBN None
in IN None
a DT None
prospective JJ None
randomized VBN None
fashion NN None
in IN None
92 CD Size
patients NNS None
. . None
Fifty-one CD None
procedures NNS None
-DOCSTART- -X- N

multiple JJ Condition
sclerosis NN Condition
: : None
MS NNP Condition
patients NNS None
-DOCSTART- -X- N

an DT None
observer NN None
seated VBN None
in IN None
the DT None
center NN None
of IN None
an DT None
anechoic JJ None
chamber NN None
. . None
observer NN None
's POS None
front JJ None
hemifield NN None
at IN None
ear JJ None
level NN None
Observers NNS None
judged VBD None
the DT None
direction NN None
of IN None
motion NN None
( ( None
left VBD None
or CC None
right JJ None
) ) None
of IN None
each DT None
probe NN None
. . None
-DOCSTART- -X- N

Erythema JJ Condition
migrans NNS Condition
: : None
64 CD Size
patients NNS None
with IN None
typical JJ None
erythema NN Condition
migrans NNS Condition
. . None
-DOCSTART- -X- N

included VBD None
132 CD Size
patients NNS None
with IN None
grass JJ Condition
pollen-induced JJ Condition
rhinoconjunctivitis NN Condition
. . None
patients NNS None
received VBD None
6 CD None
weekly JJ None
patches NNS None
. . None
-DOCSTART- -X- N

Malpura NNP None
ewes FW None
under IN None
semi-arid JJ None
tropical JJ None
environment NN None
. . None
Malpura NNP None
ewes NN None
. . None
Twenty-eight JJ Size
adult NN None
Malpura NNP None
ewes NN None
were VBD None
used VBN None
animals NNS None
were VBD None
stall JJ None
fed VBN None
-DOCSTART- -X- N

intestinal JJ Condition
metaplasia NN Condition
H. NNP None
pylori FW None
infection NN None
: : None
Volunteers NNPS None
from IN None
the DT None
Yantai NNP None
County NNP None
in IN None
China NNP None
underwent JJ None
upper JJ None
endoscopy NN None
with IN None
biopsy NN None
specimens NNS None
obtained VBN None
from IN None
the DT None
antrum NN None
and CC None
corpus NN None
. . None
H. NNP None
pylori-infected JJ None
subjects NNS None
total NN None
of IN None
587 CD Size
H. NNP None
pylori-infected JJ None
subjects NNS None
were VBD None
randomized VBN None
to TO None
OAC NNP None
245 CD Size
patients NNS None
remained VBD None
H. NNP None
pylori NN None
infected VBD None
. . None
-DOCSTART- -X- N

primary JJ None
mediastinal JJ None
B-cell NNP None
lymphoma NN None
: : None
patients NNS None
with IN None
primary JJ None
mediastinal JJ None
B-cell NNP None
lymphoma NN None
( ( None
PMBCL NNP None
) ) None
From IN None
1989 CD None
to TO None
1997 CD None
, , None
68 CD None
patients NNS None
diagnosed VBN None
with IN None
previously RB None
untreated VBN None
PMBCL NNP None
, , None
aged VBD None
18-65 CD None
years NNS None
and CC None
negative JJ None
for IN None
immunodeficiency NN None
virus NN None
test NN None
patients NNS None
with IN None
PMBCL NNP None
-DOCSTART- -X- N

polycystic JJ Condition
ovarian JJ Condition
syndrome NN Condition
patients NNS None
. . None
polycystic JJ None
ovarian JJ None
syndrome NN None
( ( Condition
PCOS NNP Condition
) ) Condition
patients NNS None
. . None
patients NNS None
with IN None
PCOS NNP None
undergoing VBG None
controlled VBN Condition
ovarian JJ Condition
hyperstimulation NN Condition
( ( Condition
COH NNP Condition
) ) Condition
with IN None
GnRH NNP None
agonist VBP None
112 CD Size
infertile JJ None
PCOS NNP None
patients NNS None
entering VBG None
assisted JJ None
reproduction NN None
cycles NNS None
. . None
-DOCSTART- -X- N

metastatic JJ Condition
breast NN Condition
carcinoma NN Condition
. . None
Two CD Size
hundred VBD Size
twenty-four JJ Size
patients NNS None
with IN None
MBC NNP Condition
and CC None
no DT None
prior JJ None
therapy NN None
for IN None
metastatic JJ None
disease NN None
Patients NNS None
were VBD None
removed VBN None
from IN None
study NN None
if IN None
LVEF NNP None
declined VBD None
20 CD None
or CC None
more JJR None
EF JJ None
units NNS None
from IN None
baseline NN None
to TO None
a DT None
final JJ None
value NN None
of IN None
greater JJR None
than IN None
or CC None
equal JJ None
to TO None
50 CD None
% NN None
, , None
or CC None
by IN None
10 CD None
or CC None
more JJR None
units NNS None
to TO None
a DT None
final JJ None
value NN None
of IN None
less JJR None
than IN None
50 CD None
% NN None
, , None
or CC None
onset NN None
of IN None
clinical JJ None
congestive JJ None
heart NN None
failure NN None
( ( None
CHF NNP None
) ) None
Median JJ None
age NN None
was VBD None
54 CD Age
years NNS Age
in IN None
both DT None
treatment NN None
groups NNS None
. . None
-DOCSTART- -X- N

subjects NNS None
> VBP None
or CC None
=50 CD None
years NNS None
of IN None
age NN None
Subjects VBZ None
with IN None
a DT None
negative JJ None
history NN None
for IN None
HZ NNP None
Enrollment NN None
was VBD None
stratified VBN None
1:2 CD None
by IN None
age NN None
( ( None
50 CD None
to TO None
59 CD None
years NNS None
and CC None
> NN None
or CC None
=60 CD None
years NNS None
-DOCSTART- -X- N

pterygium NN Condition
pterygium NN Condition
208 CD Size
patients NNS Size
( ( None
229 CD None
eyes NNS None
) ) None
with IN None
initial JJ None
pterygium NN Condition
-DOCSTART- -X- N

modification NN None
of IN None
agonist-antagonist JJ None
electromyographic JJ None
activity NN None
for IN None
rapid JJ None
movement NN None
inhibition NN None
. . None
Subjects NNS None
made VBD None
a DT None
fast JJ None
elbow NN None
extension NN None
movement NN None
to TO None
designated VBN None
target NN None
in IN None
response NN None
to TO None
a DT None
go JJ None
signal NN None
. . None
-DOCSTART- -X- N

chronically RB Condition
hospitalized VBN Condition
, , None
disabled JJ Condition
patients NNS None
with IN None
stroke NN Condition
. . None
chronically RB None
hospitalized VBN None
, , None
disabled VBD None
, , None
elderly JJ Age
patients NNS None
after IN None
stroke NN None
. . None
Duration NN None
of IN None
hospitalization NN None
was VBD None
more JJR None
than IN None
1 CD None
year NN None
because IN None
of IN None
insufficiency NN None
of IN None
nursing NN None
homes NNS None
. . None
elderly JJ None
patients NNS None
who WP None
are VBP None
chronically RB None
hospitalized VBN None
and CC None
disabled VBN None
as IN None
a DT None
result NN None
of IN None
hemiparesis NN Condition
after IN None
stroke NN None
. . None
Patients NNS None
with IN None
stroke NN None
chronically RB None
hospitalized VBN None
patients NNS None
poststroke VBD None
-DOCSTART- -X- N

urinary JJ None
incontinent NN None
elderly JJ None
women NNS None
. . None
elderly JJ None
women NNS None
urinary JJ None
incontinence NN None
in IN None
elderly JJ None
women NNS None
. . None
Postmenopausal NNP None
women NNS None
( ( None
age NN None
65 CD None
years NNS None
or CC None
older JJR None
) ) None
Twenty-four JJ None
women NNS None
treated VBN None
with IN None
ES NNP None
and CC None
11 CD None
women NNS None
treated VBN None
with IN None
Kegel NNP None
exercises NNS None
elderly JJ None
women NNS None
-DOCSTART- -X- N

adult NN Age
subjects NNS None
with IN None
a DT None
history NN None
of IN None
moderate-severe JJ Condition
grass NN Condition
pollen NN Condition
induced VBD Condition
rhinoconjunctivitis NN Condition
inadequately RB Condition
controlled VBN None
by IN None
symptomatic JJ None
medications NNS None
. . None
Subjects NNS None
-DOCSTART- -X- N

16 CD None
Japanese JJ None
subjects NNS None
-DOCSTART- -X- N

stage NN Condition
III NNP Condition
melanoma NN Condition
. . None
stage NN Condition
III NNP Condition
( ( Condition
regional JJ Condition
lymph NN Condition
nodes NNS Condition
) ) Condition
melanoma NN Condition
. . None
patients NNS None
without IN None
any DT None
detectable JJ None
metastases NNS Condition
Eighty-eight JJ Size
patients NNS None
determined VBD None
as IN None
eligible JJ None
for IN None
treatment NN None
were VBD None
enrolled VBN None
in IN None
the DT None
study NN None
. . None
-DOCSTART- -X- N

Final NNP None
height NN None
in IN None
girls NNS None
with IN None
turner NN Condition
syndrome NN Condition
growth NN None
hormone NN None
treatment NN None
60 CD Size
girls NNS Sex
with IN None
Turner NNP Condition
syndrome NN Condition
treated VBD None
in IN None
a DT None
randomized JJ None
dose-response JJ None
trial NN None
Girls NNP None
Fifty NNP Size
of IN None
the DT None
60 CD None
girls NNS None
( ( None
83 CD None
% NN None
) ) None
had VBD None
reached VBN None
a DT None
normal JJ None
FH NNP None
( ( None
FH NNP None
SD NNP None
score NN None
, , None
more JJR None
than IN None
-2 NN None
) ) None
-DOCSTART- -X- N

hemodialysis NN Condition
patients NNS None
: : None
hemodialysis NN Condition
( ( Condition
HD NNP Condition
) ) Condition
patients NNS None
. . None
HD NNP Condition
patients NNS None
. . None
HD NNP None
patients NNS None
undergoing JJ None
periprocedure NN None
bridging VBG None
anticoagulation NN Condition
. . None
29 CD Size
eligible JJ None
and CC None
consenting VBG None
patients NNS None
HD NNP None
patients NNS None
at IN None
-DOCSTART- -X- N

combined JJ None
spinal JJ None
epidural JJ None
anaesthesia NN None
. . None
116 CD None
parturients NNS None
undergoing JJ None
elective JJ None
Caesarean JJ None
section NN None
to TO None
receive VB None
anaesthesia NN None
using VBG None
one CD None
of IN None
these DT None
techniques NNS None
. . None
-DOCSTART- -X- N

Forty-eight JJ Size
nurses NNS None
with IN None
critical JJ None
care NN None
experience NN None
volunteered VBD None
to TO None
take VB None
part NN None
in IN None
this DT None
randomized VBN None
, , None
blinded VBD None
, , None
controlled VBD None
study NN None
conducted VBN None
in IN None
the DT None
simulation NN None
centre NN None
of IN None
an DT None
urban JJ None
hospital NN None
. . None
simulated JJ None
patient NN None
with IN None
septic JJ Condition
shock NN Condition
. . None
-DOCSTART- -X- N

cognitive JJ None
functioning NN None
patients NNS None
with IN None
MS NNP None
. . None
A NNP None
total NN None
of IN None
45 CD None
ambulatory JJ None
patients NNS None
with IN None
MS NNP None
and CC None
severe JJ None
fatigue NN None
-DOCSTART- -X- N

[ JJ None
Cannulation NNP Condition
of IN Condition
the DT Condition
internal JJ Condition
jugular NN Condition
vein NN Condition
using VBG None
2 CD None
ultrasonic JJ None
technics NNS None
. . None
-DOCSTART- -X- N

complex JJ Condition
regional JJ Condition
pain NN Condition
syndrome NN Condition
Twenty VB Size
subjects NNS None
with IN None
chronic JJ Condition
CRPS1 NNP Condition
initiated VBN None
by IN None
wrist JJ Condition
fracture NN Condition
and CC None
who WP None
satisfied VBD None
stringent JJ None
inclusion NN None
criteria NNS None
-DOCSTART- -X- N

breast NN Condition
cancer NN Condition
breast NN Condition
cancer NN Condition
long-term JJ None
follow-up NN None
of IN None
the DT None
HIP NNP None
breast NN Condition
cancer NN Condition
screening VBG None
trial NN None
. . None
breast NN Condition
cancer NN Condition
cases NNS None
breast NN Condition
cancer NN Condition
breast NN Condition
cancer NN Condition
entire JJ None
population NN None
-DOCSTART- -X- N

population NN None
based VBN None
Swedish JJ None
sample NN None
. . None
postpartum NN None
41 CD None
women NNS None
identified VBN None
as IN None
depressed JJ None
-DOCSTART- -X- N

patients NNS None
with IN None
unresectable JJ Condition
squamous JJ Condition
cell NN Condition
cancer NN Condition
of IN Condition
the DT Condition
esophagus NN Condition
. . None
patients NNS None
with IN None
unresectable JJ Condition
squamous JJ Condition
cell NN Condition
cancer NN Condition
of IN Condition
the DT Condition
esophagus NN Condition
. . None
Between NNP None
April NNP None
1999 CD None
and CC None
December NNP None
2005 CD None
, , None
125 CD Size
patients NNS None
were VBD None
randomised VBN None
-DOCSTART- -X- N

patients NNS None
with IN None
acute JJ Condition
migraine NN Condition
. . None
patients NNS None
acute JJ Condition
migraine NN Condition
attack NN None
. . None
-DOCSTART- -X- N

Tensile IN None
bond NN None
strength NN None
of IN None
a DT None
lithium-disilicate JJ None
pressed JJ None
glass NN None
ceramic NN None
to TO None
dentin VB None
adhesive JJ None
and CC None
ceramic JJ None
Sixty NNP None
7x3 CD None
mm NN None
pressed VBN None
ceramic JJ None
discs NN None
of IN None
IPS NNP None
e.max NN None
dentin NN None
surface NN None
treatments NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
insulin-dependent JJ Condition
diabetes NNS Condition
mellitus FW Condition
( ( None
IDDM NNP Condition
) ) None
in IN None
the DT None
Diabetes NNP None
Control NNP None
and CC None
Complications NNP None
Trial NNP None
( ( None
DCCT NNP None
) ) None
. . None
29 CD Size
DCCT NNP None
clinics NNS None
-DOCSTART- -X- N

superficial JJ None
basal NN None
cell NN None
carcinoma NN None
. . None
superficial JJ None
basal NN None
cell NN None
carcinoma NN None
( ( None
sBCC NN None
) ) None
. . None
Patients NNPS None
( ( None
n JJ None
= NNP None
32 CD None
) ) None
30 CD None
patients NNS None
( ( None
13 CD None
females NNS None
) ) None
, , None
14 CD None
on IN None
R1 NNP None
and CC None
16 CD None
on IN None
R2 NNP None
sBCC NN None
. . None
-DOCSTART- -X- N

after IN None
treatment NN None
of IN None
cryptococcal JJ Condition
meningitis NN Condition
in IN None
the DT None
acquired JJ Condition
immunodeficiency NN Condition
syndrome NN Condition
. . Condition
patients NNS None
with IN None
the DT None
acquired JJ Condition
immunodeficiency NN Condition
syndrome NN Condition
( ( Condition
AIDS NNP Condition
) ) Condition
all DT None
participants NNS None
had VBD None
sterile JJ None
cultures NNS None
of IN None
cerebrospinal JJ None
fluid NN None
, , None
blood NN None
, , None
and CC None
urine JJ None
after IN None
following VBG None
a DT None
standardized JJ None
course NN None
of IN None
therapy NN None
for IN None
culture-proved JJ None
cryptococcal JJ Condition
meningitis NN Condition
. . None
Of IN None
84 CD Size
patients NNS None
initially RB None
enrolled VBD None
, , None
16 CD Size
( ( None
19 CD None
percent NN None
) ) None
were VBD None
found VBN None
to TO None
have VB None
silent JJ None
, , None
persistent JJ None
infection NN Condition
on IN None
the DT None
basis NN None
of IN None
cultures NNS None
that WDT None
became VBD None
positive JJ None
after IN None
entry NN None
into IN None
the DT None
study NN None
; : None
7 CD Size
other JJ None
patients NNS None
were VBD None
lost VBN None
to TO None
follow-up NNS None
shortly RB None
after IN None
entry NN None
remaining VBG None
61 CD Size
patients NNS None
patients NNS None
with IN None
AIDS NNP Condition
-DOCSTART- -X- N

chronic JJ None
stroke NN None
patients NNS None
. . None
A NNP None
total NN None
of IN None
41 CD None
chronic JJ None
stroke NN None
patients NNS None
received VBD None
excitatory JJ None
TBS NNP None
to TO None
the DT None
ipsilesional NN None
hemisphere NN None
or CC None
inhibitory NN None
TBS NNP None
to TO None
the DT None
contralesional NN None
hemisphere NN None
in IN None
2 CD None
centers NNS None
; : None
-DOCSTART- -X- N

volunteers NNS None
. . None
Volunteer NNP None
subjects NNS None
( ( None
N NNP None
= NNP None
37 CD None
) ) None
subjects NNS None
taking VBG None
placebo NN None
. . None
-DOCSTART- -X- N

great JJ Condition
saphenous JJ Condition
varicose NN Condition
veins NNS Condition
. . None
Consecutive JJ None
patients NNS None
with IN None
symptomatic JJ Condition
varicose NN Condition
veins NNS Condition
due JJ Condition
to TO Condition
isolated JJ Condition
great JJ Condition
saphenous JJ Condition
vein NN Condition
( ( Condition
GSV NNP Condition
) ) Condition
incompetence NN Condition
and CC None
suitable JJ None
for IN None
RFA NNP None
GSV NNP None
in IN None
all DT None
47 CD Condition
patients NNS None
. . None
patients NNS None
with IN None
great JJ Condition
saphenous JJ Condition
varicose NN Condition
veins NNS Condition
. . None
-DOCSTART- -X- N

hypertensive JJ None
patients NNS None
undergoing VBG None
coronary JJ None
intervention NN None
by IN None
serial JJ None
volumetric JJ None
intravascular NN None
ultrasound NN None
analysis NN None
in IN None
Juntendo NNP None
university NN None
( ( None
ALPS-J NNP None
) ) None
patients NNS None
with IN None
coronary JJ None
artery NN None
disease NN None
( ( None
CAD NNP None
) ) None
. . None
hypertensive JJ None
CAD NNP None
patients NNS None
undergoing VBG None
elective JJ None
percutaneous JJ None
coronary JJ None
intervention NN None
( ( None
PCI NNP None
) ) None
. . None
Patients NNPS None
who WP None
have VBP None
hypertension NN None
and CC None
are VBP None
scheduled VBN None
for IN None
PCI NNP None
will MD None
be VB None
enrolled VBN None
. . None
hypertensive JJ None
patients NNS None
undergoing VBG None
elective JJ None
PCI NNP None
. . None
-DOCSTART- -X- N

condylomata NN None
acuminata NNS None
] RB None
treatment NN None
of IN None
condylomata NN Condition
acuminata NNS Condition
. . None
118 CD Size
evaluable JJ None
patients NNS None
: : None
32 CD Size
in IN None
the DT None
laser-CO2 JJ None
group NN None
, , None
34 CD Size
in IN None
the DT None
5-fluorouracil JJ None
group NN None
and CC None
52 CD Size
in IN None
the DT None
interferon NN None
group NN None
. . None
-DOCSTART- -X- N

24 CD Size
elderly JJ Age
patients NNS None
requiring VBG None
chronic JJ None
diuretic JJ None
therapy NN None
-DOCSTART- -X- N

14 CD Size
patients NNS None
with IN None
colonic JJ Condition
cancer NN Condition
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
: : None
children NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorder NN Condition
. . None
51 CD Size
children NNS Age
aged VBN Age
2 CD Age
years NNS Age
0 CD Age
months NNS Age
to TO Age
4 CD Age
years NNS Age
11 CD Age
months NNS Age
. . None
children NNS Age
with IN None
autism NN Condition
. . None
children NNS Age
's POS Age
-DOCSTART- -X- N

herpes NNS None
zoster NN None
. . None
herpes NNS None
zoster JJ None
infection NN None
. . None
-DOCSTART- -X- N

endotoxemia NN Condition
20 CD Size
healthy JJ Condition
, , None
male JJ Sex
subjects NNS None
-DOCSTART- -X- N

for IN None
patients NNS None
undergoing VBG None
coronary JJ None
artery NN None
bypass NN None
graft NN None
surgery NN None
. . None
for IN None
patients NNS None
undergoing VBG None
isolated JJ None
coronary JJ None
artery NN None
bypass NN None
graft NN None
surgery NN None
from IN None
2000 CD None
to TO None
2008 CD None
. . None
for IN None
patients NNS None
who WP None
received VBD None
preoperative JJ None
?-blockers NNS None
with IN None
those DT None
of IN None
patients NNS None
who WP None
did VBD None
not RB None
. . None
RESULTS VB None
12,855 CD None
patients NNS None
, , None
of IN None
whom WP None
7,967 CD None
( ( None
62.0 CD None
% NN None
) ) None
were VBD None
treated VBN None
preoperatively RB None
with IN None
?-blockers NNS None
. . None
Using VBG None
-DOCSTART- -X- N

chronic JJ None
low JJ None
back RB None
pain NN None
Sixty-one CD None
patients NNS None
( ( None
mean JJ None
age NN None
, , None
41 CD None
years NNS None
) ) None
with IN None
nonspecific JJ None
low JJ None
back RB None
pain NN None
were VBD None
randomized VBN None
patients NNS None
with IN None
chronic JJ None
low JJ None
back RB None
pain NN None
. . None
-DOCSTART- -X- N

prostate NN Condition
cancer NN Condition
. . None
Italian JJ None
PROSIT NNP None
study NN None
. . None
patients NNS None
with IN None
prostate JJ None
cancer NN None
and CC None
treated VBN None
with IN None
total JJ None
androgen NN None
ablation NN None
either DT None
for IN None
three CD None
or CC None
six CD None
months NNS None
before IN None
RP NNP None
. . None
Between NNP None
January NNP None
1996 CD None
and CC None
February NNP None
1998 CD None
, , None
259 CD None
men NNS Sex
with IN None
prostate NN Condition
cancer NN Condition
underwent JJ None
radical JJ None
retropubic NN None
prostatectomy NN None
and CC None
bilateral JJ None
pelvic JJ None
node NN None
dissection NN None
in IN None
the DT None
26 CD None
centres NNS None
participating VBG None
in IN None
the DT None
Italian JJ None
randomised VBD None
prospective JJ None
PROSIT NNP None
study NN None
. . None
114 CD None
patients NNS None
-DOCSTART- -X- N

acute JJ None
contrast NN None
nephropathy NN Condition
. . None
after IN None
exposure NN None
to TO None
radiocontrast VB Condition
media NNS None
. . None
98 CD Size
subjects NNS None
who WP None
underwent VBP None
cardiac JJ Condition
catheterization NN Condition
The DT None
mean JJ None
age NN None
, , None
baseline NN None
serum NN None
Cr NNP None
, , None
and CC None
Cr NNP None
clearance NN None
( ( None
CrCl NNP None
) ) None
were VBD None
69.3 CD Age
+/- JJ Age
10.8 CD Age
years NNS Age
, , None
2.5 CD None
+/- JJ None
0.9 CD None
mg/dL NN None
, , None
and CC None
31.4 CD None
+/- JJ None
12.1 CD None
mL/min NN None
, , None
respectively RB None
. . None
-DOCSTART- -X- N

higher-functioning JJ None
children NNS None
with IN None
autistic JJ None
spectrum NN None
disorders NNS None
. . None
children NNS None
with IN None
Autistic NNP None
Spectrum NNP None
Disorder NNP None
higher-functioning JJ None
children NNS None
more RBR None
severely RB None
impaired JJ None
children NNS None
. . None
-DOCSTART- -X- N

Three CD None
hundred VBD None
forty-one NN None
Tanzanian JJ None
preschool NN None
children NNS None
children NNS None
-DOCSTART- -X- N

preoperative JJ None
intentional JJ None
hemodilution NN None
surgical JJ Condition
patients NNS None
. . None
University NNP None
teaching VBG None
hospital NN None
. . None
Two CD None
groups NNS None
( ( None
control NN None
group NN None
[ NNP None
group NN None
1 CD None
] NN None
and CC None
hemodiluted VBN None
group NN None
[ NNP None
group NN None
2 CD None
] NN None
) ) None
of IN None
13 CD Size
healthy JJ None
patients NNS None
hemodiluted VBN None
group NN None
( ( None
group NN None
2 CD None
) ) None
group NN None
1 CD None
( ( None
0.7 CD None
+/- JJ None
0.4 CD None
vs. FW None
1.4 CD None
+/- JJ None
1.0 CD None
mL/min NN None
, , None
respectively RB None
; : None
p CC None
< NNP None
.05 NNP None
) ) None
. . None
preoperative JJ None
hemodilution NN None
. . None
-DOCSTART- -X- N

vivo NN None
in IN None
humans NNS None
. . None
humans NNS None
. . None
higher JJR None
insulin NN None
dosing VBG None
in IN None
obese JJ Condition
subjects NNS Condition
than IN None
lean JJ Condition
subjects NNS Condition
( ( None
30 CD None
vs. FW None
10 CD None
mU.m NN None
( ( None
-2 NNP None
) ) None
.min NNP None
( ( None
-1 NNP None
) ) None
, , None
respectively RB None
) ) None
-DOCSTART- -X- N

hypotensive JJ Condition
eye NN Condition
surgery NN Condition
. . None
Thirty NN Size
patients NNS None
undergoing VBG None
elective JJ Condition
eye NN Condition
surgery NN Condition
-DOCSTART- -X- N

postmenopausal JJ Condition
women NNS Condition
. . Condition
Filipino NNP None
female JJ None
adults NNS None
( ( None
30.8 CD None
% NN None
) ) None
was VBD None
found VBN None
in IN None
the DT None
age NN None
group NN None
from IN None
40 CD None
to TO None
59 CD None
years NNS None
. . None
postmenopausal JJ None
women NNS None
. . None
Women NNP None
who WP None
were VBD None
at IN None
least JJS None
5 CD None
years NNS None
postmenopausal NN None
were VBD None
invited VBN None
to TO None
participate VB None
Sixty NNP None
women NNS None
were VBD None
qualified VBN None
to TO None
participate VB None
postmenopausal JJ None
women NNS None
. . None
-DOCSTART- -X- N

RUPP NNP Condition
autism NN Condition
study NN None
: : None
Research NNP None
Units NNP None
on IN None
Pediatric NNP None
Psychopharmacology NNP None
( ( None
RUPP NNP None
) ) None
Autism NNP None
Network NNP None
parents NNS None
94 CD Size
participants NNS None
had VBD None
usable JJ None
data NNS None
. . None
parents NNS None
of IN None
autistic JJ Condition
children NNS Age
with IN None
irritable JJ Condition
behavior NN Condition
. . None
-DOCSTART- -X- N

extensor NN None
mechanism NN None
power NN None
following VBG None
total JJ Condition
knee JJ Condition
arthroplasty NN Condition
. . None
patients NNS None
by IN None
direct JJ None
physical JJ None
testing NN None
. . None
212 CD Condition
TKA JJ Condition
patients NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
adrenal JJ Condition
incidentaloma NN Condition
: : None
patients NNS None
with IN None
incidentally RB None
discovered VBN None
adrenal JJ Condition
adenomas NN Condition
. . None
patients NNS None
who WP None
do VBP None
not RB None
present VB None
with IN None
any DT None
clear JJ None
Cushingoid NNP None
sign NN None
. . None
10 CD Size
patients NNS None
( ( None
3 CD Size
men NNS Sex
and CC None
7 CD Size
women NNS Sex
, , None
aged VBD None
48-63 JJ Age
yr NN Age
) ) None
with IN None
an DT None
adrenal JJ None
mass NN None
discovered VBD None
serendipitously RB None
Thirteen JJ Size
age-matched JJ None
healthy JJ Condition
volunteers NNS Condition
served VBD None
as IN None
controls NNS Condition
. . None
Patients NNS None
with IN None
obesity NN Condition
and/or NN Condition
diabetes NNS Condition
were VBD Condition
excluded VBN Condition
. . None
patients NNS None
bearing VBG None
adrenal JJ Condition
incidentaloma NNS Condition
patients NNS None
with IN None
incidental JJ Condition
adrenal JJ Condition
adenomas IN Condition
-DOCSTART- -X- N

Internet-based JJ None
cognitive-behavioral JJ None
intervention NN None
for IN None
complicated JJ None
grief NN None
. . None
Treatment NNP None
group NN None
patients NNS None
( ( None
n JJ None
= NNP None
22 CD Size
) ) None
were VBD None
administered VBN None
various JJ None
assessments NNS None
of IN None
complicated JJ None
grief NN None
indicators NNS None
-DOCSTART- -X- N

false-negative JJ Condition
sextant JJ Condition
prostate NN Condition
biopsies NNS Condition
. . Condition
false-negative JJ None
sextant JJ None
prostate NN None
biopsies NNS None
in IN None
patients NNS None
undergoing VBG None
radical JJ None
prostatectomy NN None
. . None
A NNP None
total NN None
of IN None
118 CD None
patients NNS None
with IN None
biopsy NN None
proved VBN None
prostate JJ None
cancer NN None
118 CD None
patients NNS None
-DOCSTART- -X- N

benign VB Condition
paroxysmal JJ Condition
positional JJ Condition
vertigo NN Condition
in IN Condition
the DT Condition
elderly JJ Condition
. . Condition
benign JJ None
positional JJ None
paroxysmal NN None
vertigo NN None
( ( None
BPPV NNP None
) ) None
in IN None
elderly JJ None
persons NNS None
. . None
Forty-seven JJ None
patients NNS None
( ( None
> JJ None
/=70 CD None
years NNS None
old JJ None
) ) None
with IN None
the DT None
diagnosis NN None
of IN None
unilateral JJ None
posterior JJ None
semicircular JJ None
canal NN None
BPPV NNP None
BPPV NNP None
in IN None
the DT None
elderly JJ None
. . None
-DOCSTART- -X- N

young JJ Age
children NNS Age
during IN None
general JJ None
anesthesia NN Condition
. . Condition
young JJ Age
children NNS Age
. . None
patients NNS None
Full-term NNP Age
newborns NNS Age
and CC Age
children NNS Age
( ( None
n JJ None
= NNP None
488 CD Size
) ) Condition
through IN None
8 CD None
yr NN None
of IN None
age NN None
who WP None
required VBD None
general JJ Condition
anesthesia NN Condition
and CC Condition
tracheal JJ Condition
intubation NN Condition
young JJ Age
children NNS Age
. . None
full-term JJ Age
newborns NNS Age
and CC Age
children NNS Age
during IN None
anesthesia NN Condition
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
Helicobacter NNP Condition
pylori JJ Condition
infection NN Condition
. . None
Fourteen JJ Size
patients NNS None
with IN None
Helicobacter NNP None
pylori FW None
infection NN None
-DOCSTART- -X- N

healthy JJ None
male NN None
volunteers NNS None
healthy JJ None
subjects NNS None
. . None
-DOCSTART- -X- N

16 CD Size
patients NNS None
with IN None
relapsing VBG Condition
non-Hodgkin NN Condition
's POS Condition
malignant JJ Condition
lymphomas NN Condition
considered VBN None
as IN None
clinical JJ None
stage NN None
I PRP None
or CC None
II NNP None
5 CD Size
of IN None
them PRP None
were VBD None
included VBN None
in IN None
a DT None
randomized JJ None
trial NN None
11 CD Size
were VBD None
systematically RB None
treated VBN None
by IN None
BCG NNP None
-DOCSTART- -X- N

five CD Size
normal JJ Condition
subjects NNS None
-DOCSTART- -X- N

autistic JJ None
disorder NN None
. . None
12 CD None
autistic JJ None
subjects NNS None
12 CD None
different JJ None
subjects NNS None
A DT None
referral JJ None
sample NN None
of IN None
30 CD None
male NN None
and CC None
female JJ None
autistic JJ None
patients NNS None
were VBD None
enrolled VBN None
, , None
and CC None
24 CD None
completed VBD None
the DT None
study NN None
. . None
autistic JJ None
disorder NN None
-DOCSTART- -X- N

early-stage JJ None
non-small-cell JJ None
lung NN None
cancer NN None
( ( None
IFCT NNP None
0002 CD None
trial NN None
) ) None
. . None
resectable JJ None
StageI-II JJ None
non-small-cell JJ None
lung NN None
cancer NN None
( ( None
NSCLC NNP None
) ) None
. . None
RESULTS VB None
A DT None
total NN None
of IN None
528 CD None
patients NNS None
in IN None
early-stage JJ None
NSCLC NNP None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
refractory JJ Condition
monosymptomatic JJ Condition
nocturnal JJ Condition
enuresis NN Condition
28 CD Size
patients NNS None
with IN None
refractory JJ None
monosymptomatic JJ None
nocturnal JJ None
enuresis NN None
patients NNS None
with IN None
refractory JJ None
monosymptomatic JJ None
nocturnal JJ None
enuresis NN None
-DOCSTART- -X- N

90 CD None
patients NNS None
( ( None
78 CD None
women NNS None
; : None
median JJ None
age NN None
, , None
52 CD None
yr NN None
; : None
range NN None
, , None
22-83 JJ None
) ) None
with IN None
a DT None
nontoxic JJ None
nodular JJ None
goiter NN None
( ( None
median JJ None
size NN None
, , None
63 CD None
ml NN None
; : None
range NN None
, , None
25-379 JJ None
ml NN None
) ) None
were VBD None
randomized VBN None
-DOCSTART- -X- N

patients NNS None
undergoing VBG None
coronary JJ None
artery NN None
bypass NN None
surgery NN None
. . None
patients NNS None
undergoing VBG None
coronary JJ None
artery NN None
bypass NN None
graft NN None
surgery NN None
( ( None
CABG NNP None
) ) None
. . None
Sixty JJ None
patients NNS None
( ( None
age NN None
40-73 CD None
yr NN None
, , None
56 CD None
male NN None
) ) None
were VBD None
assigned VBN None
randomly RB None
to TO None
receive VB None
alfentanil NN None
, , None
fentanyl NN None
or CC None
sufentanil NN None
and CC None
propofol NN None
patients NNS None
undergoing VBG None
CABG NNP None
-DOCSTART- -X- N

osteoarthritis NN Condition
of IN None
the DT None
ankle NN Condition
. . None
patients NNS None
with IN None
osteoarthritis NN None
( ( None
OA NNP Condition
) ) None
of IN None
the DT None
ankle NN None
. . None
43 CD None
ankles NNS None
( ( None
30 CD Size
patients NNS None
) ) None
with IN None
radiographic JJ None
Kellgren NNP None
Lawrence NNP None
grade VBD None
III NNP None
OA NNP None
-DOCSTART- -X- N

Endometrial JJ None
cytodiagnosis NN None
cytological JJ None
screening NN None
for IN None
endometrial JJ None
cancer NN None
315 CD Size
women NNS Size
( ( None
premenopause IN None
251 CD Size
, , None
postmenopause RB None
64 CD Size
) ) None
were VBD None
randomly RB None
assigned VBN None
to TO None
two CD None
groups NNS None
who WP None
underwent VBP None
the DT None
endometrial JJ None
cytological JJ None
screening NN None
with IN None
either CC None
the DT None
softcyte NN None
or CC None
the DT None
endocyte NN None
. . None
screening VBG None
for IN None
endometrial JJ None
cancer NN None
. . None
-DOCSTART- -X- N

laparoscopically RB None
assisted VBN None
vaginal JJ None
hysterectomy NN None
: : None
abdominal JJ None
hysterectomy NN None
in IN None
patients NNS None
with IN None
symptomatic JJ Condition
uterine JJ Condition
fibroids NNS Condition
. . None
patients NNS None
with IN None
uterine JJ Condition
fibroids NNS Condition
. . None
The DT None
San NNP None
Paolo NNP None
Hospital NNP None
, , None
Milan NNP None
. . None
Sixty-two JJ Size
patients NNS None
, , None
who WP None
were VBD None
not RB None
suitable JJ None
for IN None
a DT None
vaginal JJ None
hysterectomy NN None
, , None
requiring VBG None
treatment NN None
for IN None
uterine JJ Condition
fibroids NNS Condition
. . None
-DOCSTART- -X- N

Prospective NNP None
study NN None
of IN None
104 CD None
consecutive JJ None
patients NNS None
undergoing VBG None
coronary JJ None
angiography NN None
who WP None
were VBD None
randomized VBN None
-DOCSTART- -X- N

Syncope NNP Condition
syncope VB None
patients NNS None
with IN None
syncope NN None
who WP None
are VBP None
at IN None
intermediate JJ None
risk NN None
for IN None
an DT None
adverse JJ None
cardiovascular JJ None
outcome NN None
. . None
single-center JJ None
study NN None
, , None
patients NNS None
One CD None
hundred VBD None
three CD None
consecutive JJ None
patients NNS None
( ( None
53 CD None
women NNS None
; : None
mean JJ None
age NN None
64+/-17 CD None
years NNS None
) ) None
entered VBD None
the DT None
study NN None
. . None
intermediate-risk JJ None
patients NNS None
. . None
-DOCSTART- -X- N

mixed-disability JJ None
families NNS None
of IN None
a DT None
child NN None
with IN None
a DT None
disability NN None
. . None
mixed-disability NN None
group NN None
. . None
Participants NNS None
were VBD None
52 CD Condition
families NNS Condition
of IN Condition
children NNS Condition
diagnosed VBN None
with IN None
an DT None
Autism NNP Condition
Spectrum NNP Condition
Disorder NNP Condition
, , None
Down NNP Condition
syndrome NN Condition
, , None
Cerebral NNP Condition
Palsy NNP Condition
, , None
or CC None
an DT None
intellectual JJ Condition
disability NN Condition
. . None
-DOCSTART- -X- N

in IN None
preschoolers NNS None
with IN None
developmental JJ None
disorders NNS None
. . None
understudied JJ None
population NN None
of IN None
preschoolers NNS None
with IN None
pervasive JJ None
developmental JJ None
disorder NN None
( ( None
PDD NNP None
) ) None
or CC None
intellectual JJ None
disability NN None
( ( None
ID NNP None
) ) None
. . None
Fourteen NNP None
preschoolers NNS None
with IN None
developmental JJ None
disorders NNS None
( ( None
DD NNP None
, , None
n JJ None
= VBP None
14 CD None
; : None
PDD NNP None
, , None
n JJ None
= VBP None
12 CD None
; : None
ID NNP None
, , None
n JJ None
= NNP None
2 CD None
) ) None
PDD NNP None
subgroup NN None
preschoolers NNS None
preschoolers NNS None
with IN None
both DT None
ADHD NNP None
and CC None
PDD/ID NNP None
-DOCSTART- -X- N

depression NN None
in IN None
Parkinson NNP None
's POS None
disease NN None
. . None
people NNS None
with IN None
Parkinson NNP None
's POS None
disease NN None
( ( None
PD NNP None
) ) None
after IN None
their PRP$ None
participation NN None
in IN None
an DT None
NIH-sponsored JJ None
, , None
randomized VBN None
, , None
controlled VBD None
trial NN None
of IN None
cognitive-behavioral JJ None
treatment NN None
for IN None
depression NN None
. . None
-DOCSTART- -X- N

participants NNS Condition
with IN Condition
knee NN Condition
osteoarthritis NN Condition
: : Condition
participants NNS Condition
with IN Condition
knee NN Condition
osteoarthritis NN Condition
. . Condition
Participants NNS None
( ( None
N=106 NNP None
) ) None
-DOCSTART- -X- N

menopause NN Condition
menopausal NN Condition
hot JJ Condition
flushes NNS Condition
, , None
sleep JJ Condition
disturbances NNS Condition
, , None
and CC None
mood NN Condition
changes NNS Condition
. . None
experimental JJ None
acupuncture NN None
treatment NN None
group NN None
acupuncture NN None
treatment NN None
group NN None
experimental JJ None
acupuncture NN None
treatment NN None
group NN None
experimental JJ None
acupuncture NN None
treatment NN None
group NN None
and CC None
the DT None
comparison NN None
acupuncture NN None
treatment NN None
group NN None
-DOCSTART- -X- N

radiation-induced JJ None
xerostomic JJ None
subjects NNS None
. . None
head NN None
and CC None
neck NN None
cancer NN None
patients NNS None
. . None
Twenty-two JJ None
head NN None
and CC None
neck NN None
cancer NN None
patients NNS None
from IN None
U. NNP None
T. NNP None
M. NNP None
D. NNP None
Anderson NNP None
Cancer NNP None
Center NNP None
, , None
with IN None
radiation-induced JJ None
xerostomia NN None
Patients NNS None
in IN None
both DT None
groups NNS None
Patients NNS None
in IN None
the DT None
control NN None
group NN None
-DOCSTART- -X- N

paediatric JJ Age
cuffed NN Condition
tracheal NN Condition
tubes NNS Condition
50 CD Size
children NNS Age
undergoing VBG None
general JJ Condition
anaesthesia NN Condition
with IN Condition
tracheal JJ Condition
intubation NN Condition
and CC None
standardized JJ Condition
anaesthesia NN Condition
technique NN Condition
( ( None
including VBG None
66 CD None
% NN None
N2O NNP None
in IN None
O2 NNP None
) ) None
and CC None
ventilator JJ Condition
settings NNS Condition
. . None
-DOCSTART- -X- N

70 CD Size
patients NNS None
. . None
70 CD Size
patients NNS None
hospitalized VBN None
in IN None
the DT None
Coronary NNP None
Care NNP None
Unit NNP None
for IN None
unstable JJ Condition
angina NN Condition
, , None
defined VBN None
as IN None
recent JJ None
( ( None
less JJR None
than IN None
one CD None
month NN None
) ) None
appearance NN None
or CC None
aggravation NN None
of IN None
spontaneous JJ None
chest NN Condition
pains NNS Condition
. . Condition
Among IN None
the DT None
70 CD Size
patients NNS None
, , None
24 CD Size
had VBD None
angina VBN Condition
only RB None
at IN None
rest NN None
. . None
patients NNS None
have VBP None
been VBN None
divided VBN None
into IN None
two CD None
groups NNS None
according VBG None
to TO None
ST-T JJ None
changes NNS None
during IN None
chest NN Condition
pain NN Condition
: : None
29 CD Size
with IN None
ST NNP None
elevation NN None
( ( None
group NN None
A NNP None
) ) None
and CC None
41 CD Size
with IN None
other JJ None
repolarization NN Condition
abnormalities NNS Condition
( ( Condition
group NN Condition
B NNP Condition
) ) Condition
. . None
24 CD Size
patients NNS None
with IN None
angina JJ Condition
exclusively RB None
at IN None
rest NN None
unstable JJ None
angina NNS Condition
in IN None
patients NNS None
with IN None
angina NN Condition
which WDT None
is VBZ None
exclusively RB None
spontaneous JJ None
. . None
-DOCSTART- -X- N

breast NN None
cancer NN None
patients NNS None
: : None
postmenopausal JJ None
breast NN None
cancer NN None
patients NNS None
postmenopausal NN None
patients NNS None
with IN None
a DT None
history NN None
of IN None
breast NN None
cancer NN None
. . None
Seventy-one NNP None
postmenopausal NN None
patients NNS None
patients NNS None
with IN None
a DT None
history NN None
of IN None
breast NN None
cancer NN None
-DOCSTART- -X- N

obstetric JJ None
care NN None
practitioners NNS None
: : None
obstetric JJ None
care NN None
practitioners NNS None
Thirty NNP None
health NN None
care NN None
practitioners NNS None
Obstetric NNP None
care NN None
practitioners NNS None
-DOCSTART- -X- N

HIV NNP None
risk NN None
reduction NN None
among IN None
women NNS None
. . None
333 CD None
seronegative JJ None
African JJ None
American JJ None
female JJ None
drug NN None
users NNS None
( ( None
aged VBN None
18-59 CD None
years NNS None
) ) None
participating VBG None
in IN None
an DT None
HIV NNP None
intervention NN None
and CC None
with IN None
higher JJR None
levels NNS None
of IN None
emotional JJ None
distress NN None
, , None
specifically RB None
symptoms NNS None
of IN None
depression NN None
and CC None
anxiety NN None
Participants NNS None
recruited VBN None
between IN None
June NNP None
1998 CD None
and CC None
January NNP None
2001 CD None
from IN None
inner-city NN None
Atlanta NNP None
( ( None
Georgia NNP None
, , None
U.S. NNP None
) ) None
neighborhoods NNS None
randomly RB None
assigned VBN None
to TO None
one CD None
of IN None
two CD None
enhanced JJ None
gender-specific JJ None
and CC None
culturally RB None
specific JJ None
HIV NNP None
intervention NN None
conditions NNS None
high-risk JJ None
women NNS None
who WP None
may MD None
be VB None
most RBS None
resistant JJ None
to TO None
behavioral JJ None
change NN None
. . None
-DOCSTART- -X- N

cultural JJ None
differences NNS None
in IN None
emotional JJ None
self-reports NNS None
. . None
European JJ Age
Americans NNPS Age
were VBD Age
more JJR Age
accurate JJ Age
than IN Age
were VBD Age
Asian JJ Age
Americans NNPS Age
European JJ None
Americans NNPS None
Asian JJ None
Americans NNPS None
. . None
-DOCSTART- -X- N

patients NNS None
treated VBN None
with IN None
CDDP NNP None
( ( None
80 CD None
mg/m2 NN None
) ) None
-DOCSTART- -X- N

patients NNS None
Seventy-five JJ None
patients NNS None
undergoing VBG None
open JJ None
hernia NN None
repair NN None
as IN None
day NN None
care NN None
surgery NN None
-DOCSTART- -X- N

81 CD None
patients NNS None
with IN None
epilepsy NN None
69 CD None
completed VBD None
a DT None
1-month JJ None
monitoring NN None
period NN None
-DOCSTART- -X- N

outpatients NNS None
with IN None
cardiovascular JJ Condition
disease NN Condition
or CC None
cardiovascular JJ Condition
risk NN Condition
: : None
patients NNS None
with IN None
cardiovascular JJ Condition
disease NN Condition
( ( None
CVD NNP Condition
) ) None
patients NNS None
with IN None
CVD NNP Condition
. . None
patients NNS None
with IN None
CVD NNP None
and/or VBP None
high JJ Condition
or CC Condition
intermediate JJ Condition
cardiovascular NN Condition
( ( Condition
CV NNP Condition
) ) Condition
risk NN Condition
attending VBG None
community NN None
pharmacies NNS None
in IN None
Spain NNP None
. . None
Patients NNPS None
aged VBD None
25 CD Age
to TO Age
74 CD Age
years NNS None
attending VBG None
community NN None
pharmacies NNS None
with IN None
a DT None
prescription NN None
for IN None
at IN None
least JJS None
1 CD None
drug NN None
indicated VBN None
for IN None
CVD NNP None
or CC None
CV NNP Condition
risk NN None
factors NNS None
Patients NNS None
were VBD None
recruited VBN None
from IN None
December NNP None
2005 CD None
to TO None
September NNP None
2006 CD None
714 CD Size
patients NNS None
mean JJ None
[ NNP None
SD NNP None
] NNP None
age NN None
was VBD None
62.8 CD Age
[ JJ None
8.1 CD None
] JJ None
years NNS None
. . None
patients NNS None
with IN None
CVD NNP None
and/or VBP None
high JJ None
or CC None
intermediate JJ None
CV NNP None
risk NN None
attending VBG None
community NN None
pharmacies NNS None
in IN None
Spain NNP None
. . None
-DOCSTART- -X- N

infertility NN Condition
and CC None
endometriosis NN Condition
surgery NN None
. . None
Sixty-three JJ Size
infertility NN Condition
patients NNS None
-DOCSTART- -X- N

Fifty-one CD Size
patients NNS None
with IN None
raised VBN Condition
intraocular JJ Condition
pressure NN Condition
( ( Condition
IOP NNP Condition
) ) Condition
-DOCSTART- -X- N

50 CD Size
patients NNS None
were VBD None
investigated VBN None
during IN None
induction NN None
of IN None
anaesthesia NN Condition
and CC None
infrarenal JJ Condition
aortic JJ Condition
bypass NN Condition
surgery NN Condition
. . None
26 CD Size
were VBD None
operated VBN None
on IN None
under IN None
neuroleptanaesthesia NN Condition
( ( None
NA NNP None
group NN None
) ) None
and CC None
24 CD Size
under IN None
continuous JJ None
epidural JJ None
combined VBN None
with IN None
a DT None
light JJ Condition
general JJ Condition
anaesthesia NN Condition
( ( None
epidural JJ None
group NN None
) ) None
. . None
-DOCSTART- -X- N

older JJR Age
, , None
undernourished JJ Condition
, , None
community-dwelling JJ None
individuals NNS None
in IN None
primary JJ None
care NN None
: : None
older JJR None
, , None
community-dwelling JJ None
individuals NNS None
. . None
older JJR None
, , None
undernourished JJ Condition
, , None
community-dwelling JJ None
individuals NNS None
. . None
146 CD Size
non-institutionalized JJ Condition
, , Condition
undernourished JJ Condition
individuals NNS None
aged VBN None
?65 CD None
years NNS None
in IN None
primary JJ None
care NN None
. . None
functioning NN None
in IN None
older JJR None
, , None
undernourished JJ None
, , None
community-dwelling JJ None
individuals NNS None
. . None
-DOCSTART- -X- N

anthropometric NN None
, , None
metabolic JJ None
and CC None
biochemical JJ None
parameters NNS None
. . None
analysed VBD None
anthropometric JJ None
and CC None
metabolic JJ None
parameters NNS None
in IN None
five CD None
groups NNS None
of IN None
10 CD None
males NNS None
: : None
four CD None
receiving VBG None
testosterone NN None
undecanoate NN None
-DOCSTART- -X- N

angina JJ Condition
pectoris NN Condition
: : None
12 CD Size
patients NNS None
with IN None
chronic JJ None
stable JJ None
angina NN None
receiving VBG None
treatment NN None
with IN None
beta-adrenergic JJ None
blocking NN None
or CC None
calcium NN None
channel NNS None
blocking VBG None
agents NNS None
. . None
-DOCSTART- -X- N

rocuronium NN None
under IN None
stable JJ None
nitrous JJ None
oxide-fentanyl JJ None
or CC None
nitrous JJ None
oxide-sevoflurane JJ None
anesthesia NN Condition
in IN None
children NNS Age
. . None
children NNS Age
anesthetized VBN None
with IN None
nitrous JJ None
oxide NN None
( ( None
N2O NNP None
) ) None
and CC None
fentanyl $ None
or CC None
with IN None
N2O NNP None
and CC None
sevoflurane NN None
. . None
Twenty-four JJ Size
children NNS Age
( ( None
3-11 CD Age
years NNS Age
old JJ Age
, , None
ASA NNP Condition
PS NNP Condition
I PRP Condition
or CC Condition
II NNP Condition
) ) None
were VBD None
randomized VBN None
-DOCSTART- -X- N

ventricular JJ Condition
arrhythmias NN Condition
. . None
German JJ None
speaking NN None
countries NNS None
. . None
20 CD Size
patients NNS None
with IN None
ventricular JJ Condition
arrhythmias NNS Condition
( ( None
VA NNP Condition
) ) None
of IN None
various JJ None
origin NN None
. . None
-DOCSTART- -X- N

autism NN Condition
. . None
autistic JJ Condition
disorder NN Condition
. . Condition
Fifty-six JJ Size
subjects NNS None
with IN None
autistic JJ Condition
disorder NN Condition
-DOCSTART- -X- N

purulent NN Condition
meningitis NN Condition
. . None
86 CD Size
pediatric JJ Age
and CC None
adult NN Age
patients NNS None
( ( None
41 CD Size
Haemophilus NNP None
influenzae NN None
, , None
22 CD Size
Streptococcus NNP None
pneumoniae NN None
, , None
13 CD Size
Neisseria NNP None
meningitidis NN None
, , None
and CC None
10 CD Size
of IN None
unknown JJ None
etiology NN None
) ) None
. . None
H. NNP None
influenzae NN None
patients NNS None
patients NNS None
with IN None
H. NNP None
influenzae NN None
. . None
-DOCSTART- -X- N

serotonin-migraine JJ Condition
30 CD Size
patients NNS None
30 CD Size
patients NNS Size
receiving VBG None
3 CD None
x JJ None
0.5 CD None
mg NN None
or CC None
placebo JJ None
daily RB None
-DOCSTART- -X- N

Polish JJ None
emergency NN None
department NN None
: : None
drinking NN None
and CC None
related JJ None
problems NNS None
among IN None
at-risk JJ None
and CC None
dependent JJ None
drinkers NNS None
emergency NN None
department NN None
( ( None
ED NNP None
) ) None
in IN None
Sosnowiec NNP None
, , None
Poland NNP None
, , None
among IN None
patients NNS None
ages VBZ None
18 CD None
years NNS None
and CC None
older JJR None
. . None
Data NNP None
were VBD None
collected VBN None
over IN None
a DT None
23-week JJ None
period NN None
, , None
from IN None
4:00 CD None
PM NNP None
to TO None
midnight VB None
446 CD None
patients NNS None
being VBG None
recruited VBN None
into IN None
the DT None
study NN None
( ( None
90 CD None
% NN None
of IN None
those DT None
who WP None
screened VBD None
positive JJ None
) ) None
-DOCSTART- -X- N

Belarus NNP Condition
. . None
The DT None
Promotion NN None
of IN None
Breastfeeding NNP Condition
Intervention NNP None
Trial NNP None
( ( None
PROBIT NNP None
) ) None
is VBZ None
a DT None
cluster-randomized JJ None
trial NN None
of IN None
a DT None
breast-feeding JJ None
promotion NN None
intervention NN None
17,046 CD Size
healthy JJ None
breast-fed JJ None
infants NNS None
were VBD None
enrolled VBN None
from IN None
31 CD None
Belarussian JJ None
maternity NN None
hospitals NNS None
and CC None
affiliated JJ None
clinics NNS None
13,889 CD Size
( ( None
81.5 CD None
% NN None
) ) None
were VBD None
followed VBN None
up RP None
at IN None
6.5 CD None
y NN None
-DOCSTART- -X- N

primary JJ Condition
pterygium NN Condition
. . None
primary JJ None
pterygium NN None
A NNP None
total NN None
of IN None
66 CD None
eyes NNS None
of IN None
54 CD Size
patients NNS None
with IN None
primary JJ None
pterygium NN None
primary JJ None
pterygium NN None
. . None
-DOCSTART- -X- N

children NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
and CC None
high JJ None
levels NNS None
of IN None
repetitive JJ None
behavior NN None
: : None
children NNS None
with IN None
autism NN None
. . None
children NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
. . None
children NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
. . None
Six NNP None
academic JJ None
centers NNS None
, , None
including VBG None
Mount NNP None
Sinai NNP None
School NNP None
of IN None
Medicine NNP None
, , None
North NNP None
Shore-Long NNP None
Island NNP None
Jewish NNP None
Health NNP None
System NNP None
, , None
University NNP None
of IN None
North NNP None
Carolina NNP None
at IN None
Chapel NNP None
Hill NNP None
, , None
University NNP None
of IN None
California NNP None
at IN None
Los NNP None
Angeles NNP None
, , None
Yale NNP None
University NNP None
, , None
and CC None
Dartmouth NNP None
Medical NNP None
School NNP None
. . None
One CD None
hundred VBD None
forty-nine JJ None
volunteers NNS None
5 CD None
to TO None
17 CD None
years NNS None
old JJ None
( ( None
mean JJ None
[ NNP None
SD NNP None
] NNP None
age NN None
, , None
9.4 CD None
[ NN None
3.1 CD None
] CD None
years NNS None
) ) None
Participants NNS None
had VBD None
autistic JJ None
spectrum NN None
disorders NNS None
, , None
Asperger NNP None
disorder NN None
, , None
or CC None
pervasive JJ None
developmental JJ None
disorder NN None
, , None
not RB None
otherwise RB None
specified VBN None
; : None
had VBD None
illness JJ None
severity NN None
ratings NNS None
of IN None
at IN None
least JJS None
moderate JJ None
on IN None
the DT None
Clinical NNP None
Global NNP None
Impressions NNP None
, , None
Severity NNP None
of IN None
Illness NNP None
Scale NNP None
; : None
and CC None
scored VBD None
at IN None
least JJS None
moderate JJ None
on IN None
compulsive JJ None
behaviors NNS None
measured VBN None
with IN None
the DT None
Children NNP None
's POS None
Yale-Brown JJ None
Obsessive NNP None
Compulsive NNP None
Scales NNP None
modified VBD None
for IN None
pervasive JJ None
developmental NN None
disorders NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
acute JJ Condition
myocardial JJ Condition
infarction NN Condition
. . None
40 CD Size
patients NNS None
with IN None
AMI NNP Condition
within IN None
12 CD None
hours NNS None
after IN None
the DT None
onset NN None
of IN None
the DT None
symptom NN None
and CC None
who WP None
randomly VBP None
received VBN None
early JJ None
treatment NN None
with IN None
either CC None
the DT None
ACE NNP None
inhibitor NN None
imidapril NN None
or CC None
a DT None
placebo NN None
( ( None
20 CD Size
patients NNS None
in IN None
the DT None
imidapril NN None
group NN None
and CC None
20 CD Size
in IN None
the DT None
placebo NN None
group NN None
) ) None
. . None
-DOCSTART- -X- N

Children NNP None
's POS None
Yale-Brown JJ None
Obsessive NNP None
Compulsive NNP None
Scales NNP None
administered VBN None
to TO None
172 CD None
medication-free JJ None
children NNS None
( ( None
mean JJ None
8.2 CD None
+/- JJ None
2.6 CD None
years NNS None
) ) None
with IN None
PDD NNP None
( ( None
autistic JJ None
disorder NN None
, , None
n JJ None
= VBP None
152 CD None
; : None
Asperger NNP None
's POS None
disorder NN None
, , None
n JJ None
= VBP None
6 CD None
; : None
PDD NNP None
not RB None
otherwise RB None
specified VBN None
, , None
n JJ None
= NNP None
14 CD None
) ) None
participating NN None
in IN None
RUPP NNP None
clinical JJ None
trials NNS None
. . None
Children NNP None
with IN None
higher JJR None
scores NNS None
-DOCSTART- -X- N

cardiovascular JJ Condition
function NN Condition
. . None
32 CD Size
healthy JJ None
middle-aged JJ None
males NNS Sex
( ( None
X JJ None
age NN None
= VBD None
42.2 CD Age
+/- JJ Age
2.1 CD Age
yr NN Age
) ) None
. . None
-DOCSTART- -X- N

for IN None
pre-school JJ Age
children NNS Age
with IN None
autistic JJ Condition
spectrum NN Condition
disorders NNS Condition
. . None
of IN None
preschool NN None
children NNS None
with IN None
autistic JJ Condition
spectrum NN Condition
disorder NN Condition
. . None
Measures NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
social JJ Condition
phobia NN Condition
Thirty NNP Size
social JJ Condition
phobic NN Condition
patients NNS Condition
( ( Condition
DSM-IV NNP Condition
) ) Condition
patients NNS None
with IN None
social JJ Condition
phobia NNS Condition
treated VBN None
with IN None
buspirone NN None
. . None
-DOCSTART- -X- N

children NNS Age
diagnosed VBN None
with IN None
autism NN Condition
spectrum NN Condition
disorder NN Condition
individuals NNS None
diagnosed VBN None
with IN None
autism NN Condition
45 CD Size
children NNS None
diagnosed VBN None
with IN None
Autism NNP Condition
Spectrum NNP Condition
Disorder NNP Condition
( ( Condition
ASD NNP Condition
) ) Condition
ages VBZ None
7-14 CD Age
-DOCSTART- -X- N

tamoxifen NN None
prevent VB None
breast NN None
cancer NN None
in IN None
high-risk JJ None
women NNS None
. . None
-DOCSTART- -X- N

after IN None
congenital JJ None
heart NN None
surgery NN None
. . None
after IN None
congenital JJ None
heart NN None
surgery NN None
. . None
Between NNP None
September NNP None
2002 CD None
and CC None
September NNP None
2004 CD None
, , None
among IN None
a DT None
group NN None
of IN None
postoperative JJ None
children NNS None
with IN None
large JJ None
septal JJ None
defects NNS None
, , None
moderate VBP None
to TO None
severe VB None
pulmonary JJ None
hypertension NN None
[ NNP None
pulmonary JJ None
artery NN None
( ( None
PA NNP None
) ) None
to TO None
aortic JJ None
( ( None
Ao NNP None
) ) None
pressure NN None
ratio NN None
of IN None
0.76 CD None
+/- JJ None
0.17 CD None
] NN None
and CC None
systemic JJ None
desaturation NN None
( ( None
Ao NNP None
Sat NNP None
= VBD None
0.89 CD None
+/- JJ None
0.11 CD None
) ) None
, , None
oral JJ None
sildenafil NN None
( ( None
0.3 CD None
mg NN None
x NN None
kg NN None
( ( None
-1 NNP None
) ) None
, , None
every DT None
3 CD None
hours NNS None
) ) None
was VBD None
administered VBN None
for IN None
a DT None
period NN None
of IN None
24-48 JJ None
hours NNS None
( ( None
sildenafil JJ None
group NN None
) ) None
. . None
patients NNS None
22 CD None
children NNS None
with IN None
similar JJ None
pathologies NNS None
who WP None
did VBD None
not RB None
receive VB None
sildenafil NN None
( ( None
control VB None
group NN None
) ) None
. . None
-DOCSTART- -X- N

Fifteen NNP Size
white-coat JJ Condition
hypertensive JJ Condition
out-patients NNS None
and CC None
23 CD Size
essential JJ Condition
hypertensive JJ Condition
out-patients NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
a DT None
history NN None
of IN None
seasonal JJ None
allergic JJ None
rhinitis NN None
. . None
susceptible JJ None
individuals NNS None
eight CD None
subjects NNS None
with IN None
a DT None
history NN None
of IN None
seasonal JJ None
allergic JJ None
rhinitis NN None
, , None
who WP None
were VBD None
tested VBN None
out IN None
of IN None
season NN None
Another DT None
group NN None
of IN None
eight CD None
subjects NNS None
with IN None
a DT None
history NN None
of IN None
seasonal JJ None
allergic JJ None
rhinitis NN None
-DOCSTART- -X- N

aortic JJ None
valve NN None
surgery NN None
-- : None
a DT None
Thirty NNP None
patients NNS None
scheduled VBN None
for IN None
aortic JJ None
valve NNS None
replacement NN None
were VBD None
included VBN None
. . None
-DOCSTART- -X- N

progressive JJ None
, , None
metastatic JJ None
, , None
castration-resistant JJ None
prostate NN None
cancer NN None
. . None
metastatic JJ None
castration-resistant JJ None
prostate NN None
cancer NN None
( ( None
mCRPC NN None
) ) None
. . None
Men NNP None
with IN None
progressive JJ None
mCRPC NN None
after IN None
docetaxel-based JJ None
chemotherapy NN None
873 CD None
patients NNS None
were VBD None
randomly RB None
assigned VBN None
-DOCSTART- -X- N

chronic JJ Condition
schizophrenic JJ Condition
patients NNS None
: : None
cyproheptadine JJ None
augmentation NN None
of IN None
ongoing VBG None
haloperidol NN None
treatment NN None
40 CD Size
chronic JJ None
schizophrenic JJ None
in-patients NNS None
. . None
chronic JJ None
schizophrenic JJ None
patients NNS None
who WP None
are VBP None
intolerant JJ None
of IN None
extrapyramidal JJ None
side NN None
effects NNS None
of IN None
conventional JJ None
antipsychotics NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
stage-1 JJ None
or CC None
stage-2 JJ None
hypertension NN Condition
. . None
648 CD Condition
patients NNS None
with IN None
stage-1 JJ None
or CC None
stage-2 JJ None
hypertension NN None
( ( None
age=52.6+/-10 JJ Age
years NNS Age
; : None
54 CD None
% NN None
male NN Age
; : None
baseline VB None
blood NN None
pressure NN None
( ( None
BP NNP None
) ) None
=161/98 VBP None
mm JJ None
Hg NNP None
, , None
32 CD None
% NN None
stage NN None
1 CD None
) ) None
. . None
patients NNS None
with IN None
stage-1 JJ None
and CC None
stage-2 JJ None
hypertension NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
a DT None
presumptive JJ None
diagnosis NN None
of IN None
acute JJ Condition
pyelonephritis NN Condition
patients NNS None
. . None
patients NNS None
who WP None
satisfied VBD None
the DT None
criteria NNS None
for IN None
switch NN None
therapy NN None
group NN None
A NNP None
group NN None
B NNP None
Eighty-two JJ Size
patients NNS None
were VBD None
enrolled VBN None
; : None
41 CD Size
( ( None
50 CD None
% NN None
) ) None
patients NNS None
in IN None
group NN None
A NNP None
and CC None
41 CD Size
( ( None
50 CD None
% NN None
) ) None
patients NNS None
in IN None
group NN None
B NNP None
were VBD None
evaluated VBN None
. . None
-DOCSTART- -X- N

during IN None
minor JJ None
elective JJ None
surgery NN None
. . None
Forty NNP None
adult NN None
patients NNS None
, , None
ASA NNP None
I-II NNP None
-DOCSTART- -X- N

Veterans NNS Age
Affairs VBP None
congestive JJ Condition
heart NN Condition
failure NN Condition
patients NNS None
with IN None
congestive JJ Condition
heart NN Condition
failure NN Condition
and CC None
ventricular JJ Condition
arrhythmia NN Condition
. . None
Eligible JJ None
patients NNS None
include VBP None
those DT None
with IN None
ischemic JJ None
and CC None
nonischemic JJ None
congestive JJ Condition
heart NN Condition
failure NN Condition
and CC None
with IN None
> NNP None
or CC None
= $ None
10 CD None
ventricular JJ Condition
premature NN Condition
beats NNS Condition
per IN None
hour NN None
. . None
All DT None
patients NNS None
must MD None
have VB None
shortness NN Condition
of IN Condition
breath NN Condition
with IN None
minimal JJ None
exertion NN None
or CC None
paroxysmal JJ Condition
nocturnal JJ Condition
dyspnea NN Condition
, , None
a DT None
left JJ None
ventricular JJ None
internal JJ None
dimension NN None
( ( None
LVIDd NNP None
) ) None
by IN None
echocardiogram NN None
of IN None
> NN None
or CC None
= $ None
55 CD None
mm NN None
or CC None
a DT None
cardiothoracic JJ None
ratio NN None
of IN None
> $ None
0.5 CD None
and CC None
an DT None
ejection NN None
fraction NN None
of IN None
< NN None
or CC None
= VB None
40 CD None
% NN None
. . None
Patients NNS None
will MD None
be VB None
entered VBN None
into IN None
the DT None
study NN None
for IN None
2.5 CD None
years NNS None
and CC None
followed VBD None
for IN None
an DT None
additional JJ None
2 CD None
years NNS None
. . None
674 CD None
patients NNS None
will MD None
be VB None
entered VBN None
into IN None
the DT None
study NN None
from IN None
25 CD None
participating VBG None
centers NNS None
. . None
-DOCSTART- -X- N

refractive JJ Condition
surgery NN Condition
. . None
corneal NN Condition
pain NN Condition
after IN None
refractive JJ None
surgery NN None
Thirty NNP Size
patients NNS None
-DOCSTART- -X- N

Eight NNP Size
male NN Sex
volunteers NNS None
-DOCSTART- -X- N

48 CD Condition
healthy JJ Condition
volunteers NNS None
( ( None
24 CD Condition
men NNS Sex
and CC None
24 CD Condition
women NNS Sex
) ) None
. . None
-DOCSTART- -X- N

frozen JJ Condition
shoulder NN Condition
. . None
frozen JJ Condition
shoulder NN Condition
. . None
All DT None
primary JJ None
care NN None
referrals NNS None
of IN None
frozen JJ Condition
shoulder NN Condition
to TO None
our PRP$ None
physiotherapy NN None
department NN None
were VBD None
included VBN None
during IN None
a DT None
12-month JJ None
period NN None
. . None
Of IN None
these DT None
referrals NNS None
, , None
17 CD None
% NN None
met VBD None
the DT None
inclusion NN None
criteria NNS None
for IN None
primary JJ Condition
idiopathic JJ Condition
frozen JJ Condition
shoulder NN Condition
. . None
75 CD Size
patients NNS None
frozen JJ Condition
shoulder NN Condition
-DOCSTART- -X- N

METHODS NNP None
Three NNP None
groups NNS None
of IN None
30 CD None
edentulous JJ None
patients NNS None
were VBD None
treated VBN None
with IN None
two CD None
endosseous JJ None
implants NNS None
in IN None
mandibular JJ None
overdenture NN None
in IN None
the DT None
edentulous JJ None
patient NN None
. . None
After IN None
-DOCSTART- -X- N

males NNS Sex
with IN None
latent JJ Condition
myofascial JJ Condition
trigger NN Condition
points NNS Condition
. . None
Thirty NNP Size
physically RB Condition
active JJ Condition
males NNS None
with IN None
tight JJ Condition
hamstrings NNS Condition
and CC Condition
at IN Condition
least JJS Condition
one CD Condition
latent NN Condition
MTrP NNP Condition
on IN Condition
muscles NNS Condition
innervated VBN Condition
by IN Condition
the DT Condition
lumbosacral JJ Condition
, , Condition
sciatic JJ Condition
, , Condition
tibial JJ Condition
and CC Condition
common JJ Condition
peroneal JJ Condition
nerves NNS Condition
. . None
young JJ Age
and CC None
physically RB Condition
active JJ Condition
males NNS None
-DOCSTART- -X- N

outpatient JJ None
epidural JJ None
anesthesia NN None
. . None
84 CD None
outpatients NNS None
undergoing JJ None
surgery NN None
( ( None
extracorporeal JJ None
shock NN None
wave NN None
lithotripsy NN None
( ( None
ESWL NNP None
] NNP None
. . None
-DOCSTART- -X- N

Diabetes NNPS Condition
: : Condition
Families NNS None
of IN None
104 CD None
adolescents NNS None
with IN None
diabetes NNS None
were VBD None
randomized VBN None
-DOCSTART- -X- N

contrast-induced JJ None
acute JJ None
kidney NN None
injury NN None
in IN None
acute JJ None
ST-segment-elevation NNP None
myocardial JJ None
infarction NN None
: : None
substudy NN None
from IN None
the DT None
HORIZONS-AMI NNP None
trial NN None
. . None
Contrast-induced NNP None
acute NN None
kidney NN None
injury NN None
( ( None
CI-AKI NNP None
) ) None
patients NNS None
at IN None
risk NN None
for IN None
CI-AKI NNP None
trial NN None
database NN None
of IN None
patients NNS None
with IN None
ST-segment-elevation NNP None
myocardial JJ None
infarction NN None
979 CD None
ST-segment-elevation JJ None
myocardial JJ None
infarction NN None
patients NNS None
enrolled VBN None
in IN None
the DT None
Harmonizing NNP None
Outcomes NNP None
with IN None
Revascularization NNP None
and CC None
Stents NNP None
in IN None
Acute NNP None
Myocardial NNP None
Infarction NNP None
( ( None
HORIZONS-AMI NNP None
) ) None
trial NN None
occurred VBD None
in IN None
131 CD None
patients NNS None
( ( None
13.3 CD None
% NN None
) ) None
. . None
Baseline NNP None
identify VB None
patients NNS None
who WP None
are VBP None
at IN None
risk NN None
for IN None
developing VBG None
CI-AKI NNP None
after IN None
primary JJ None
percutaneous JJ None
coronary JJ None
intervention NN None
in IN None
ST-segment-elevation NNP None
myocardial JJ None
infarction NN None
. . None
CLINICAL NNP None
-DOCSTART- -X- N

Intraoperative JJ None
microscopy NN None
of IN None
bile NN None
-- : None
is VBZ None
during IN None
cholecystectomy NN Condition
in IN None
111 CD Size
patients NNS None
in IN None
23 CD Size
patients NNS None
, , None
11 CD Size
of IN None
83 CD Size
undergoing JJ None
cholecystectomy NN Condition
alone RB None
and CC None
12 CD Size
of IN None
28 CD Size
undergoing JJ None
exploration NN Condition
of IN Condition
the DT Condition
common JJ Condition
bile NN Condition
duct NN Condition
23 CD Size
patients NNS None
were VBD None
randomly RB None
allocated VBN None
to TO None
an DT None
antibiotic JJ None
group NN None
or CC None
a DT None
control NN None
group NN None
; : None
14 CD Size
patients NNS None
intraoperative JJ None
microscopy NN None
of IN None
bile NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
newly RB None
diagnosed VBN None
, , None
previously RB None
untreated VBN None
chronic JJ None
myeloid NN None
leukemia NN None
in IN None
chronic JJ None
phase NN None
patients NNS None
with IN None
newly RB None
diagnosed VBN None
chronic JJ None
myeloid NN None
leukemia NN None
in IN None
chronic JJ None
phase NN None
. . None
A NNP None
total NN None
of IN None
476 CD None
patients NNS None
were VBD None
randomly RB None
assigned VBN None
-DOCSTART- -X- N

acute JJ Condition
nonspecific NN Condition
low JJ Condition
back RB Condition
pain NN Condition
( ( Condition
LBP NNP Condition
) ) Condition
. . None
Five CD None
community-based JJ None
research NN None
facilities NNS None
. . None
Two-hundred JJ Size
nineteen JJ Size
subjects NNS None
, , None
aged VBD Age
18 CD Age
to TO Age
55 CD Age
years NNS Age
, , None
with IN None
acute JJ Condition
nonspecific JJ Condition
LBP NNP None
. . None
-DOCSTART- -X- N

Type NNP Condition
2 CD Condition
diabetes NNS Condition
. . None
Twenty NNP Size
Type NNP None
2 CD None
diabetic JJ None
patients NNS None
with IN Condition
dyslipidemia NN Condition
were VBD None
treated VBN None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
receiving VBG None
targeted VBN None
interventions NNS None
on IN None
joint JJ None
attention NN None
and CC None
play NN None
. . None
children NNS None
with IN None
an DT None
autism NN Condition
spectrum NN Condition
disorder NN Condition
( ( None
ASD NNP Condition
) ) None
over IN None
a DT None
5-year JJ None
period NN None
after IN None
receiving VBG None
targeted VBD None
early JJ None
interventions NNS None
that WDT None
focused VBD None
on IN None
joint JJ None
attention NN None
and CC None
play NN None
skills NNS None
. . None
Forty NNP Size
children NNS None
from IN None
the DT None
original JJ None
study NN None
( ( None
n JJ None
= NNP None
58 CD Size
) ) None
had VBD None
complete JJ None
data NNS None
at IN None
the DT None
5-year JJ None
follow-up NN None
. . None
children NNS Age
who WP None
participated VBD None
in IN None
preschool NN None
early JJ None
interventions NNS None
aimed VBN None
at IN None
targeting VBG None
core NN Condition
developmental NN Condition
difficulties NNS Condition
. . None
-DOCSTART- -X- N

first-time JJ Condition
blood NN Condition
donors NNS Condition
who WP Condition
experience VBP Condition
a DT Condition
mild JJ Condition
adverse JJ Condition
event NN Condition
. . Condition
first-time JJ Condition
donors NNS Condition
-DOCSTART- -X- N

healthy JJ Condition
volunteers NNS Condition
. . Condition
healthy JJ None
volunteers NNS None
Healthy NNP None
male NN None
and CC None
female JJ None
volunteers NNS None
aged VBN None
18-75 CD None
years NNS None
were VBD None
included VBN None
. . None
All DT None
volunteers NNS None
received VBD None
ASA NNP None
81 CD None
mg NN None
once RB None
daily JJ None
for IN None
5 CD None
days NNS None
prior RB None
to TO None
the DT None
study NN None
( ( None
pre-screen JJ None
) ) None
. . None
Subjects NNS None
were VBD None
eligible JJ None
for IN None
inclusion NN None
if IN None
they PRP None
had VBD None
aspirin VBN None
reactivity NN None
units NNS None
( ( None
ARU NNP None
, , None
as IN None
measured VBN None
by IN None
the DT None
VerifyNow NNP None
ASA NNP None
assay VBP None
) ) None
of IN None
< $ None
550 CD None
on IN None
Day NNP None
6 CD None
. . None
A DT None
total NN None
of IN None
29 CD None
volunteers NNS None
( ( None
19 CD None
aged VBN None
?50 CD None
years NNS None
; : None
8 CD None
women NNS None
; : None
21 CD None
men NNS None
) ) None
were VBD None
evaluable JJ None
for IN None
-DOCSTART- -X- N

humans NNS None
. . None
Twelve NNP None
healthy JJ None
volunteers NNS None
were VBD None
included VBN None
( ( None
with IN None
valid JJ None
results NNS None
available JJ None
in IN None
9 CD None
) ) None
adenosine NN None
in IN None
normal JJ None
humans NNS None
induces NNS None
-DOCSTART- -X- N

vulvovaginal JJ None
and CC None
sexual JJ None
dysfunction NN None
in IN None
postmenopausal JJ None
women NNS None
. . None
postmenopausal JJ None
women NNS None
postmenopausal JJ None
women NNS None
. . None
Seventy-five JJ None
postmenopausal NN None
women NNS None
symptomatic JJ None
for IN None
urogenital JJ None
atrophy NN None
and CC None
sexual JJ None
dysfunction NN None
study NN None
groups NNS None
control NN None
group NN None
. . None
symptomatic JJ None
postmenopausal NN None
women NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
seasonal JJ Condition
allergic JJ Condition
rhinitis NN Condition
. . None
seasonal JJ Condition
allergic JJ Condition
rhinitis NN Condition
due JJ None
to TO None
ragweed VB None
. . None
One CD Size
hundred VBD Size
forty NN Size
patients NNS None
seasonal JJ Condition
allergic JJ Condition
rhinitis NN Condition
due JJ None
to TO None
ragweed VB None
. . None
-DOCSTART- -X- N

METHODS NNP None
Between NNP None
July NNP None
2002 CD None
and CC None
July NNP None
2003 CD None
, , None
candidates NNS None
to TO None
prostate VB None
biopsies NNS None
were VBD None
RESULTS $ None
308 CD None
patients NNS None
were VBD None
included VBN None
in IN None
this DT None
trial NN None
with IN None
156 CD None
patients NNS None
in IN None
group NN None
1 CD None
and CC None
152 CD None
in IN None
group NN None
2 CD None
. . None
Group NNP None
-DOCSTART- -X- N

90 CD Size
patients NNS None
scheduled VBN None
for IN None
minor JJ Condition
gynaecological JJ Condition
( ( None
hysteroscopy NN Condition
) ) None
or CC None
urological JJ Condition
( ( None
ureteroscopy JJ Condition
) ) None
procedures NNS None
planned VBN None
to TO None
last JJ None
1-2 JJ None
h NN None
under IN None
sevoflurane NN None
anaesthesia NN None
with IN None
spontaneous JJ None
ventilation NN None
of IN None
the DT None
lungs NNS None
via IN None
a DT None
laryngeal JJ None
mask NN None
airway NN None
. . None
patients NNS None
who WP None
experienced VBD None
postoperative JJ Condition
nausea NN Condition
and CC None
vomiting NN Condition
in IN None
the DT None
first JJ None
24 CD None
h NN None
( ( None
30 CD None
% NN None
and CC None
27 CD None
% NN None
for IN None
the DT None
midazolam NN None
and CC None
ondansetron NN None
groups NNS None
, , None
respectively RB None
) ) None
were VBD None
similar JJ None
in IN None
the DT None
two CD None
groups NNS None
. . None
patients NNS None
' POS None
underlying JJ None
risks NNS None
( ( None
midazolam JJ None
group NN None
: : None
p NN None
= VBZ None
0.018 CD None
; : None
ondansetron VBN None
group NN None
: : None
p NN None
= VBZ None
0.017 CD None
) ) None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
panic JJ Condition
disorder NN Condition
and CC None
in IN None
social JJ Condition
phobics NNS Condition
Twenty-nine JJ Size
patients NNS Size
received VBD None
epinephrine JJ None
, , None
ten JJ Size
patients NNS Size
received VBD None
placebo NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
progressive JJ Condition
hormone-escaped JJ Condition
metastatic JJ Condition
prostate NN Condition
cancer NN Condition
. . None
92 CD Size
patients NNS None
were VBD None
randomised VBN None
into IN None
a DT None
Phase NNP None
II NNP None
study NN None
-DOCSTART- -X- N

vasculogenic JJ Condition
sexual JJ Condition
dysfunction NN Condition
men NNS None
with IN None
mild NN None
to TO None
moderate VB None
penile IN None
vascular JJ None
insufficiency NN None
. . None
Sexual JJ None
Dysfunction NNP None
Clinic NNP None
at IN None
VA NNP None
Medical NNP None
Center NNP None
, , None
Sepulveda NNP None
, , None
CA NNP None
. . None
Convenience NNP None
sample NN None
of IN None
couples NNS None
. . None
patient JJ None
partner NN None
impotent JJ None
men NNS None
men NNS None
with IN None
the DT None
pelvic JJ None
steal JJ None
syndrome NN None
; : None
erectile JJ None
dysfunction NN None
in IN None
patients NNS None
with IN None
mild JJ None
to TO None
moderate VB None
penile IN None
vascular JJ None
disease NN None
. . None
-DOCSTART- -X- N

healthy JJ None
young JJ None
adults NNS None
. . None
nonsmoking VBG None
adults NNS None
( ( None
6 CD None
male NN None
, , None
5 CD None
female NN None
; : None
ages VBZ None
23-36 CD None
years NNS None
) ) None
-DOCSTART- -X- N

subarachnoid NN Condition
and CC None
intraventricular JJ Condition
cysticercosis NN Condition
. . None
Thirty-six JJ Size
patients NNS None
with IN None
subarachnoid JJ Condition
and CC None
intraventricular JJ Condition
cysticercosis NN Condition
-DOCSTART- -X- N

Long-term NNP None
followup NN None
was VBD None
assessed VBN None
in IN None
551 CD None
participants NNS None
enrolled VBN None
in IN None
a DT None
prospective JJ None
, , None
randomized JJ None
study NN None
of IN None
fluorescence NN None
cystoscopy NN None
for IN None
Ta NNP None
or CC None
T1 NNP None
urothelial JJ None
bladder NN None
cancer NN None
. . None
280 CD None
patients NNS None
in IN None
the DT None
white JJ None
light JJ None
cystoscopy NN None
group NN None
271 CD None
in IN None
the DT None
fluorescence NN None
cystoscopy NN None
group NN None
were VBD None
followed VBN None
with IN None
cystoscopy NN None
information NN None
was VBD None
obtained VBN None
for IN None
261 CD None
of IN None
the DT None
280 CD None
patients NNS None
( ( None
93 CD None
% NN None
) ) None
in IN None
the DT None
white JJ None
light NN None
group NN None
255 CD None
of IN None
the DT None
271 CD None
( ( None
94 CD None
% NN None
) ) None
in IN None
the DT None
fluorescence NN None
group NN None
. . None
-DOCSTART- -X- N

very-low-birth-weight JJ Condition
infants NNS Age
. . None
premature JJ Condition
infants NNS Age
. . None
2416 CD Size
infants NNS Age
were VBD None
stratified VBN None
according VBG None
to TO None
birth NN None
weight NN None
( ( None
501 CD None
to TO None
1000 CD None
g NN None
and CC None
1001 CD None
to TO None
1500 CD None
g NN None
) ) None
Control NN None
infants NNS None
Infants NNS Age
weighing VBG None
501 CD None
to TO None
1000 CD None
g NN None
at IN None
birth NN None
very-low-birth-weight JJ None
infants NNS Age
. . None
-DOCSTART- -X- N

Parkinson NNP Condition
disease NN Condition
. . None
26 CD Condition
patients NNS None
with IN None
mild JJ None
to TO None
moderate VB None
PD NNP Condition
: : None
PD NNP None
. . None
-DOCSTART- -X- N

Helicobacter NNP None
pylori VBP None
6-year JJ None
period NN None
, , None
patients NNS None
with IN None
persistent JJ None
H. NNP None
pylori FW None
infection NN None
following VBG None
omeprazole-clarithromycin-amoxicillin JJ None
eradication NN None
therapy NN None
95 CD None
randomized JJ None
patients NNS None
, , None
88 CD None
( ( None
93 CD None
% NN None
) ) None
completed VBD None
the DT None
study NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
lymphoma NN None
and CC None
resolved VBD None
hepatitis NN None
B NNP None
. . None
patients NNS None
with IN None
lymphoma NN None
and CC None
resolved VBD None
hepatitis NN None
B NNP None
Eighty NNP None
patients NNS None
with IN None
CD20 NNP None
( ( None
+ NNP None
) ) None
lymphoma NN None
and CC None
resolved VBD None
hepatitis NN None
B NNP None
Fifty-eight JJ None
patients NNS None
one CD None
patient NN None
seven CD None
patients NNS None
control NN None
group NN None
Four CD None
patients NNS None
control NN None
group NN None
patients NNS None
with IN None
lymphoma NN None
and CC None
resolved VBD None
hepatitis NN None
B NNP None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
systemic JJ Condition
ventricular JJ Condition
dysfunction NN Condition
treated VBN None
with IN None
carvedilol NN None
. . None
adults NNS Age
and CC None
children NNS Age
. . None
in IN None
a DT None
population NN None
of IN None
children NNS Age
with IN None
systemic JJ Condition
ventricular JJ Condition
dysfunction NN Condition
and CC None
symptomatic JJ None
heart NN None
failure NN None
treated VBN None
with IN None
carvedilol NN None
or CC None
placebo NN None
. . None
Pediatric NNP None
Carvedilol NNP None
Trial NNP None
( ( None
PCT NNP None
) ) None
participants NNS None
( ( None
carvedilol JJ None
n RB None
= JJ None
161 CD None
; : None
placebo NN None
n IN None
= $ None
55 CD None
) ) None
children NNS None
treated VBD None
with IN None
carvedilol NN None
carvedilol NN None
group NN None
. . None
children NNS None
-DOCSTART- -X- N

traditional JJ None
British JJ None
antenatal JJ None
visit NN None
schedule NN None
with IN None
a DT None
reduced JJ None
schedule NN None
of IN None
visits NNS None
low JJ None
risk NN None
women NNS Sex
women NNS Sex
receiving VBG None
shared VBN None
care NN None
2794 CD Size
women NNS Sex
at IN None
low JJ None
risk NN None
fulfilling VBG None
the DT None
trial NN None
's POS None
inclusion NN None
criteria NNS None
between IN None
June NNP None
1993 CD None
and CC None
July NNP None
1994 CD None
. . None
Pregnant JJ Condition
women NNS Sex
allocated VBD None
to TO None
new JJ None
style NN None
care NN None
-DOCSTART- -X- N

autistic JJ Condition
children NNS Age
. . None
infantile JJ Age
autism NN None
. . None
autistic JJ None
children NNS None
. . None
children NNS None
with IN None
autism NN None
, , None
12 CD Size
subjects NNS None
In IN None
addition NN None
, , None
four CD None
cases NNS Condition
describing VBG Condition
unusual JJ Condition
effects NNS Condition
found VBN None
in IN None
a DT None
sample NN None
of IN None
170 CD None
patients NNS None
treated VBN None
with IN None
fenfluramine NN None
are VBP None
also RB None
reported VBN None
. . None
autism NN None
. . None
-DOCSTART- -X- N

Treatment NN None
of IN None
bladder NN Condition
cancer NN Condition
with IN None
intravesical JJ None
instillation NN None
of IN None
adriamycin NN None
. . None
-DOCSTART- -X- N

Thailand NNP Condition
. . Condition
Patients NNS None
( ( None
15-65 CD None
years NNS None
old JJ None
) ) None
were VBD None
assigned VBN None
to TO None
1 CD None
of IN None
4 CD None
treatments NNS None
regimens VBZ None
in IN None
a DT None
serial JJ None
order NN None
. . None
Ninety NNP None
percent NN None
of IN None
the DT None
patients NNS None
were VBD None
infected VBN None
at IN None
Thailand-Myanmar NNP None
border NN None
. . None
-DOCSTART- -X- N

head NN Condition
and CC Condition
neck NN Condition
cancer NN Condition
patients NNS None
. . None
head NN Condition
and CC Condition
neck NN Condition
cancer NN Condition
patients NNS None
undergoing VBG None
treatment NN None
for IN None
head NN Condition
and CC Condition
neck NN Condition
cancers NNS Condition
. . None
patients NNS None
undergoing VBG None
treatment NN None
for IN None
head NN Condition
and CC Condition
neck NN Condition
cancers NNS Condition
. . None
-DOCSTART- -X- N

women NNS Sex
with IN None
breast NN Condition
cancer NN Condition
. . None
96 CD Size
women NNS Sex
with IN None
breast NN Condition
cancer NN Condition
who WP None
experienced VBD None
nausea NN Condition
at IN Condition
their PRP$ Condition
first JJ Condition
chemotherapy NN Condition
treatment NN Condition
. . None
female JJ Sex
breast NN Condition
cancer NN Condition
patients NNS None
. . None
-DOCSTART- -X- N

anterior JJ None
cruciate JJ None
ligament NN None
reconstruction NN None
. . None
anterior JJ None
cruciate JJ None
ligament NN None
reconstruction NN None
( ( None
ACLR NNP None
) ) None
subjects NNS None
with IN None
induced JJ None
knee NNS None
joint JJ None
effusion NN None
. . None
twenty JJ None
subjects NNS None
. . None
subjects NNS None
patients NNS None
with IN None
extensive JJ None
preoperative JJ None
quadriceps NNS None
dysfunction NN None
. . None
-DOCSTART- -X- N

catheter NN Condition
insertion NN Condition
sites NNS Condition
Consecutively RB None
scheduled VBD None
central JJ None
venous JJ None
catheters NNS None
inserted VBN None
into IN None
jugular NN None
or CC None
subclavian JJ None
veins NNS None
538 CD Size
catheters NNS None
randomized VBD None
, , None
481 CD Size
( ( None
89.4 CD None
% NN None
) ) None
produced VBD None
evaluable JJ None
culture NN None
results NNS None
. . None
-DOCSTART- -X- N

insomnia NN Condition
in IN None
children NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
. . None
why WRB None
parents NNS None
seek VBP None
medical JJ None
intervention NN None
in IN None
children NNS None
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
( ( Condition
ASDs NNP Condition
) ) None
. . None
Thirty-six JJ Size
children NNS Age
with IN None
ASD NNP Condition
, , None
ages VBZ Age
2 CD Age
to TO Age
10 CD Age
years NNS Age
, , None
were VBD None
enrolled VBN None
. . None
All DT None
had VBD None
prolonged VBN Condition
sleep JJ Condition
latency NN Condition
confirmed VBN None
by IN None
actigraphy NN None
showing VBG None
a DT None
mean JJ None
sleep JJ None
latency NN None
of IN None
30 CD None
minutes NNS None
or CC None
more JJR None
. . None
Parents NNS None
were VBD None
randomly RB None
assigned VBN None
to TO None
receive VB None
the DT None
sleep JJ None
education NN None
pamphlet NN None
or CC None
no DT None
intervention NN None
. . None
sleep JJ Condition
latency NN Condition
in IN None
children NNS None
with IN None
ASDs NNP Condition
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
type JJ Condition
2 CD Condition
diabetes NNS Condition
in IN None
the DT None
PROactive NNP None
Study NNP None
Patients NNPS None
with IN None
type JJ None
2 CD None
diabetes NNS None
high-risk JJ None
patients NNS None
with IN None
type JJ None
2 CD None
diabetes NNS None
. . None
5238 CD Size
patients NNS None
with IN None
type JJ None
2 CD None
diabetes NNS None
who WP None
had VBD None
evidence NN None
of IN None
macrovascular JJ Condition
disease NN Condition
. . None
patients NNS None
from IN None
primary-care JJ None
practices NNS None
and CC None
hospitals NNS None
. . None
514 CD Size
of IN None
2605 CD Size
patients NNS None
patients NNS None
with IN None
type JJ Condition
2 CD Condition
diabetes NNS Condition
who WP None
have VBP None
a DT None
high JJ None
risk NN None
of IN None
macrovascular JJ None
events NNS None
. . None
-DOCSTART- -X- N

idiopathic JJ None
dilated VBN None
cardiomyopathy NN None
. . None
idiopathic JJ None
dilated VBN None
cardiomyopathy NN None
( ( None
IDC NNP None
) ) None
. . None
From IN None
February NNP None
1 CD None
, , None
1997 CD None
, , None
to TO None
October NNP None
1 CD None
, , None
1999 CD None
, , None
186 CD None
patients NNS None
( ( None
131 CD None
men NNS None
and CC None
55 CD None
women NNS None
, , None
mean JJ None
age NN None
56 CD None
+/- JJ None
12 CD None
years NNS None
) ) None
with IN None
IDC NNP None
, , None
ejection NN None
fraction NN None
< VBD None
35 CD None
% NN None
, , None
and CC None
angiographically RB None
normal JJ None
coronary JJ None
arteries NNS None
were VBD None
studied VBN None
by IN None
high-dose NN None
( ( None
up IN None
to TO None
40 CD None
micro/kg/min NN None
) ) None
dobutamine NN None
echo NN None
in IN None
6 CD None
centers NNS None
, , None
all DT None
quality NN None
controlled VBN None
for IN None
stress NN None
echo NN None
reading NN None
. . None
patients NNS None
with IN None
IDC NNP None
-DOCSTART- -X- N

symptomatic JJ Condition
contact NN Condition
lens VBZ Condition
wearers NNS Condition
: : None
contact NN Condition
lens NN Condition
wearers NNS Condition
experiencing VBG None
symptoms NNS None
of IN None
ocular JJ Condition
dryness NN Condition
. . None
Thirty-nine JJ Size
subjects NNS None
were VBD None
enrolled VBN None
( ( None
23 CD Size
PVP NNP None
; : None
16 CD Size
NaCl NNP None
) ) None
. . None
average JJ None
age NN None
was VBD None
30 CD Age
; : None
subjects NNS None
were VBD None
predominantly RB None
female JJ Sex
, , None
and CC None
mostly RB None
wore VBD Condition
frequent-replacement JJ Condition
contact NN Condition
lenses NNS Condition
. . None
They PRP None
were VBD None
all DT None
exposed VBN None
to TO None
environmental JJ None
factors NNS None
such JJ None
as IN None
routine JJ None
use NN None
of IN None
video NN None
monitors NNS None
or CC None
air NN None
conditioning NN None
. . None
-DOCSTART- -X- N

anesthesia NN None
in IN None
dogs NNS None
sedated VBN None
with IN None
acepromazine NN None
and CC None
oxymorphone NN None
. . None
dogs NNS None
sedated VBN None
with IN None
acepromazine JJ None
maleate NN None
and CC None
oxymorphone NN None
hydrochloride NN None
. . None
ANIMALS $ None
10 CD Size
healthy JJ None
adult NN None
Beagles NNP None
. . None
-DOCSTART- -X- N

randomized JJ None
, , None
prospective JJ None
study NN None
was VBD None
undertaken VBN None
with IN None
150 CD Size
volunteers NNS None
who WP None
performed VBD None
management NN None
of IN None
a DT None
standardized JJ None
simulated JJ None
cardiac NN None
arrest NN None
in IN None
a DT None
manikin NN None
. . None
-DOCSTART- -X- N

thrombocytopenic JJ Condition
patients NNS None
with IN None
acute JJ Condition
leukemia NN Condition
. . None
54 CD Size
thrombocytopenic JJ Condition
patients NNS None
with IN None
acute JJ Condition
leukemia NN Condition
. . None
-DOCSTART- -X- N

nocturia NNS None
: : None
Adults NNP None
aged VBD None
> NNP None
or CC None
=18 NNP None
yr NN None
with IN None
nocturia NNS None
( ( None
> CD None
or CC None
=2 VB None
voids/night NN None
) ) None
127 CD None
patients NNS None
were VBD None
randomised VBN None
-DOCSTART- -X- N

recurrent NN None
aphthous JJ Condition
stomatitis NN Condition
. . None
Forty-nine JJ Size
volunteers NNS None
who WP None
passed VBD None
the DT None
initial JJ None
assessment NN None
for IN None
recurrent NN None
aphthous JJ Condition
stomatitis NN Condition
entered VBD None
a DT None
pretrial JJ None
phase NN None
in IN None
which WDT None
their PRP$ None
eligibility NN None
for IN None
the DT None
trial NN None
phase NN None
of IN None
the DT None
study NN None
was VBD None
assessed VBN None
. . None
Sixteen JJ Size
subjects NNS None
were VBD None
deemed VBN None
ineligible JJ None
26 CD Size
subjects NNS None
-DOCSTART- -X- N

human JJ None
immune NN None
response NN None
to TO None
hepatitis VB None
B NNP None
surface NN None
antigen NN None
50 CD Size
subjects NNS None
receiving VBG Condition
four CD Condition
doses NNS Condition
of IN Condition
hepatitis NN Condition
B NNP Condition
vaccine NN Condition
according VBG None
to TO None
a DT None
0 CD None
, , None
1 CD None
, , None
2 CD None
, , None
12 CD None
month NN None
vaccination NN None
scheme NN None
. . None
Twenty-three JJ None
subjects NNS None
were VBD None
given VBN None
a DT None
plasma-derived JJ None
vaccine NN None
( ( None
Hevac NNP None
B NNP None
) ) None
and CC None
27 CD None
received VBD None
a DT None
recombinant JJ None
HBsAg NNP None
vaccine NN None
( ( None
yeast-derived JJ None
; : None
Engerix-B NNP None
) ) None
. . None
-DOCSTART- -X- N

Eleven JJ None
patients NNS None
with IN None
well-documented JJ None
hepatorenal JJ None
syndrome NN None
-DOCSTART- -X- N

non-nephrotic JJ Condition
syndrome JJ Condition
IgA NNP Condition
nephropathy NN Condition
non-nephrotic JJ Condition
syndrome NN Condition
IgA NNP Condition
nephropathy NN Condition
( ( Condition
IgAN NNP Condition
) ) Condition
. . None
Seventy NNP Size
primary JJ Condition
IgAN NNP Condition
patients NNS None
-DOCSTART- -X- N

diabetic JJ Condition
nephropathy NN Condition
. . Condition
progressive JJ Condition
glomerular JJ Condition
injury NN Condition
. . None
34 CD Size
patients NNS None
with IN None
non-insulin-dependent JJ Condition
diabetes NNS Condition
mellitus NNS Condition
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
severe JJ Condition
acute NN Condition
pancreatitis NN Condition
. . None
One CD Size
hundred VBD Size
seventy-six JJ Size
patients NNS None
with IN None
necrotizing JJ None
pancreatitis NN None
patients NNS None
treated VBN None
with IN None
meropenem NN None
and CC None
those DT None
treated VBN None
with IN None
imipenem NN None
in IN None
terms NNS None
of IN None
incidence NN None
of IN None
pancreatic JJ None
infection NN None
( ( None
11.4 CD None
% NN None
versus IN None
13.6 CD None
% NN None
) ) None
and CC None
extrapancreatic JJ None
infections NNS None
( ( None
21.6 CD None
% NN None
versus IN None
23.9 CD None
% NN None
) ) None
and CC None
clinical JJ None
outcome NN None
. . None
-DOCSTART- -X- N

postmenopausal JJ Condition
women NNS Sex
. . None
Twenty NNP Size
six CD Size
postmenopausal JJ Condition
women NNS Sex
with IN None
climacteric JJ Condition
symptoms NNS Condition
were VBD None
two CD None
groups NNS None
; : None
one CD None
group NN None
who WP None
displayed VBD None
a DT None
significant JJ None
variance NN None
in IN None
negative JJ None
mood NN None
symptoms NNS None
during IN None
HRT NNP None
( ( None
cyclicity NN None
) ) None
and CC None
one CD None
group NN None
with IN None
no DT None
cyclical JJ None
changes NNS None
in IN None
negative JJ None
mood NN None
symptoms NNS None
during IN None
treatment NN None
. . None
Women NNP None
expressing VBG None
cyclicity NN None
in IN None
negative JJ None
mood NN None
symptoms NNS None
-DOCSTART- -X- N

autism NN Condition
spectrum NN Condition
disorder NN Condition
. . None
compulsive-like JJ Condition
symptoms NNS Condition
of IN None
autism NN Condition
spectrum NN Condition
disorder NN Condition
( ( Condition
ASD NNP Condition
) ) Condition
. . None
Thirteen JJ Size
individuals NNS None
with IN None
ASD NNP Condition
ASD NNP None
. . None
-DOCSTART- -X- N

nonresectable JJ Condition
rectal JJ Condition
cancer NN Condition
: : None
locally RB Condition
advanced JJ Condition
rectal JJ Condition
cancer NN Condition
Patients NNP None
( ( None
N NNP None
= NNP None
207 CD None
) ) None
with IN None
nonresectable JJ None
rectal JJ None
cancer NN None
were VBD None
randomized VBN None
to TO None
preoperative VB None
CRT NNP None
or CC None
RT NNP None
( ( None
2 CD None
Gy NNP None
? . None
25 CD None
? . None
5-fluorouracil/leucovorin JJ None
) ) None
. . None
the DT None
105 CD None
patients NNS None
alive JJ None
in IN None
Norway NNP None
and CC None
Sweden NNP None
after IN None
4 CD None
to TO None
12 CD None
years NNS None
of IN None
follow-up NN None
, , None
78 CD None
( ( None
74 CD None
% NN None
) ) None
responded VBD None
44 CD None
patients NNS None
in IN None
the DT None
CRT NNP None
group NN None
, , None
for IN None
locally RB None
advanced JJ None
rectal JJ None
cancer NN None
. . None
-DOCSTART- -X- N

symptomatic JJ Condition
carotid NN Condition
stenosis NN Condition
. . Condition
patients NNS Condition
with IN Condition
symptomatic JJ Condition
stenoses NNS Condition
. . Condition
1,214 CD None
patients NNS None
patients NNS Condition
with IN Condition
symptomatic JJ Condition
carotid NN Condition
artery NN Condition
stenosis NN Condition
. . Condition
-DOCSTART- -X- N

combined JJ None
study NN None
population NN None
( ( None
N NNP None
= NNP None
2813 CD Size
) ) None
of IN None
participants NNS None
with IN None
moderate JJ Condition
to TO Condition
severe VB Condition
acne JJ Condition
vulgaris NN Condition
. . None
significantly RB None
improved VBN None
participant-reported JJ None
HRQL NNP None
-DOCSTART- -X- N

children NNS None
with IN None
autism NN Condition
. . None
101 CD Age
children NNS Age
and CC None
adolescents NNS Age
with IN None
a DT None
lifetime JJ None
diagnosis NN None
of IN None
autistic JJ Condition
disorder NN Condition
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
hepatocellular JJ None
carcinoma NN None
Group NNP None
A NNP None
( ( None
19 CD None
patients NNS None
) ) None
group NN None
B NNP None
( ( None
18 CD None
patients NNS None
) ) None
-DOCSTART- -X- N

granulocytopenic JJ None
cancer NN None
patients NNS None
. . None
747 CD None
febrile JJ None
granulocytopenic JJ None
patients NNS None
with IN None
cancer NN None
cancer NN None
patients NNS None
with IN None
fever NN None
and CC None
granulocytopenia NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
panic JJ Condition
disorder NN Condition
in IN None
primary JJ None
care NN None
. . None
One CD Size
hundred VBD Size
fifteen JJ Size
patients NNS None
with IN None
PD NNP Condition
from IN None
3 CD None
primary JJ None
care NN None
clinics NNS None
primary JJ None
care NN None
PD NNP Condition
patients NNS None
. . None
-DOCSTART- -X- N

obese JJ None
adults NNS None
on IN None
a DT None
weight JJ None
loss NN None
diet NN None
. . None
cardiovascular JJ None
disease NN None
in IN None
obese JJ None
individuals NNS None
. . None
obese JJ None
participants NNS None
on IN None
a DT None
weight JJ None
loss NN None
diet NN None
25 CD None
% NN None
energy NN None
weight VBD None
loss NN None
diet NN None
alone RB None
( ( None
WL NNP None
) ) None
( ( None
n JJ None
= NNP None
12 CD None
) ) None
WL NNP None
plus CC None
4 CD None
g/d NN None
Omacor NNP None
( ( None
46 CD None
% NN None
EPA NNP None
and CC None
38 CD None
% NN None
DHA NNP None
) ) None
supplementation NN None
( ( None
WL+FAEE NNP None
) ) None
( ( None
n JJ None
= NNP None
13 CD None
) ) None
obese JJ None
adults NNS None
. . None
obese JJ None
adults NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
moderate JJ Condition
coronary JJ Condition
disease NN Condition
. . None
348 CD Size
patients NNS None
with IN None
moderate JJ Condition
coronary JJ Condition
artery NN Condition
disease NN Condition
, , None
standardized VBD None
coronary JJ None
angiograms NNS None
were VBD None
taken VBN None
3 CD None
years NNS None
apart RB None
-DOCSTART- -X- N

patients NNS None
with IN None
ocular JJ Condition
hypertension NN Condition
A DT None
total NN None
of IN None
1433 CD Size
of IN None
1636 CD Size
participants NNS None
randomized VBN None
to TO None
OHTS NNP Condition
who WP None
had VBD None
complete JJ None
baseline NN None
data NNS None
for IN None
factors NNS None
in IN None
the DT None
prediction NN None
model NN None
: : None
age NN None
, , None
IOP NNP None
, , None
CCT NNP None
, , None
vertical JJ None
cup-to-disc NN None
ratio NN None
( ( None
VCDR NNP None
) ) None
, , None
and CC None
pattern JJ None
standard JJ None
deviation NN None
( ( None
PSD NNP None
) ) None
. . None
ocular JJ Condition
hypertensive JJ Condition
individuals NNS None
-DOCSTART- -X- N

122 CD None
patients NNS None
with IN None
evolving VBG Condition
MI NNP Condition
to TO Condition
PTCA NNP Condition
therapy NN Condition
with IN None
or CC None
without IN None
adjunctive JJ None
intravenous JJ None
streptokinase NN None
therapy NN None
. . None
Patients NNP None
with IN None
ECG NNP Condition
ST NNP Condition
segment NN Condition
elevation NN Condition
who WP None
presented VBD None
within IN None
4 CD None
hours NNS None
of IN None
symptom JJ None
onset NN None
, , None
had VBD None
no DT None
contraindication NN None
to TO None
thrombolytic JJ None
therapy NN None
, , None
and CC None
were VBD None
not RB None
in IN None
cardiogenic JJ None
shock NN None
were VBD None
enrolled VBN None
. . None
106 CD None
patients NNS None
were VBD None
treated VBN Condition
with IN Condition
PTCA NNP Condition
. . None
-DOCSTART- -X- N

obese JJ Condition
men NNS Sex
. . None
22 CD Size
obese JJ Condition
men NNS Sex
and CC None
10 CD Size
normal JJ Condition
controls NNS None
seven CD None
male JJ None
patients NNS None
with IN None
subclinical JJ Condition
hypothyroidism NN Condition
obese JJ Condition
subjects NNS None
after IN None
substantial JJ None
weight JJ None
loss NN None
. . None
control NN None
and CC None
obese JJ Condition
men NNS None
. . None
obese JJ Condition
men NNS None
hypothyroid JJ Condition
men NNS None
obese JJ Condition
subjects NNS None
. . None
-DOCSTART- -X- N

children NNS None
and CC None
adolescents NNS None
with IN None
autism NN None
: : None
autism NN None
spectrum NN None
disorder NN None
( ( None
ASD NNP None
) ) None
. . None
sample NN None
of IN None
children NNS None
and CC None
adolescents NNS None
with IN None
ASD NNP None
. . None
Thirty-four JJ None
children NNS None
and CC None
adolescents NNS None
with IN None
ASD NNP None
( ( None
age NN None
range NN None
8-17 CD None
years NNS None
; : None
IQ NNP None
> NNP None
75 CD None
) ) None
were VBD None
enrolled VBN None
-DOCSTART- -X- N

patients NNS None
with IN None
advanced JJ Condition
human JJ Condition
immunodeficiency NN Condition
virus NN Condition
disease NN Condition
. . None
310 CD Size
patients NNS None
entering VBG None
a DT None
controlled JJ None
trial NN None
of IN None
prophylaxis NN None
with IN None
valaciclovir JJ None
versus NN None
acyclovir NN None
. . None
-DOCSTART- -X- N

urban JJ None
population NN None
of IN None
primiparas NNS None
in IN None
Lebanon NNP None
: : None
mothers NNS None
who WP None
exclusively RB None
breastfeed VBP None
their PRP$ None
babies NNS None
Beirut NNP None
breastfeeding VBG None
behavior NN None
in IN None
this DT None
population NN None
. . None
Healthy JJ None
first-time JJ None
mothers NNS None
delivering VBG None
in IN None
the DT None
capital NN None
Beirut NNP None
between IN None
March NNP None
and CC None
July NNP None
2009 CD None
maternal JJ None
work NN None
planned VBN None
pregnancy NN None
intention NN None
to TO None
breastfeed VB None
source NN None
of IN None
maternal JJ None
emotional JJ None
support NN None
healthy JJ None
first-time JJ None
mothers NNS None
who WP None
exclusively RB None
breastfeed VBP None
in IN None
Beirut NNP None
-DOCSTART- -X- N

patients NNS None
with IN None
respiratory JJ None
allergies NNS None
. . None
Adult NNP None
and CC None
pediatric JJ None
patients NNS None
with IN None
allergic JJ None
rhinoconjunctivitis NN None
and/or NN None
asthma NN None
were VBD None
included VBN None
in IN None
the DT None
study NN None
. . None
Ten CD None
subjects VBZ None
Forty-three JJ None
subjects NNS None
patients NNS None
with IN None
respiratory JJ None
allergies NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
claudication NN Condition
. . None
patients NNS None
with IN None
claudication NN None
. . None
Sixty-eight JJ Size
patients NNS None
with IN None
peripheral JJ Condition
obstructive JJ Condition
arterial JJ Condition
disease NN Condition
and CC None
intermittent JJ Condition
claudication NN Condition
( ( None
Fontaine NNP None
stage NN None
II NNP None
) ) None
patients NNS None
with IN None
claudication NN None
. . None
-DOCSTART- -X- N

adults NNS Age
with IN None
high-functioning JJ Condition
autism NN Condition
spectrum NN Condition
disorders NNS Condition
: : None
Adults NNP Age
with IN None
high-functioning JJ Condition
autism NN Condition
spectrum NN Condition
disorders NNS Condition
( ( Condition
ASD NNP Condition
) ) Condition
have VBP None
difficulties NNS None
in IN None
social JJ None
communication NN None
; : None
adults NNS Age
with IN None
ASD NNP Condition
children NNS Age
with IN None
ASD NNP Condition
. . None
adults NNS Age
with IN None
ASD NNP Condition
. . None
The DT None
participants NNS None
will MD None
be VB None
60 CD None
adults NNS None
with IN None
ASD NNP Condition
; : None
30 CD None
will MD None
be VB None
assigned VBN None
to TO None
a DT None
CBT NNP None
group NN None
and CC None
30 CD None
to TO None
a DT None
waitlist NN None
control NN None
group NN None
. . None
-DOCSTART- -X- N

healthy JJ None
adult NN None
subjects NNS None
. . None
Under IN None
fasting VBG None
conditions NNS None
, , None
24 CD None
healthy JJ None
Egyptian JJ None
male NN None
volunteers NNS None
-DOCSTART- -X- N

six CD Size
subjects NNS None
who WP None
received VBD None
either DT None
placebo NN None
, , None
practolol VBP None
50 CD None
mg NN None
, , None
practolol VBP None
200 CD None
mg NN None
, , None
propranolol VBP None
10 CD None
mg NN None
or CC None
propranolol VB None
40 CD None
mg. NN None
-DOCSTART- -X- N

Forty-eight NNP Size
matched VBD None
pairs NNS None
of IN None
osteoarthritic JJ Condition
knees NNS None
from IN None
patients NNS None
who WP None
underwent VBP None
primary JJ None
total JJ None
knee NN None
arthroplasty NN None
with IN None
a DT None
round-on-round NN None
, , None
Apollo NNP None
Knee NNP None
System NNP None
Patients NNS None
were VBD None
matched VBN None
for IN None
patient JJ None
factors NNS None
, , None
preoperative JJ None
deformities NNS Condition
, , None
cruciate JJ None
salvage NN None
or CC None
sacrifice NN None
, , None
and CC None
surgical JJ None
technique NN None
. . None
elderly JJ Age
patients NNS None
( ( None
> JJ Age
70 CD Age
years NNS None
old JJ None
) ) None
-DOCSTART- -X- N

able-bodied JJ None
participants NNS None
. . None
Participants NNS None
( ( None
n=14 CC None
) ) None
and CC None
a DT None
control NN None
group NN None
( ( None
n=7 RB None
) ) None
. . None
able-bodied JJ None
participants NNS None
. . None
-DOCSTART- -X- N

pain NN Condition
associated VBN None
with IN None
propofol JJ None
injection NN None
. . None
One-hundred-twenty-four JJ Size
adult NN Age
patients NNS None
, , None
ASA NNP None
physical JJ None
status NN None
I-II NNP None
, , None
undergoing VBG None
elective JJ None
surgery NN None
-DOCSTART- -X- N

Seventy-six JJ Condition
patients NNS Condition
took VBD Condition
part NN Condition
in IN Condition
a DT Condition
randomized JJ Condition
, , Condition
comparative JJ Condition
study NN Condition
of IN Condition
the DT Condition
efficacy NN Condition
of IN Condition
buflomedil NN Condition
hydrochloride NN Condition
and CC Condition
dihydrogenated VBD Condition
ergot JJ Condition
alkaloids NNS Condition
in IN Condition
the DT Condition
treatment NN Condition
of IN Condition
senile JJ Condition
dementia NN Condition
associated VBN Condition
with IN Condition
cerebrovascular JJ Condition
insufficiency NN Condition
. . Condition
senile JJ None
dementia NN None
associated VBN None
with IN None
cerebrovascular JJ None
insufficiency NN None
-DOCSTART- -X- N

Four NNP None
hundred VBD None
sixty-nine JJ None
assessable JJ None
advanced JJ None
cancer NN None
patients NNS None
were VBD None
randomized VBN None
to TO None
( ( None
1 CD None
) ) None
oral JJ None
megestrol NN None
acetate VBP None
800 CD None
mg/d NN None
liquid NN None
suspension NN None
plus CC None
placebo NN None
, , None
( ( None
2 CD None
) ) None
oral JJ None
dronabinol $ None
2.5 CD None
mg NN None
twice RB None
a DT None
day NN None
plus CC None
placebo NN None
, , None
or CC None
( ( None
3 CD None
) ) None
both DT None
agents NNS None
. . None
Eligible JJ None
patients NNS None
acknowledged VBD None
that IN None
loss NN None
of IN None
appetite NN None
or CC None
weight NN None
was VBD None
a DT None
problem NN None
and CC None
reported VBD None
the DT None
loss NN None
of IN None
5 CD None
pounds NNS None
or CC None
more JJR None
during IN None
2 CD None
months NNS None
and/or IN None
a DT None
daily JJ None
intake NN None
of IN None
less JJR None
than IN None
20 CD None
calories/kg NN None
of IN None
body NN None
weight NN None
. . None
megestrol NN None
acetate-treated JJ None
patients NNS None
dronabinol-treated JJ None
patients NNS None
: : None
megestrol JJ None
acetate-treated JJ None
and CC None
combination-treated JJ None
patients NNS None
. . None
men NNS Age
who WP None
received VBD None
megestrol NN None
acetate NN None
. . None
advanced JJ None
cancer NN None
patients NNS None
-DOCSTART- -X- N

HIV-infected JJ None
prisoners NNS None
HIV-infected JJ None
releasees NNS None
. . None
for IN None
HIV-infected JJ None
state NN None
prison NN None
inmates NNS None
. . None
the DT None
104 CD None
inmates NNS None
enrolled VBD None
, , None
89 CD None
had VBD None
at IN None
least JJS None
1 CD None
post-release JJ None
study NN None
visit NN None
. . None
HIV-infected JJ None
individuals NNS None
released VBN None
from IN None
prison NN None
. . None
-DOCSTART- -X- N

youth NN None
-DOCSTART- -X- N

cervical JJ Condition
cancer NN Condition
patients NNS None
before IN None
and CC None
after IN None
treatment NN None
. . None
cervical JJ Condition
cancer NN Condition
patients NNS None
104 CD Size
cervical JJ None
cancer NN None
patients NNS None
selected VBN None
for IN None
the DT None
present JJ None
study NN None
, , None
54 CD Size
and CC None
50 CD Size
patients NNS None
were VBD None
treated VBN None
with IN None
chemo- JJ None
and CC None
radiotherapy NN None
respectively RB None
. . None
cervical JJ Condition
cancer NN Condition
patients NNS None
patients NNS None
treated VBN None
with IN None
chemotherapy NN None
. . None
cervical JJ Condition
cancer NN Condition
patients NNS None
. . None
-DOCSTART- -X- N

in IN None
patients NNS None
with IN None
bipolar JJ Condition
I PRP Condition
disorder VBP Condition
after IN None
an DT None
acute JJ Condition
manic NN Condition
or CC Condition
mixed JJ Condition
episode NN Condition
. . None
in IN None
patients NNS None
with IN None
bipolar JJ Condition
I PRP Condition
disorder VBP Condition
. . None
clinically RB Condition
stable JJ Condition
patients NNS None
with IN None
this DT None
disorder NN None
. . None
Patients NNPS None
( ( None
n=766 JJ Size
) ) None
, , None
aged VBD None
18 CD Age
to TO Age
65 CD Age
years NNS Age
inclusive JJ None
, , None
with IN None
current JJ Condition
manic NN Condition
or CC Condition
mixed JJ Condition
episodes NNS Condition
were VBD None
initially RB None
randomized VBN None
Patients NNS None
on IN None
paliperidone NN None
ER NNP None
who WP None
achieved VBD None
remission NN None
to TO None
patients NNS None
not RB None
previously RB None
stabilized VBN None
on IN None
paliperidone NN None
ER NNP None
. . None
in IN None
patients NNS None
with IN None
bipolar JJ Condition
I PRP Condition
disorder VBP Condition
. . None
-DOCSTART- -X- N

patients NNS None
entering VBG None
outpatient JJ None
opiate JJ None
detoxification NN None
. . None
Participants NNS None
( ( None
N NNP None
= NNP None
211 CD None
) ) None
-DOCSTART- -X- N

women NNS Condition
after IN Condition
myocardial JJ Condition
infarction NN Condition
: : Condition
women NNS None
with IN None
average JJ None
cholesterol NN None
levels NNS None
after IN None
myocardial JJ None
infarction NN None
( ( None
MI NNP None
) ) None
. . None
coronary JJ None
heart NN None
disease NN None
( ( None
CHD NNP None
) ) None
in IN None
women NNS None
; : None
in IN None
particular JJ None
, , None
those DT None
with IN None
CHD NNP None
and CC None
average JJ None
cholesterol NN None
levels NNS None
. . None
576 CD None
postmenopausal NN None
women NNS None
, , None
between IN None
3 CD None
and CC None
20 CD None
months NNS None
after IN None
MI NNP None
, , None
with IN None
a DT None
total JJ None
cholesterol NN None
level NN None
< VBD None
240 CD None
mg/dl NN None
and CC None
a DT None
low JJ None
density NN None
lipoprotein NN None
cholesterol NN None
level NN None
115 CD None
to TO None
174 CD None
mg/dl NNS None
The DT None
3,583 CD None
men NNS None
in IN None
the DT None
CARE NNP None
trial NN None
men NNS None
and CC None
women NNS None
. . None
post-MI JJ None
women NNS None
with IN None
average JJ None
cholesterol NN None
levels NNS None
. . None
-DOCSTART- -X- N

type JJ None
2 CD None
diabetes NNS None
inadequately RB None
controlled VBN None
on IN None
metformin NN None
monotherapy NN None
. . None
subjects NNS None
with IN None
type JJ None
2 CD None
diabetes NNS None
mellitus NN None
who WP None
have VBP None
inadequate JJ None
glycemic NNS None
control NN None
on IN None
metformin NN None
monotherapy NN None
. . None
-DOCSTART- -X- N

The DT None
preparation NN None
of IN None
patients NNS None
for IN None
cardiac JJ Condition
surgery NN Condition
. . None
patients NNS None
attending VBG None
a DT None
preadmission NN None
teaching VBG None
program NN None
prior RB None
to TO None
cardiac VB Condition
surgery NN Condition
. . None
-DOCSTART- -X- N

major JJ None
depressive JJ None
disorder NN None
Depressive NNP None
disorder NN None
depressive JJ None
disorder NN None
depressive JJ None
disorder NN None
primary JJ None
care NN None
in IN None
the DT None
Netherlands NNP None
Forty NNP Size
general JJ None
practices NNS None
patients NNS None
who WP None
are VBP None
diagnosed VBN None
with IN None
moderate JJ None
to TO None
severe JJ None
depression NN None
, , None
based VBN None
on IN None
DSM-IV NNP None
criteria NNS None
, , None
and CC None
stratified VBD None
according VBG None
to TO None
comorbid VB None
chronic JJ None
physical JJ None
illness NN None
. . None
patients NNS None
with IN None
a DT None
depressive JJ None
disorder NN None
major JJ None
depressive JJ None
disorder NN None
-DOCSTART- -X- N

asthma NN Condition
. . None
bronchial JJ Condition
asthma NN Condition
a DT None
group NN None
of IN None
asthmatic JJ Condition
subjects NNS None
. . None
asthmatic JJ Condition
patients NNS None
. . None
-DOCSTART- -X- N

neonatal JJ None
seizures NNS None
. . None
neonates NNS None
admitted VBN None
to TO None
an DT None
intensive JJ None
care NN None
unit NN None
. . None
59 CD None
neonates NNS None
with IN None
seizures NNS None
that WDT None
were VBD None
confirmed VBN None
by IN None
electroencephalography NN None
. . None
neonates NNS None
30 CD None
neonates NNS None
assigned VBN None
to TO None
receive VB None
phenobarbital NN None
29 CD None
neonates NNS None
assigned VBN None
to TO None
receive VB None
phenytoin NN None
neonates NNS None
. . None
-DOCSTART- -X- N

chronic JJ Condition
obstructive JJ Condition
pulmonary JJ Condition
disease NN Condition
. . None
59 CD Size
patients NNS None
with IN None
COPD NNP Condition
randomized VBD None
-DOCSTART- -X- N

patients NNS None
with IN None
symptomatic JJ None
peripheral JJ None
arterial JJ None
disease NN None
73 CD None
patients NNS None
were VBD None
assigned VBN None
to TO None
CT NNP None
angiography NN None
, , None
and CC None
72 CD None
were VBD None
assigned VBN None
to TO None
DSA NNP None
. . None
patients NNS None
with IN None
symptomatic JJ None
peripheral JJ None
arterial JJ None
disease NN None
. . None
-DOCSTART- -X- N

Maximal NNP None
bioavailability NN None
of IN None
digoxin NN None
from IN None
tablets NNS None
and CC None
oral JJ None
solution NN None
in IN None
steady JJ None
state NN None
. . None
-DOCSTART- -X- N

social JJ None
disability NN None
in IN None
autism NN None
spectrum NN None
disorder NN None
: : None
Research NNP None
Units NNP None
on IN None
Pediatric NNP None
Psychopharmacology NNP None
( ( None
RUPP NNP None
) ) None
Autism NNP None
Network NNP None
trials NNS None
. . None
autism NN None
spectrum NN None
disorders NNS None
data NNS None
from IN None
two CD None
federally-funded JJ None
, , None
multi-site JJ None
, , None
randomized JJ None
trials NNS None
with IN None
risperidone NN None
. . None
Study NNP None
1 CD None
included VBD None
52 CD None
subjects NNS None
assigned VBN None
to TO None
placebo VB None
and CC None
49 CD None
subjects NNS None
to TO None
risperidone VB None
under IN None
double-blind JJ None
conditions NNS None
. . None
Study NNP None
2 CD None
included VBD None
49 CD None
subjects NNS None
assigned VBN None
to TO None
risperidone VB None
only RB None
and CC None
75 CD None
subjects NNS None
assigned VBN None
to TO None
risperidone VB None
plus JJ None
parent NN None
training NN None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
: : None
16 CD Size
children NNS None
with IN None
autism NN Size
parents NNS None
child NN None
-DOCSTART- -X- N

major JJ None
depression NN Condition
. . None
75 CD Size
outpatients NNS None
. . None
moclobemide NN None
( ( None
25 CD Size
patients NNS None
) ) None
Imipramine NNP None
( ( None
25 CD Size
patients NNS None
) ) None
25 CD Size
patients NNS None
-DOCSTART- -X- N

advanced JJ Condition
ovarian JJ Condition
cancer NN Condition
. . None
May NNP None
1978 CD None
until IN None
November NNP None
1980 CD None
, , None
169 CD Size
previously RB Condition
untreated JJ Condition
patients NNS None
with IN None
advanced JJ Condition
epithelial JJ Condition
ovarian JJ Condition
cancer NN Condition
Eleven JJ Size
patients NNS None
153 CD Size
patients NNS None
evaluable JJ None
for IN None
response NN None
, , None
there EX None
were VBD None
47 CD None
, , None
or CC None
30.7 CD None
% NN None
, , None
complete JJ None
responders NNS None
158 CD Size
patients NNS None
-DOCSTART- -X- N

obese JJ Condition
hypertensive JJ Condition
men NNS None
: : None
30 CD Size
middle NNS Age
aged VBN Age
obese JJ Condition
men NNS None
with IN None
essential JJ Condition
hypertension NN Condition
attending VBG None
the DT None
outpatient JJ None
department NN None
. . None
group NN None
1 CD None
group NN None
2 CD None
hypertensive JJ Condition
obese JJ Condition
men NNS Sex
-DOCSTART- -X- N

patients NNS None
with IN None
advanced JJ Condition
cervical JJ Condition
cancer NN Condition
. . None
advanced JJ Condition
cervical JJ Condition
carcinoma NN Condition
. . None
Between NNP None
May NNP None
2000 CD None
and CC None
May NNP None
2004 CD None
, , None
31 CD Size
women NNS None
with IN None
FIGO NNP Condition
stage NN Condition
IB2-IVA NNP Condition
cervical JJ Condition
cancer NN Condition
or CC Condition
with IN Condition
postsurgical JJ Condition
pelvic JJ Condition
recurrence NN Condition
were VBD None
enrolled VBN None
into IN None
this DT None
phase NN None
II NNP None
study NN None
RESULTS NNP None
Patient NNP None
and CC None
tumor NN None
characteristics NNS None
were VBD None
for IN None
advanced JJ None
carcinoma NN None
of IN None
the DT None
cervix NN None
. . None
-DOCSTART- -X- N

haemorrhoids NNS Condition
. . None
89 CD Size
consecutive JJ None
patients NNS None
with IN None
haemorrhoids NNS Condition
. . None
-DOCSTART- -X- N

lung NN None
adenocarcinoma NN None
patients NNS None
with IN None
lung NN None
adenocarcinoma NN None
prospective JJ None
study NN None
on IN None
30 CD None
patients NNS None
with IN None
lung NN None
adenocarcinoma NN None
, , None
divided VBN None
into IN None
two CD None
groups NNS None
of IN None
15 CD None
patients NNS None
each DT None
. . None
-DOCSTART- -X- N

Eighty NNP Size
freshly RB Size
extracted VBD Size
maxillary JJ Size
premolars NNS Size
were VBD None
randomly RB None
divided VBN None
into IN None
4 CD None
groups NNS None
( ( None
20 CD None
in IN None
each DT None
group NN None
) ) None
. . None
teeth NNS None
-DOCSTART- -X- N

Adult NNP Age
height NN None
in IN None
short JJ None
children NNS Age
born VBN None
SGA NNP Condition
treated VBD None
with IN None
growth NN None
hormone NN None
and CC None
gonadotropin NN None
releasing VBG None
hormone NN None
analog NN None
: : None
short JJ Condition
children NNS Condition
born VBP Condition
small JJ Condition
for IN Condition
gestational JJ Condition
age NN Condition
( ( Condition
SGA NNP Condition
) ) Condition
. . None
expectation NN None
. . None
included VBD None
121 CD None
short JJ None
SGA NNP None
children NNS None
( ( None
60 CD None
boys NNS None
) ) None
at IN None
least JJS None
8 CD None
yr NN None
of IN None
age NN None
. . None
performed VBD None
intention-to-treat JJ None
analyses NNS None
on IN None
all DT None
children NNS None
and CC None
uncensored JJ None
case NN None
analyses VBZ None
on IN None
84 CD None
children NNS None
who WP None
reached VBD None
AH NNP None
. . None
RESULTS NNP None
Short NNP None
SGA NNP None
children NNS None
started VBD None
short JJ None
SGA NNP None
children NNS None
, , None
particularly RB None
with IN None
GH NNP None
2 CD None
mg/m NN None
( ( None
2 CD None
) ) None
? . None
d NN None
during IN None
puberty NN None
. . None
When WRB None
-DOCSTART- -X- N

prostate NN None
cancer NN None
follow-up NN None
of IN None
212 CD None
randomized JJ None
patients NNS None
. . None
Two CD None
hundred VBD None
and CC None
twelve JJ None
patients NNS None
treated VBN None
for IN None
prostatic JJ None
cancer NN None
grade NN None
I PRP None
or CC None
II NNP None
were VBD None
The DT None
patients NNS None
were VBD None
part NN None
of IN None
a DT None
multicentre NN None
study NN None
in IN None
the DT None
Stockholm NNP None
area NN None
and CC None
had VBD None
been VBN None
randomized VBN None
to TO None
treatment NN None
with IN None
either DT None
estramustine JJ None
phosphate NN None
( ( None
Estracyt NNP None
) ) None
or CC None
polyestradiol JJ None
phosphate NN None
and CC None
ethinyl JJ None
estradiol NN None
. . None
-DOCSTART- -X- N

previously RB None
untreated VBN None
advanced JJ Condition
breast NN Condition
cancer NN Condition
previously RB None
untreated VBN None
metastatic JJ Condition
breast NN Condition
cancer NN Condition
patients NNS None
Patients NNS None
had VBD None
to TO None
have VB None
histologically RB None
documented VBN None
measurable JJ None
breast NN Condition
cancer NN Condition
and CC None
a DT None
performance NN None
status NN None
of IN None
0-1 NNP None
. . None
Patients NNS None
could MD None
not RB None
have VB None
had VBN None
prior JJ None
chemotherapy NN Condition
for IN None
metastatic JJ Condition
disease NN Condition
. . None
Prior NNP None
adjuvant JJ Condition
chemotherapy NN Condition
was VBD None
permitted VBN None
. . None
Patients NNS None
could MD None
not RB None
have VB None
visceral JJ Condition
crisis NN Condition
. . None
previously RB None
untreated VBN None
breast NN Condition
cancer NN Condition
patients NNS None
-DOCSTART- -X- N

reversible JJ Condition
chronic JJ Condition
airway NN Condition
obstruction NN Condition
. . Condition
20 CD Condition
adult NN Condition
patients NNS Condition
with IN Condition
reversible JJ Condition
chronic JJ Condition
airway NN Condition
obstruction NN Condition
( ( Condition
intrinsic JJ Condition
asthma NN Condition
or CC Condition
COPD NNP Condition
) ) Condition
-DOCSTART- -X- N

chronic JJ Condition
coronary JJ Condition
insufficiency NN Condition
] NNP Condition
29 CD Size
male JJ Sex
patients NNS None
with IN None
coronary JJ Condition
insufficiency NN Condition
who WP None
had VBD None
persistent JJ Condition
ST NNP Condition
depression NN Condition
on IN None
exercise NN None
tolerance NN None
test NN None
( ( None
greater JJR None
than IN None
or CC None
equal JJ None
to TO None
1 CD None
mm NN None
) ) None
, , None
despite IN None
treatment NN None
with IN None
nifedipine JJ None
40 CD None
mg JJ None
per IN None
day NN None
. . None
-DOCSTART- -X- N

Neonatal NNP None
intensive JJ None
care NN None
unit NN None
in IN None
a DT None
106-bed JJ None
quaternary JJ None
care NN None
pediatric JJ None
hospital NN None
. . None
Nine NNP None
neonates VBZ None
receiving VBG None
ECMO NNP None
who WP None
required VBD None
intravenous JJ None
nutrition NN None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
autistic JJ Condition
spectrum NN Condition
disorders NNS Condition
. . None
children NNS None
with IN None
autistic JJ None
spectrum NN None
disorders NNS None
Ten CD Size
children NNS Age
were VBD None
trained VBN None
on IN None
theory NN None
of IN None
mind NN None
, , None
whilst WP None
ten EX Size
were VBD None
trained VBN None
in IN None
executive JJ None
function NN None
. . None
Seven JJ Size
children NNS None
were VBD None
assigned VBN None
to TO None
a DT None
control NN None
group NN None
, , None
receiving VBG None
no DT None
intervention NN None
. . None
-DOCSTART- -X- N

recovery NN None
enhancement NN None
after IN None
stroke VBD Condition
2 CD None
to TO None
60 CD None
patients NNS None
3 CD None
to TO None
30 CD None
days NNS None
after IN None
ischemic JJ None
or CC None
hemorrhagic JJ None
stroke NN None
. . None
RESULTS NNP None
Sixty NNP None
patients NNS None
were VBD None
recruited VBN None
at IN None
mean NN None
of IN None
8 CD None
days NNS None
( ( None
SD NNP None
? . None
5 CD None
) ) None
post NN None
ictus NN None
, , None
with IN None
mean JJ None
age NN None
71 CD None
years NNS None
( ( None
? . None
12 CD None
years NNS None
) ) None
and CC None
53 CD None
% NN None
men NNS None
. . None
The DT None
were VBD None
no DT None
significant JJ None
differences NNS None
between IN None
groups NNS None
in IN None
baseline NN None
in IN None
G-CSF-treated JJ None
patients NNS None
( ( None
P=0.06 NNP None
in IN None
patients NNS None
with IN None
ischemic JJ None
stroke NN None
. . None
CLINICAL NNP None
-DOCSTART- -X- N

septic JJ None
acute NN None
lung NN None
injury NN None
patients NNS None
with IN None
septic JJ Condition
acute NN Condition
lung NN Condition
injury NN Condition
( ( Condition
ALI NNP Condition
) ) Condition
-DOCSTART- -X- N

patients NNS None
with IN None
Fisher NNP Condition
grade NN Condition
III NNP Condition
subarachnoid JJ Condition
hemorrhage NN Condition
: : Condition
patients NNS None
with IN None
ruptured JJ None
aneurysms NNS None
. . None
One CD Size
hundred CD Size
and CC Size
seventy JJ Size
patients NNS Size
with IN None
Fisher NNP Condition
Grade NNP Condition
III NNP Condition
subarachnoid JJ Condition
hemorrhage NN Condition
were VBD None
enrolled VBN None
in IN None
the DT None
study NN None
. . None
patients NNS None
with IN None
Fisher NNP Condition
grade NN Condition
III NNP Condition
subarachnoid NN Condition
hemorrhage NN Condition
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
. . None
3 CD None
children NNS Age
with IN None
autistic JJ Condition
spectrum NN Condition
disorders NNS Condition
after IN None
the DT None
administration NN None
of IN None
secretin NN None
, , None
a DT None
peptide NN None
hormone NN None
. . None
12 CD Size
autistic JJ None
children NNS Age
autistic JJ None
children NNS Age
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ Condition
renal JJ Condition
disease NN Condition
. . None
patients NNS None
exhibiting VBG None
a DT None
progressive JJ Condition
decline NN Condition
in IN Condition
renal JJ Condition
function NN Condition
because IN None
of IN None
chronic JJ Condition
renal JJ Condition
disease NN Condition
. . None
group NN None
of IN None
patients NNS None
with IN None
progressive JJ Condition
chronic JJ Condition
renal JJ Condition
failure NN Condition
( ( None
creatinine JJ Condition
clearance NN Condition
20-45 JJ Condition
ml/min NN Condition
) ) None
either CC None
with IN Condition
or CC Condition
without IN Condition
proteinuria NNS Condition
and CC Condition
hypertension NN Condition
. . None
( ( None
n JJ None
= NNP None
22 CD Size
) ) None
; : None
( ( None
n JJ None
= NNP None
42 CD Size
) ) None
; : None
( ( None
n JJ None
= NNP None
44 CD Size
) ) None
patients NNS None
with IN None
moderate JJ Condition
chronic JJ Condition
renal JJ Condition
failure NN Condition
. . None
-DOCSTART- -X- N

labour JJ None
analgesia NN None
. . None
UK NNP None
mother NN None
and CC None
neonate NN None
. . None
labour NN None
and CC None
their PRP$ None
side NN None
effects NNS None
in IN None
mother NN None
, , None
fetus NN None
and CC None
neonate NN None
. . None
women NNS None
in IN None
the DT None
antenatal JJ None
period NN None
or CC None
in IN None
early JJ None
labour NN None
. . None
406 CD None
women NNS None
with IN None
data NNS None
on IN None
primary JJ None
outcomes NNS None
. . None
mother NN None
and CC None
neonate NN None
-DOCSTART- -X- N

healthy JJ None
volunteers NNS None
. . None
healthy JJ None
human JJ None
volunteers NNS None
. . None
-DOCSTART- -X- N

high-risk JJ None
patients NNS None
. . None
fat JJ Condition
embolism NN Condition
syndrome NN Condition
high-risk JJ Condition
patients NNS Condition
with IN Condition
long-bone JJ Condition
fractures NNS Condition
. . Condition
corticosteroid- NN None
( ( None
0 CD None
of IN None
21 CD None
) ) None
and CC None
placebo-treated JJ None
patients NNS None
( ( None
9 CD None
of IN None
41 CD None
) ) None
patients NNS Condition
at IN Condition
high JJ Condition
risk NN Condition
for IN Condition
the DT Condition
fat JJ Condition
embolism NN Condition
syndrome NN Condition
-DOCSTART- -X- N

cancer NN Condition
patients NNS None
. . None
patients NNS None
undergoing VBG None
therapy NN None
with IN None
neurotoxic JJ None
chemotherapy NN None
100 CD Size
patients NNS None
per IN None
arm NN None
Two-hundred JJ Size
seven CD Size
patients NNS None
were VBD None
enrolled VBN None
between IN None
December NNP None
1 CD None
, , None
2006 CD None
and CC None
December NNP None
14 CD None
, , None
2007 CD None
, , None
producing VBG None
189 CD Size
evaluable JJ None
cases NNS None
for IN None
analysis NN None
. . None
group NN None
of IN None
patients NNS None
receiving VBG None
neurotoxic JJ None
chemotherapy NN None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
autistic JJ Condition
disorder NN Condition
: : None
patients NNS None
with IN None
autism NN Condition
. . None
Twelve CD Size
patients NNS None
were VBD None
enrolled VBN None
, , None
and CC None
10 CD Size
patients NNS None
( ( None
mean JJ None
age NN None
6 CD Age
years NNS Age
3 CD Age
months NNS Age
) ) None
were VBD None
able JJ None
to TO None
complete VB None
the DT None
study NN None
. . None
-DOCSTART- -X- N

postmenopausal JJ Condition
women NNS None
with IN None
and CC None
without IN None
hormone-replacement JJ Condition
therapy NN Condition
. . None
postmenopausal JJ Condition
women NNS None
consuming VBG None
a DT None
fish JJ None
oil NN None
supplement NN None
. . None
Forty-eight JJ Size
women NNS None
, , None
equally RB None
divided VBD None
between IN None
women NNS None
using VBG None
and CC None
not RB None
using VBG None
HRT NNP Condition
-DOCSTART- -X- N

in IN None
patients NNS None
with IN None
rheumatoid JJ None
arthritis NN None
. . None
RESULTS NNP None
One CD None
hundred VBD None
forty-three JJ None
non-diabetic JJ None
adult NN None
RA NNP None
patients NNS None
( ( None
76.2 CD None
% NN None
female NN None
, , None
age NN None
55.2 CD None
? . None
12.1 CD None
[ JJ None
mean NN None
? . None
SD NNP None
] NNP None
) ) None
on IN None
stable JJ None
RA NNP None
standard NN None
of IN None
care NN None
treatment NN None
were VBD None
-DOCSTART- -X- N

90 CD None
Brazilian JJ None
women NNS None
, , None
diagnosed VBD None
to TO None
CIN2 NNP None
and CC None
high-risk JJ None
human JJ None
papillomavirus NN None
infection NN None
, , None
were VBD None
randomized VBN None
into IN None
two CD None
groups NNS None
of IN None
equal JJ None
size NN None
: : None
45 CD None
women NNS None
whose WP$ None
lesions NNS None
were VBD None
excised VBN None
and CC None
45 CD None
women NNS None
subjected VBN None
to TO None
prospective JJ None
follow-up NN None
at IN None
3-month JJ None
intervals NNS None
at IN None
least JJS None
for IN None
1 CD None
year NN None
( ( None
mean JJ None
6.8 CD None
months NNS None
) ) None
. . None
45 CD None
women NNS None
-DOCSTART- -X- N

obsessive-compulsive JJ None
disorder NN None
: : None
Twelve CD None
patients NNS None
were VBD None
given VBN None
fluoxetine NN None
( ( None
20 CD None
mg/d NN None
) ) None
plus CC None
zinc NN None
( ( None
440 CD None
mg/d NN None
) ) None
and CC None
11 CD None
patients NNS None
were VBD None
given VBN None
fluoxetine JJ None
plus CC None
placebo NN None
for IN None
8 CD None
wk NNS None
. . None
-DOCSTART- -X- N

memory NN Condition
Four CD Size
experiments NNS None
memory NN Condition
for IN None
high JJ Condition
imagery NN Condition
and CC None
low JJ Condition
imagery NN Condition
texts NN None
. . None
between-subjects NNS None
subjects NNS None
-DOCSTART- -X- N

microdose JJ Condition
flare-up JJ Condition
cycles NNS Condition
in IN Condition
poor JJ Condition
responders NNS Condition
microdose JJ None
gonadotropin-releasing JJ None
hormone NN None
analog NN None
( ( None
GnRH-a NNP None
) ) None
flare NN None
cycles NNS None
in IN None
poor JJ None
responders NNS None
. . None
total NN None
of IN None
119 CD None
women NNS None
119 CD None
patients NNS None
-DOCSTART- -X- N

nasal JJ Condition
congestion NN Condition
. . None
patients NNS None
with IN None
nasal JJ None
congestion NN None
. . None
Twenty-four JJ Size
patients NNS None
with IN None
perennial JJ Condition
rhinitis NN Condition
due JJ None
to TO None
house-dust-mite JJ Condition
( ( Condition
HDM NNP Condition
) ) Condition
allergy NN Condition
were VBD None
recruited VBN None
-DOCSTART- -X- N

postgraduate NN None
cancer NN Condition
pain NN None
education NN None
cancer NN Condition
pain NN None
education NN None
program NN None
for IN None
nurses NNS None
of IN None
patients NNS None
from IN None
11 CD None
different JJ None
ethnic JJ None
groups NNS None
. . None
Four CD Size
hundred VBD Size
ninety NN Size
six CD Size
home NN None
, , None
hospital NN None
, , None
and CC None
hospice NN None
nurses NNS None
participated VBD None
in IN None
a DT None
one-day JJ None
workshop NN None
or CC None
two CD None
half-day JJ None
workshops NNS None
on IN None
cancer NN Condition
pain NN None
assessment NN None
and CC None
management NN None
. . None
oncology NN None
nurse JJ None
Eighty-six JJ Size
nurses NNS None
served VBD None
as IN None
controls NNS None
. . None
postgraduate NN None
nurses NNS None
-DOCSTART- -X- N

advanced JJ Condition
breast NN Condition
cancer NN Condition
. . None
155 CD None
consecutive JJ None
patients NNS None
with IN None
Stage NNP None
IV NNP None
breast NN None
cancer NN None
randomly RB None
allocated VBN None
to TO None
receive VB None
either DT None
( ( None
1 CD None
) ) None
vincristin NN None
( ( None
V NNP None
) ) None
1.2 CD None
mg/m2 NN None
( ( None
maximum JJ None
dose NN None
, , None
2 CD None
mg NN None
) ) None
, , None
Adriamycin NNP None
( ( None
A NNP None
) ) None
( ( None
doxorubicin NN None
) ) None
40 CD None
mg/m2 NN None
, , None
and CC None
cyclophosphamide NN None
( ( None
C NNP None
) ) None
500 CD None
mg/m2 NN None
, , None
all DT None
intravenously RB None
on IN None
day NN None
1 CD None
, , None
every DT None
4 CD None
weeks NNS None
, , None
in IN None
combination NN None
with IN None
medroxyprogesteron NN None
acetate NN None
( ( None
MPA NNP None
) ) None
600 CD None
mg NN None
orally RB None
on IN None
days NNS None
1 CD None
through IN None
14 CD None
, , None
500 CD None
mg NNS None
intramuscularly RB None
on IN None
days NNS None
1 CD None
through IN None
28 CD None
, , None
and CC None
twice RB None
weekly JJ None
afterwards NNS None
( ( None
combined VBN None
chemoendocrine NN None
approach NN None
) ) None
or CC None
( ( None
2 CD None
) ) None
the DT None
same JJ None
combination NN None
chemotherapy NN None
( ( None
VAC NNP None
) ) None
for IN None
three CD None
cycles NNS None
alternating VBG None
with IN None
MPA NNP None
in IN None
the DT None
above-mentioned JJ None
dosage NN None
during IN None
8 CD None
weeks NNS None
( ( None
alternating VBG None
chemoendocrine VB None
approach NN None
) ) None
patients NNS None
with IN None
more JJR None
than IN None
one CD None
metastatic JJ None
site NN None
estrogen NN None
receptor NN None
( ( None
ER NNP None
) ) None
-negative JJ None
patients NNS None
patients NNS None
younger JJR None
than IN None
51 CD None
years NNS None
of IN None
age NN None
patients NNS None
with IN None
a DT None
disease-free JJ None
interval NN None
of IN None
1 CD None
year NN None
or CC None
less JJR None
. . None
Patients NNS None
with IN None
these DT None
parameters NNS None
probably RB None
belong RB None
to TO None
the DT None
same JJ None
population NN None
. . None
-DOCSTART- -X- N

acute JJ None
lung JJ None
injury NN None
: : None
patients NNS None
with IN None
acute JJ None
lung NN None
injury NN None
( ( None
ALI NNP None
) ) None
ALI NNP None
patients NNS None
152 CD None
patients NNS None
with IN None
ALI NNP None
enrolled VBD None
in IN None
the DT None
Fluid NNP None
and CC None
Catheter NNP None
Treatment NNP None
Trial NNP None
( ( None
FACTT NNP None
) ) None
from IN None
five CD None
NHLBI NNP None
ARDS NNP None
( ( None
Acute NNP None
Respiratory NNP None
Distress NNP None
Syndrome NNP None
) ) None
Network NNP None
sites NNS None
. . None
71 CD None
and CC None
152 CD None
patients NNS None
provided VBD None
in IN None
patients NNS None
with IN None
ALI NNP None
. . None
Due NNP None
in IN None
patients NNS None
with IN None
acute JJ None
lung NN None
injury NN None
-DOCSTART- -X- N

myofascial JJ None
pain NN None
dysfunction NN None
( ( None
MPD NNP None
) ) None
10 CD None
patients NNS None
with IN None
MPD NNP None
with IN None
subthreshold JJ None
TENS NNP None
( ( None
frequency NN None
35 CD None
Hz NNP None
, , None
pulse RB None
width VBZ None
100 CD None
milliseconds NNS None
, , None
modulation NN None
50 CD None
% NN None
) ) None
compared VBN None
with IN None
sham NN None
TENS NNP None
at IN None
8 CD None
visits NNS None
over IN None
14 CD None
weeks NNS None
. . None
